All times listed are Central Daylight Time. Program and Faculty are updated often – check back for the most up-to-date information. Click on session name to view session description and component talks.
0129: Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
Location: Hall F1
Abstract Poster Presenter: Jonathan Marilao, MD – University of Texas Southwestern
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0127: Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease
0128: Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research
Location: Hall F1
Abstract Poster Presenter: Jheel Bhatt, MD – Advent Health Orlando
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0136: Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
Location: Hall F1
Abstract Poster Presenter: Ritesh Kumar Mishra, MD – JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0123: Prognosis of Cardiac Involvement in Antiphospholipid Syndrome
0125: The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0132: Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome
Abstract Poster Presenter: Koshy Thomas, MD, DM – Christian Medical College, Vellore
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0133: Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Location: Hall F1
Abstract Poster Presenter: Maria Tektonidou, PhD – National and Kapodistrian University of Athens
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0141: Cytokine profiles in antiphospholipid syndrome
0118: Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome
Location: Hall F1
Abstract Poster Presenter: Ecem Sevim, MD – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0142: Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis
Location: Hall F1
Abstract Poster Presenter: Xiaohan Wei, n/a – Shanghai JiaoTong University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0124: Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Location: Hall F1
Abstract Poster Presenter: Haoyu Pan, MD – Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0119: Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
0135: Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
Location: Hall F1
Abstract Poster Presenter: Omer Uludag, MD – Istanbul Faculty of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0144: Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
0122: The role of low profile antiphospholipid antibodies and adverse pregnancy outcomes.
Location: Hall F1
Abstract Poster Presenter: Eugenia Chock, MD – Yale School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0120: The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Location: Hall F1
Abstract Poster Presenter: Emre Sahin, MD – Hospital for Special Surgery
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0121: The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
Location: Hall F1
Abstract Poster Presenter: Emre Sahin, MD – Hospital for Special Surgery
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0138: Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis
Abstract Moderator: Jane Salmon, MD – Hospital for Special Surgery
CE: 0.00
Monday, Oct 27th
10:00 AM - 10:15 AM Central Time
0855: Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Location: W192A-C
Presenting Author: Jane Salmon, MD – Hospital for Special Surgery
Monday, Oct 27th
10:15 AM - 10:30 AM Central Time
0856: Integrated Single-Cell and Spatial Transcriptomics Reveal Vascular and Immune Pathogenesis in APS Nephropathy
0858: IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS
Location: W192A-C
Presenting Author: Kavya Sugur, PhD – Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor
Monday, Oct 27th
11:00 AM - 11:15 AM Central Time
0859: Trophoblast Dysfunction and Placental Alterations in a Mouse Model of Antiphospholipid Syndrome: The Potential Role of Neutrophil Extracellular Traps
0860: Activated Protein C Resistance and Protein C Antibodies in the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository
2550: Development of a ‘Training Toolkit’ to Support Advanced Practice Providers (APPs) Entry into a Rheumatology Musculoskeletal Ultrasound Subspecialty Clinic
2554: Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
2561: Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus
2562: Enhancing Hand Osteoarthritis Classification with Generative AI: A CycleGAN and EfficientNetB7 Approach
Location: Hall F1
Abstract Poster Presenter: Ming Zhang, PhD – Boston University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2563: Factors Associated With Medication Use in the Preconception and Perinatal Period Among Women With Autoimmune Disorders: A Systematic Review
Location: Hall F1
Abstract Poster Presenter: Olivia Novosel, BSc – Temerty Faculty of Medicine, University of Toronto
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2564: An Illustration-based Patient-reported Outcome Measure Reveals Concealed Symptoms in Patients with Rheumatoid Arthritis and the Factor Contributing to the Discrepancy Between Patient and Evaluator Global Assessments
Location: Hall F1
Abstract Poster Presenter: Tetsuya Tomita, MD – Morinomiya University of Medical Sciences
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2565: Assessing Participation in the Lupus Sister Circle Support Group
Location: Hall F1
Abstract Poster Presenter: Wendy Rodgers, MPH – Lupus Foundation of America
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2566: Using Abdominal CT-Derived Bone Mineral Density and Psoas Volume for Opportunistic Osteoporosis Screening and Fracture Risk Assessment
Location: Hall F1
Abstract Poster Presenter: Ye Liu, MD, MPH, DrPH – University of Alabama at Birmingham
Tuesday, Oct 28th
2:30 PM - 3:30 PM Central Time
28T49: From Nice to Necessary: Involving Patients as Essential Members of Your Research Team
2603: Evaluating the Feasibility, Acceptability, and Behavioral Impact of Brief Action Planning (BAP) Coaching for Physical Activity in Adults with Chronic Knee Symptoms: A Qualitative Study
0774: Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future rheumatoid arthritis conversion
Location: W375D-E
Presenting Author: Jun Inamo, MD, PhD – University of Colorado School of Medicine
Sunday, Oct 26th
10:30 AM - 10:45 AM Central Time
0775: Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression
Panelist: Michael Weisman, MD – Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA
Monday, Oct 27th
4:00 PM - 5:00 PM Central Time
NL27M11: Basic Science: Professional Development for Junior Researchers and Trainees in Basic/Translational Research
0774: Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future rheumatoid arthritis conversion
Location: W375D-E
Presenting Author: Jun Inamo, MD, PhD – University of Colorado School of Medicine
Sunday, Oct 26th
10:30 AM - 10:45 AM Central Time
0775: Increased Circulating Microbial Small RNA tDR-1 is Associated with Decreased Progression to Future Clinical Rheumatoid Arthritis In High Risk Individuals and Reduces In Vitro Type 1 Interferon Response Gene Expression
0853: Olink Proteomics Identifies Macrophage Pro-inflammatory Proteins in Maternal Sera Predictive of Fetal Atrioventricular Block Independent of Maternal Health Status
Location: W375D-E
Presenting Author: Philip Carlucci, MD – New York University School of Medicine
Monday, Oct 27th
9:15 AM - 9:30 AM Central Time
0854: The Assessments in Spondyloarthritis International Society (ASAS) and Spondyloarthritis Research and Treatment Network (SPARTAN) Revised Classification Criteria for Axial Spondyloarthritis: Development and Validation in the Classification of Axial SpA Inception Cohort Study
1725: Functional NOTCH4 Variants Drive Vasculopathy and Fibrosis in Systemic Sclerosis.
Location: W375B
Presenting Author: Urvashi Kaundal, PhD – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Tuesday, Oct 28th
9:00 AM - 9:15 AM Central Time
1726: Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
1123: Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Location: Hall F1
Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1126: Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
1140: PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs
Location: Hall F1
Abstract Poster Presenter: Sadiq Umar, PhD – University of Illinois at Chicago
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1129: Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
1130: Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Location: Hall F1
Abstract Poster Presenter: Kiara Tan, BA – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1137: Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
1127: The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
1136: The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts
2003: Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
Location: Hall F1
Abstract Poster Presenter: Julia Buchfuhrer, DO – JB Arthritis and Rheumatology Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1992: Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
1999: Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
Location: Hall F1
Abstract Poster Presenter: Herbert Baraf, MD, FACP, MACR – National Institute of Arthritis and Musculoskeletal and Skin Diseases
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2007: Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
Location: Hall F1
Abstract Poster Presenter: Min Jung Kim, MD – Seoul Metropolitan Government Boramae Medical center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2010: Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli
Location: Hall F1
Abstract Poster Presenter: Tony Merriman, PhD – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2004: Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry
2005: Elevated Serum Uric Acid as an Independent Risk Factor for Multiple Stent Placement in Non-Hypertensive, Non-Diabetic Patients with Coronary Artery Disease: A Retrospective Cohort Analysis
Location: Hall F1
Abstract Poster Presenter: Lemei An, MD – Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1990: Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Location: Hall F1
Abstract Poster Presenter: Alex Tinianow, MD – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1994: Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
2013: Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
Location: Hall F1
Abstract Poster Presenter: Yu Xue, MD – Huashan Hospital,Fudan University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1996: Hospital Burden of Crystal-related Arthritis in Spain: a nationwide dataset of 183,001 inpatients.
2008: Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
2011: A Phase 1 Placebo Controlled, Single (SAD) and Multiple Dose Escalation (MAD) Safety and Pharmacokinetic (PK) Study of a Novel Colchicine Analogue ABP-745 in Healthy Volunteers (HV)
2012: A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
2590: Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women
Location: S102
Presenting Author: Sharan Rai, PhD – Massachusetts General Hospital, Harvard Medical School
Diversity, Inclusion, and Racial Disparities
Sunday, Oct 26th
10:00 AM - 11:30 AM Central Time
26S19: Sponsoring Women and Underrepresented Minorities in Team Science and Clinical Practice
1057: Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness
1083: How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?
1067: Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma
1066: Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1077: Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort
1073: Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases
1062: Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort
1068: Association Between Social Determinants of Health Domains and covid-19-related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data
1087: Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Zoe Reed, MPH – Oklahoma Medical Research Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1069: Strengthening Rheumatology Workforce Capacity and Impact on Patient Care in Louisiana: Expanding Fellowship Training Opportunities Through Strategic Partnerships
1063: Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Location: Hall F1
Abstract Poster Presenter: Farheen Malik, MD – Jacobi Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1074: Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
1061: Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
1706: Overcoming Barriers to ANA Testing in Pediatric Populations in Africa
Location: S105
Presenting Author: Ekemini Ogbu, MD, MSc – Cincinnati Children's Hospital Medical Center
Monday, Oct 27th
3:45 PM - 4:00 PM Central Time
1707: Racial and Ethnic Disparities in Kidney Transplant Outcomes Among Patients With Systemic Lupus Erythematosus (SLE): A 20-Year Analysis Spanning Before and After the 2014 Kidney Allocation System Revision
Location: S105
Presenting Author: Soziema Salia, MD, MPH – MedStar Health Georgetown University (Baltimore) Internal Medicine Program
Monday, Oct 27th
4:00 PM - 4:15 PM Central Time
1708: Assessing Social Determinants of Health Using PRAPARE in a Rheumatology Patient Navigator Program for Underserved Brooklyn Communities
0146: Association Between Frailty and Delirium and Hospitalization Outcomes Among Older Adults with Rheumatic Diseases
Location: Hall F1
Abstract Poster Presenter: Bhavik Bansal, MBBS – UT Southwestern Medical Centre
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0147: Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations - PREST study
0155: Effect Modification of Cigarette Smoking on the Relationship between Post Traumatic Stress Disorder and Rheumatoid Arthritis Risk
Location: Hall F1
Abstract Poster Presenter: Kelsey Coziahr, MD – University of Nebraska Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0156: Heat Exposure and Acute Care Utilization among Individuals with Rheumatic Conditions: A Time Series Framework for Identifying Delayed Associations
Location: Hall F1
Abstract Poster Presenter: Leah Santacroce, MS – Brigham and Women's Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0157: Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
0158: Association Between Newer COVID-19 Vaccines and COVID-19 Related Hospitalizations Among People with Autoimmune Rheumatic Diseases in the U.S. National COVID Cohort Collaborative (N3C)
0163: Trends in hospitalization and outcomes among patients admitted with Adult-onset Still's disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)
0166: Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination
0169: The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
0173: Association Between the Ratio of Non-high-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol and All-cause Mortality Risk in Patients with Rheumatoid Arthritis: A Survival Analysis Based on NHANES Data
Location: Hall F1
Abstract Poster Presenter: Tingting Wang, n/a – Department of Rheumatology and Immunology, Dazhou Central Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0174: Genetic and Environmental Risk Factors and Incident Rheumatoid Arthritis
0197: Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
0360: Assessing Content Validity of a New Questionnaire Evaluating Glucocorticoid Toxicity
Location: Hall F1
Abstract Poster Presenter: John Stone, MD, MPH – Massachusetts General Hospital , Harvard Medical School
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0361: Transition in Focus: Health Care Utilization and Disease Status in Youth with Connective Tissue Diseases— A Single-Center Experience in British Columbia, Canada
0370: Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
0375: Association of Glucocorticoid Toxicity Index Scores with Quality-of-life and Healthcare Resource Utilization at 6 Months in a Real-world Cohort of Individuals Receiving Glucocorticoids
0376: An Internet-delivered, Arthritis-tailored Cognitive Behavioral Therapy for Insomnia Program for People with Co-morbid Sleep Disturbance: Comparing Baseline Characteristics of Cannabis Users and Non-users
0380: Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
0381: Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies
0382: Preventative Health Screening Practices Among 666 Women with Systemic Rheumatic Diseases from the Hospital for Special Surgery Rheumatology Women’s Reproductive Health and Wellness Cohort: A Cross-Sectional Analysis
0219: Increased Engagement With the RISE Registry Clinician Dashboard Is Associated With Improving Performance on Some but Not All Rheumatology Quality Measures
0223: Timely Dermatologic Diagnosis and Management Changes in Systemic Collagen Vascular Diseases: Experiences from the Rheumatology-Dermatology Combined Clinic
Location: Hall F1
Abstract Poster Presenter: Jeanie Lee, MD – Montefiore Einstein Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0177: Artificial Intelligence in Adult and Paediatric Rheumatology Practice and Research: Pilot Results from an International Survey
Location: Hall F1
Abstract Poster Presenter: Ana Isabel Rebollo-Giménez, MD – Department of Rheumatology, Gregorio Marañón University Hospital, Gregorio Marañón Health Research Institute
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0224: Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis
Location: Hall F1
Abstract Poster Presenter: John Hickernell, MD – Loyola University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0178: Prevalence and factors associated with virtual rheumatology care utilization in a national population of Veterans with RA
Location: Hall F1
Abstract Poster Presenter: Beth Wallace, MD, MS – Michigan Medicine, VA Ann Arbor Healthcare System
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0216: Evaluation of oral treatment adherence in Systemic Lupus Erythematosus patients: indentification of risks profiles
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0189: “try It, You’ll Love It”: Patterns of AI Scribes Use Among Rheumatologists
0225: Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Location: Hall F1
Abstract Poster Presenter: Juan Schmukler, MD – Rush University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0182: A Joint Effort: Implementing Depression Screening in a Safety-net Rheumatology Clinic
0211: Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration
0221: A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-centered National Rheumatoid Arthritis Network
Location: Hall F1
Abstract Poster Presenter: Grant Cannon, MD – University of Utah and Salt Lake City VA
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0186: Validation of Asynchronous Telehealth Visit for Adults and Children with Inflammatory Arthritis and Feasibility of Applying Thermal Imaging during Visits
0222: Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey
0220: National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration
0217: Development of the American College of Rheumatology Implementation Guide for Integrating Patient Reported Systemic Lupus Erythematosus Quality Measures
0183: Optimizing the Clinical Application of Rheumatology Guidelines Using Large Language Models: A Retrieval-Augmented Generation Framework Integrating EULAR and ACR Recommendations
0794: Using Artificial Intelligence to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models
1008: Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Location: Hall F1
Abstract Poster Presenter: Ahmet Gül, MD – Istanbul University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1009: Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
1010: Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Patients with Rheumatoid Arthritis: A Systematic Literature Review
1011: Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Location: Hall F1
Abstract Poster Presenter: Ethan Eickmann, BA – Brigham and Women's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1012: Racial and Gender Disparities in Gout Clinical Trials
1017: Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network
1018: Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
1019: Associations Between Mental Health Diagnoses and Acute Care Use Among Individuals with Systemic Lupus Erythematosus in the All of Us Research Program
Location: Hall F1
Abstract Poster Presenter: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1020: Cohort Study of European Ancestry, Geographic Region, Ambient Ultraviolet Irradiance and the Risk of Developing Polymyalgia Rheumatica among Women
Location: Hall F1
Abstract Poster Presenter: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1021: Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
1027: GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
1028: Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts
1031: Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
Location: Hall F1
Abstract Poster Presenter: Satani Sharkas, MD – Boston Medical Center - Brighton
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1032: Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
Location: Hall F1
Abstract Poster Presenter: Sharan Rai, PhD – Massachusetts General Hospital, Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1033: Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort
1035: Demographic and Clinical Correlates of 30 day Re-admission or Death During Admission in Patients With Rheumatologic Conditions : A Retrospective Cohort Analysis in a Single Academic Center
1252: Can LLMs Categorize Patient Priorities Like Humans? Comparing AI and Human Coders in Arthritis Nominal Group Discussions
Location: Hall F1
Abstract Poster Presenter: Melissa Mannion, MD – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1253: Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Location: Hall F1
Abstract Poster Presenter: Nisha Sapkota, MD – One Brooklyn Health- Interfaith Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1254: Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
1256: Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
Location: Hall F1
Abstract Poster Presenter: Shannon Teaw, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1257: Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
Location: Hall F1
Abstract Poster Presenter: Shannon Teaw, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1258: Upadacitinib in the treatment of Rheumatoid Arthritis - Interstitial Lung Disease. National multicenter study of 25 patients in clinical practice.
Location: Hall F1
Abstract Poster Presenter: Ana Serrano-Combarro, MD – Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1259: Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
1264: Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt
1266: Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
1267: Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Location: Hall F1
Abstract Poster Presenter: Leah Santacroce, MS – Brigham and Women's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1268: Development of the LupusCoach Chatbot: Results of a Focus Group
1637: Sleep Quality as a Modifier of the Relationship Between Physical Activity and Functional Limitation in Adults with or at High Risk of Knee Osteoarthritis
1642: The Impact of Secukinumab on Bone Density in Patients with Ankylosing Spondylitis: A 1-Year Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Lemei An, MD – Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1643: Optimizing Analyses of Chair Stand Test Outcome Data in the Multicenter Osteoarthritis Study: Exploration of Approaches to Handling Missing and/or Skewed Data with Performance-based Function Measures
Location: Hall F1
Abstract Poster Presenter: Michael LaValley, PhD – Boston University School of Public Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1644: Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Misti Paudel, PhD, MPH – Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1645: A Sex-modified Association Between Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) Blood Concentration and Prevalent Arthritis Among Young and Middle-aged US Adults
1647: Clinical Phenotypes of Participants with Radiographic Osteoarthritis Attaining Patient Acceptable Symptom State in the Multicenter Osteoarthritis Study
1648: Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
1050: Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Location: Hall F1
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1052: “prednisone… a Necessary Evil…” Developing an Evidence-based Benefits vs. Harms Shared Decision-making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Location: Hall F1
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1054: Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Location: Hall F1
Abstract Poster Presenter: Ye Liu, MD, MPH, DrPH – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1045: Bayesian Analysis of Factors Associated with Romosozumab Adherence Among Early Adopters in Medicare Beneficiaries
1044: Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
1043: The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians In The United States
Location: Hall F1
Abstract Poster Presenter: Gordon Lam, MD, FACR – Arthritis & Osteoporosis Consultants of the Carolinas
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1047: Primary Care Perspectives on Giant Cell Arteritis: Diagnostic Considerations, Referral Challenges, and Opportunities for Fast-Track Pathways in the U.S.
Location: Hall F1
Abstract Poster Presenter: Jon Golenbiewski, DO – Wake Forest University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1041: Associated Factors and Direct Cost Analysis of Dose Reduction and Discontinuation of Biological Therapies in Rheumatoid Arthritis and Spondyloarthritis: Findings from a Colombian Cohort Within the Framework of an Integrated Management Model
1661: Artificial Intelligence Applied to Patient Reported Outcomes and Passive Physiologic Sensor Data Can Accurately Classify Low Disease Activity in Rheumatoid Arthritis Patients
1878: Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database
1884: The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study
1887: Incidence, Prevalence and Mortality of Systemic Lupus Erythematosus – A 20-year territory-wide analysis of electronic health records in Hong Kong
1889: Navigating Diagnostic Challenges: Insights into the Patient Journey and Delays in Diagnosing Dermatomyositis from a Real-world Survey in the United States and Europe
1890: Quantifying the Inflammatory Toll: Smoking-Attributable Rheumatoid Arthritis Burden Across the Globe, 1990–2021
Location: Hall F1
Abstract Poster Presenter: Eva Kalra, MBBS – Trident Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1891: Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability
Location: Hall F1
Abstract Poster Presenter: Eva Kalra, MBBS – Trident Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1892: Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis
1896: Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program
1902: Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases
1903: Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California
1910: Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims
1920: Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis
Location: Hall F1
Abstract Poster Presenter: Huifang Lu, MD;PhD – UT MD Anderson Cancer Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1922: Exploration of patient and clinician perspectives on rehabilitation in contemporary rheumatology care for rheumatoid arthritis: A qualitative study
Location: Hall F1
Abstract Poster Presenter: Joel Thompson – University of North Carolina at Chapel Hill
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1923: A Real-World Survey on Physicians Perspectives of Uncontrolled Gout and Gout Management Practices
Location: Hall F1
Abstract Poster Presenter: John Botson, MD – Orthopedic Physicians Alaska
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1924: Real-World Treatment Patterns of Patients with Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease After Progression in The United States
1929: Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still's Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD)): Analysis of a US National Administrative Claims Database
1930: Can a Multinational Awareness Campaign Improve Referral Rates and Reduce Diagnostic Delays in Patients with Chronic Inflammatory Rheumatic Diseases? The Impact of a Prospective Interventional Study
1933: Specialist Wound Care Services Provision and Sharp Debridement Practices for Digital Ulcers (DU) Management in Systemic Sclerosis (SSc): An International Survey
1934: Analysis of the Determinants of Vaccine Acceptance and Hesitancy in Germany: A Mixed-methods Approach Incorporating Health Insurance Data and Qualitative Interviews with Patients and Physicians
1982: Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Location: Hall F1
Abstract Poster Presenter: Kuan-Tung Lin, MD – North East Medical Services
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1980: Improving Vaccination Rates in the Rheumatology Clinic
Location: Hall F1
Abstract Poster Presenter: Kajal Patel, DO – Prisma Health Rheumatology Fellowship Program
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1914: Performance Comparison of Artificial Intelligence tools ChatGPT, Bing AI, and Google Bard for Clinical Rheumatology Decision Support: When AI Talks Rheumatology
1979: Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis
1974: Serial ferritin as a diagnostic surrogate marker in Hemophagocytic Lymphohistiocytosis (HLH), a retrospective single-center study
Location: Hall F1
Abstract Poster Presenter: Chen Chao, MD, MBA – Montefiore Medical Center/Albert Einstein College of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1975: Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
1988: Advancing Vascular Assessment: Combining NIRS-VOT and Ultrasound-based Brachial Artery Diameter for Improved Diagnostics in Healthy Controls and APS
1985: Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
Location: Hall F1
Abstract Poster Presenter: Rachel Galvao, MD – University of Pennsylvania Health System
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1972: Enhancing Patient Safety: Improving Contraceptive Counseling for Patients on Teratogenic Medications in the Rheumatology Clinic
Moderator: Michael Weisman, MD – Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA
2572: Multi-Modal Machine Learning Prediction and Phenotyping of Systemic Lupus Erythematosus Using Longitudinal EHR and Genomic Data from the All of Us Program
2616: Real-World Implication of Clinical Disease Activity Index (CDAI) Utilization on Treatment Decisions and Clinical Outcomes in Rheumatoid Arthritis
Location: S103
Presenting Author: Ryan Clark, PharmD – University of North Carolina at Chapel Hill
Tuesday, Oct 28th
3:30 PM - 3:45 PM Central Time
2617: Design and Initial Results from a Cluster Randomized Trial of a Provider-Facing Immunization Dashboard to Improve Shingrix Vaccination in the Veterans Health Administration
2618: Effect of Implementing a Dashboard with or without a Best Practice Alert on HLA-B*58:01 Testing Rates among Allopurinol Users at VA Medical Centers
Abstract Moderator: Vivian Kawai, MD – University of Alabama at Birmingham
CE: 0.00
Wednesday, Oct 29th
11:30 AM - 11:45 AM Central Time
2657: Incidence of Rheumatic Diseases Among Patients Receiving GLP-1 Receptor Agonists: A Comparative Analysis with DPP-4 Inhibitors in a Propensity Score-Matched Cohort
2658: Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
2659: Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Systemic Autoimmune Rheumatic Diseases in Patients with Type 2 Diabetes: A Population-Based Target Trial Emulation
Location: W184B-C
Presenting Author: Jamie Chieh Lo, MD – National Taiwan University Hospital
Wednesday, Oct 29th
12:15 PM - 12:30 PM Central Time
2660: Understanding Gout in Women: Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause
0045: Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
0026: Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis
Location: Hall F1
Abstract Poster Presenter: Andrea-Hermina Györfi, MD – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0020: Bulk RNA-sequencing of Leukocytoclastic Vasculitis Skin Biopsies Show Upregulation of Leukocyte Migration Genes
0033: Development and Internal Validation of Two Human Leukocyte Antigen Genetic Risk Scores for Predicting Rheumatoid Arthritis Progression and Anti-Citrullinated Protein Antibody-Positivity
0037: A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/differentiation Factor 15 (GDF-15) Improves Prediction of All-cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Hematologic and Oncologic Associated Rheumatic Syndromes
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
Immunological Complications of Medical Therapy Poster
Location: Hall F1
CE: 0.00
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1088: Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1089: Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1090: Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
1092: Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Location: Hall F1
Abstract Poster Presenter: Binod Kc, MBBS – SUNY Upstate Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1093: Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Blake Baay, BS – UT Southwestern
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1094: Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1095: Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
1096: Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.
Location: Hall F1
Abstract Poster Presenter: Elisabet Perea-Martínez, MD – Rheumatology section, Hospital General Universitario de Elda
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1097: Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Location: Hall F1
Abstract Poster Presenter: Elvis Hysa, MD – University of Genova
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1098: Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Location: Hall F1
Abstract Poster Presenter: Francisco Arias, MD – University of Texas Rio Grande Valley
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1099: Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Location: Hall F1
Abstract Poster Presenter: Grace Haeun Lee, BA – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1100: Associations Between Pre-existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
1101: Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Heba Altarawneh, MD – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1102: Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Location: Hall F1
Abstract Poster Presenter: Julia Barasch, MD – Weill Cornell - New York Presbyterian
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1103: Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Location: Hall F1
Abstract Poster Presenter: Kayla Chubbs, MD – Dalhousie University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1104: Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1105: Association Between Pre-existing Rheumatoid Arthritis and Immune-related Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1106: Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Location: Hall F1
Abstract Poster Presenter: KO JEN LEE, MD, PhD – National Taiwan University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1107: Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1108: Baseline Features, Immunosuppression, and Immune-related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1109: Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
1113: Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Location: Hall F1
Abstract Poster Presenter: Qi Wang, MD – Metrohealth System/Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1114: Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Location: Hall F1
Abstract Poster Presenter: Qiang Xu, n/a – Guangzhou University of Traditional Chinese Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1115: Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Location: Hall F1
Abstract Poster Presenter: Samuel Bitoun, MD, PhD – Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1116: Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
1118: Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
1120: Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
Location: Hall F1
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1121: Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: Tao Ming Sim, MBBS – National University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1121: Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: Tao Ming Sim, MBBS – National University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1122: A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-related Problems
1728: Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
Location: S102
Presenting Author: Huaxia Yang, MD – Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tuesday, Oct 28th
10:15 AM - 10:30 AM Central Time
1729: The ERIN Registry: Real-World Data on Rheumatic Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy
1730: Oral glucocorticoid treatment for checkpoint inhibitor associated inflammatory arthritis do not affect progression free survival: a RADIOS Registry cohort study
1731: A Post-marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-cell Therapy Using the FDA Adverse Event Reporting System
1732: Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
Location: S102
Presenting Author: Takemichi Matsui, MD – Icahn School of Medicine at Mount Sinai
Tuesday, Oct 28th
11:15 AM - 11:30 AM Central Time
1733: Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations
1936: A Fully Automated Method for Measuring Minimum Tibiofemoral Joint Space Width in Knee Osteoarthritis Assessment: Data from the FNIH Cohort
Location: Hall F1
Abstract Poster Presenter: Ahmad Almhdie, PhD – University Hospital Center of Orleans
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1937: Does Combining Standard MRI-Based Scores with Radiographic Trabecular Bone Texture Biomarkers Improve Predictive Performance for Radiographic Knee Osteoarthritis Progression?
Location: Hall F1
Abstract Poster Presenter: Ahmad Almhdie, PhD – University Hospital Center of Orleans
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1938: Optimizing Patient Outcomes: The Experience of a Multidisciplinary Rheumatology and Hand Surgery Clinic with Point-of-Care Musculoskeletal Ultrasound Integration
1944: Musculoskeletal Ultrasound Clinic Referral Patterns and Joint Findings in a Tertiary Care Center amongst Patients with Elevated BMI and Inflammatory Arthritis
Location: Hall F1
Abstract Poster Presenter: Anna Lichtiger, MD – Montefiore Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1945: Significance of Finger Joint Tenderness With or Without Swelling in Relation to MRI, Ultrasound, and X-Ray Findings in Psoriatic Arthritis_Final results
Location: Hall F1
Abstract Poster Presenter: Ari Polachek, MD – Beilinson Hospital, Petah Tikva, Israel
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1946: Quantitative Imaging Analysis of Chest Computed Tomography in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Emily Anthone, BS – University of Nebraska Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1947: Coronary computed tomography incidental findings in rheumatoid arthritis.
1950: Pericoronary fat enhancement in rheumatoid arthritis differs from controls and associates with coronary atherosclerosis independently of epicardial fat volume
Abstract Poster Presenter: Genessis Maldonado, MD – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1955: Regional variations in the relationship between pericoronary fat enhancement and atherosclerosis may reflect differences in local vascular inflammation in rheumatoid arthritis
1958: Longitudinal analysis on imaging outcomes: should we use the individual scores from multiple readers or rather the consensus or average of readers?
Location: Hall F1
Abstract Poster Presenter: Liese de Bruin, MSc – Leiden University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1959: The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis
1963: Efficacy of Apremilast in Patients With Psoriatic Arthritis and Pre-existing Dactylitis: Dynamic Contrast-Enhanced MRI Results From the Phase 4 MOSAIC Study
1964: Performance of Artificial Intelligence-Based Salivary Gland Ultrasound in Sjögren Syndrome
Location: Hall F1
Abstract Poster Presenter: Otto Olivas, MD – Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute FJD-UAM, Madrid, Spain
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1965: Two-Year Outcomes of Microwave Ablation for Recurrent Monoarthritis with Synovial Hypertrophy Resistant to Medical Treatment: Expanded Cohort and Long-Term Follow-Up Results
1968: Relationship between ultrasonographic and elastographic findings of the median nerve and disease activity and hand function in patients with rheumatoid arthritis
1969: Enhancing Objective Evaluation of Raynaud’s in Veterans with Scleroderma-related Hand Pain: Integrating Patient Reported Outcomes and Nailfold Capillaroscopy
Location: Hall F1
Abstract Poster Presenter: Sowmika Rao, MD – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1970: Comparison of Optical Imaging with Musculoskeletal Ultrasound in Assessment of PIP Joints of Systemic Lupus Erythematosus Patients
Location: Hall F1
Abstract Poster Presenter: Wei Tang, MD – Westchester Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1971: Intracranial Arterial Stenosis in Antiphospholipid Syndrome: A Neglected Vascular Involvement?
Location: Hall F1
Abstract Poster Presenter: Yuying Fan, n/a – Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2611: Exploring the Role of a Lung Ultrasound Score in the Assessment of Severity of Connective Tissue Disease-Related Interstitial Lung Disease
Location: S105
Presenting Author: ying zhang, n/a – Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
Tuesday, Oct 28th
3:45 PM - 4:00 PM Central Time
2612: Automated, Artificial Intelligence-supported Sonographic Examination of the Hands for the Detection and Quantification of Arthritis and Osteoarthritis in the Hand and Finger Joints in Outpatient Rheumatology Care
2613: ga-fapi-04 PET/CT Reveals Increased Fibroblast Activation in Synovial and Enthesial Tissues of Psoriasis Patients with Arthralgia and Predicts the Development of Psoriatic Arthritis
Location: S105
Presenting Author: Giulia Corte, MD – University Hospital of Erlangen
Tuesday, Oct 28th
4:15 PM - 4:30 PM Central Time
2614: Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis
0013: Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Location: Hall F1
Abstract Poster Presenter: Minyun Zhou, PhD – Simcere Pharmaceutical Group
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0016: Pharmacology Analyses of Sail’s In Vivo hCD19 CAR-T Product Reveal Mechanistic Insights Underlying its Optimal Dose Efficiency Profile in Both Healthy Donors and SLE Patient Samples
0014: NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Location: Hall F1
Abstract Poster Presenter: Mira Tohmé, PhD – nkarta therapeutics
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0006: QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
0009: MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Location: Hall F1
Abstract Poster Presenter: Marisa Peluso, MS – Monte Rosa Therapeutics
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0002: KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
Location: Hall F1
Abstract Poster Presenter: Brian Kim, MS – Kite, a Gilead Company
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0003: In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
0982: Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases
Location: Hall F1
Abstract Poster Presenter: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0983: Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
0987: S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
0990: An Fc-engineered Agonistic anti-pd-1 Antibody Selectively Depletes pd-1+ Cells and Attenuates T Cell Activation in vitro and in vivo in a Xenogeneic Graft-versus-host Disease (GvHD) Model
0991: MTHFD2 is a Novel Metabolic Target in Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Laura McMillan – Sitryx Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0992: FoxP3Lo CD4+ T cells are functionally suppressive and expanded in the immune-mediated fibrotic diseases IgG4-related disease and systemic sclerosis
0993: NOD2 mutations mediate IL-17 predisposition in patients with Blau syndrome
Location: Hall F1
Abstract Poster Presenter: Leah Huey, BS – Oregon Health & Science University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0994: UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases
1000: A Deep-learning Based Approach Uncovers Novel Mediators of Micro-rna Restraint of type-2 Immunity
Location: Hall F1
Abstract Poster Presenter: Shaan Sekhon, BA – CNU College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1001: LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Location: Hall F1
Abstract Poster Presenter: Xiao Huang, MS – Leads Biolabs
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1002: ATF3 Inhibits Pulmonary Fibrosis via CD4+CD25−LAG3+ T Cells
Location: Hall F1
Abstract Poster Presenter: Xiao Zhang, n/a – The Eighth Affiliated Hospital of Sun Yat-sen University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1003: Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology
Location: Hall F1
Abstract Poster Presenter: Yan Zhang, PhD – Capstan Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1004: Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Location: Hall F1
Abstract Poster Presenter: Yang Yang, PhD – Boston Children's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1005: CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
0929: SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice
0913: Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
0908: E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Li Peng, PhD – Palleon Pharmaceuticals
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0933: Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Location: Hall F1
Abstract Poster Presenter: Yunwei Xia, BA – Feinstein Institutes for Medical Research
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0902: A Novel Approach to Study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-cell Culture
0906: Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
0910: Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
Location: Hall F1
Abstract Poster Presenter: Min-Gang Kim, PhD – Seoul National University College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0930: Potent and Selective Oral IRF5 Degrader, KT 579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Ryan Camire, PhD – Kymera Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0907: Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
0928: Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model
0918: Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)
Location: Hall F1
Abstract Poster Presenter: Anthony Cruz, BS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0915: A Fusion of TACI Variant and Anti-ifnar Antibody with Greater Therapeutic Effect on Related Autoimmune Disease Models
0919: Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
0921: Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Location: Hall F1
Abstract Poster Presenter: Hannah Johnson, BS – University of Nebraska Medical Center
Abstract Moderator: Edward Schwarz, PhD – University of Rochester, Rochester, NY, USA
CE: 0.00
Monday, Oct 27th
1:00 PM - 1:15 PM Central Time
1650: Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction
Location: W192A-C
Presenting Author: Hannah Johnson, BS – University of Nebraska Medical Center
Monday, Oct 27th
1:15 PM - 1:30 PM Central Time
1651: Compound Heterozygosity for the Ile692del and Val726Ala Pathogenic MEFV Variants and Elevated IL-18 (CHIVE-18 syndrome) Is Distinct from Familial Mediterranean Fever (FMF) and Includes a Pronounced Response to Interferon Stimulation in Myeloid Cell Populations
1779: Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium
Location: Hall F1
Abstract Poster Presenter: Wenxian Zhou, BS – University of Nebraska Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1771: Interferon- α, Anti-Interferon-Alpha Antibodies and Disease Activity in Systemic Lupus Erythematosus
1778: Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers
1776: Preclinical Development of a Novel TL1A-Targeting Antibody with Extended Half-life and Low Immunogenicity Risk for the Treatment of Inflammatory Diseases
0200: Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
0201: Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
0203: Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
0205: Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Location: Hall F1
Abstract Poster Presenter: Laura Mas Sanchez, MD – Hospital Universitari i Politecnic La Fe
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0206: Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
0207: The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)
0208: Current practices and challenges in tuberculosis screening and preventive treatment among patients with rheumatic diseases: A multiregional physician survey in China
Location: Hall F1
Abstract Poster Presenter: Xu Wang, PhD – Peking Union Medical College Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0209: A Retrospective Safety Analysis Based on Platelets in Arthrocentesis and Joint Injections in Cancer Patients
Abstract Moderator: Dimitrios Vassilopoulos, MD – Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital
2576: Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) Study: Anti-inflammatory cytokine signals related to decreased arthritis disease activity over time
2577: Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors
2578: Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases
Industry Presenter: Paolo Caimi, MD – Cleveland Clinic Taussig Cancer Institute
CE: 0.00
Monday, Oct 27th
2:30 PM - 3:15 PM Central Time
IT27M3: AVISE CTD: A Decade of Validation Driving Lupus Diagnostic Accuracy, Seronegative RA Biomarker Innovation, and Novel T-Cell Biomarkers for Lupus
Seminar Presenter: Peter Grayson, MD, MSc – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Seminar Presenter: Peter Grayson, MD, MSc – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
0338: Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis
0340: Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.
Location: Hall F1
Abstract Poster Presenter: Chern Lee Choy, MBBS – University Hospitals of Morecambe Bay NHS Foundation Trust
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0341: Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Location: Hall F1
Abstract Poster Presenter: Daniel Ramos Castro, MD – Hospital Universitari i Politecnic La Fe
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0342: Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0343: Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0344: Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
0345: Association Between Deprivation and Fracture Risk in a Regional UK Cohort
Location: Hall F1
Abstract Poster Presenter: Hashem Cheema, MBBS BSc MRCP – University Hospitals of Morecambe bay NHS foundation trust
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0346: Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
0347: Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Location: Hall F1
Abstract Poster Presenter: Kabyar Cho, MBChB, BSc – University Hospitals of Morecambe Bay NHS Foundation Trust
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0348: Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients
0354: Greater Neighborhood Walkability is Associated with Lower Incidence of Hip Fracture in Older, Community-dwelling Women in the United States: The Cardiovascular Health Study
28T24: Women Have a Bone to Pick: Hormonal Regulation of Osteoporosis
Location: W475A-B
Moderator: Julia Charles, MD, PhD – Department of Orthopedic Surgery & Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital
2107: Experience of a Fragility Fracture Coordination Unit Integrated Across Two Hospitals: An Innovative Multidisciplinary Model for Optimizing the Management of Geriatric and Non-Geriatric Patients Beyond Surgery After an Osteoporotic Bone Fragility Fracture
2108: Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
2109: Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2110: Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2111: Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis
2112: Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
2122: Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
2591: Association Between Changes in Bone Quality Parameters and Inflammatory Ratios in Postmenopausal Women Treated with Romosozumab: A Retrospective Observational Study
2593: Single Switch from Reference Denosumab to TVB-009 in Women with Postmenopausal Osteoporosis: Analysis of the Phase 3, Randomized, Double-Blind, Multinational, Multicenter Study
2595: Impact of Different Types of Physical Activity on Bone Health in Patients with Inflammatory Rheumatic Diseases: a Cross-Sectional Analysis from a Prospective Cohort Study
Location: W192A-C
Presenting Author: Edgar Wiebe, MD – Charité University Medicine Berlin
Tuesday, Oct 28th
2:15 PM - 2:30 PM Central Time
2596: Predicting Osteoporosis Using Routine Clinical Data: A Machine Learning Approach
0283: The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records
Location: Hall F1
Abstract Poster Presenter: Ana Valle, MD, MHS – Brigham and Women's Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0284: Glucocorticoid Tapering and Relapse Risk in Anti-ARS Antibody-Positive Myositis: A Retrospective Study in a Single-Center Cohort Treated with Immunosuppressants
Location: Hall F1
Abstract Poster Presenter: Ayaka Inoue, MD – Kakogawa Central City Hospital, Kakogawa, Japan.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0285: Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study
0287: Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies
Location: Hall F1
Abstract Poster Presenter: DANIEL CARRILLO VAZQUEZ, MD, MSc – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0288: Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Didem Saygin, MD – Rush University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0289: Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures
Location: Hall F1
Abstract Poster Presenter: Didem Saygin, MD – Rush University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0290: Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
0294: Clinical relevance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies in patients with an underlying malignancy.
0295: Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
Location: Hall F1
Abstract Poster Presenter: Manali Sarkar, MBBS (she/her/hers) – Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0296: Aggregation of HARS1 and Internalized Antibodies in Muscle Biopsies of Patients with Antisynthetase Syndrome and anti-jo1(hars) Autoantibodies
0304: Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region
Location: Hall F1
Abstract Poster Presenter: Takahisa Gono, MD – Nippon Medical School Graduate School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0305: From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
0861: Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Location: W190A-B
Presenting Author: Xueting Yuan, MD – Peking Union Medical College ;Beijing Chaoyang Hospital
Monday, Oct 27th
10:15 AM - 10:30 AM Central Time
0862: In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis
0863: Myeloid Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells
Location: W190A-B
Presenting Author: Raphael Kirou, BSc – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Monday, Oct 27th
10:45 AM - 11:00 AM Central Time
0864: Immunophenotyping Reveals Upregulated IL-9R on Circulating T and B Cells in Dermatomyositis
Location: W190A-B
Presenting Author: Danica Lee, BA – University of Pittsburgh School of Medicine
Monday, Oct 27th
11:00 AM - 11:15 AM Central Time
0865: Spatial Transcriptomic Analysis of Calcinosis Cutis in Dermatomyositis Uncovers Disease-Associated Pathways Involving IL-6, Tissue Remodeling, and Osteopontin
1192: Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
Location: Hall F1
Abstract Poster Presenter: ANA PAULA LUPPINO-ASSAD, MD, PhD – Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo (HC/FMUSP)
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1193: Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Location: Hall F1
Abstract Poster Presenter: Angela Chang, MD – University of British Columbia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1194: Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis
1198: Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab
1201: Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Irada Choudhuri, MD – University of Pittsburgh Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1202: High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Location: Hall F1
Abstract Poster Presenter: Iris Tang, MBBS, MRCP – Department of Medicine, LKS Faculty of Medicine, University of Hong Kong
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1203: Rituximab in Treatment Refractory vs Treatment Naive Anti Signal Recognition Particle (SRP) Myositis A Case Series
1205: Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.
Location: Hall F1
Abstract Poster Presenter: Jens Schmidt, MD – Immanuel University Hospital Rüdersdorf, Brandenburg Medical School; Department of Neurology and Pain Therapy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1206: Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Location: Hall F1
Abstract Poster Presenter: Jens Schmidt, MD – Immanuel University Hospital Rüdersdorf, Brandenburg Medical School; Department of Neurology and Pain Therapy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1207: Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Jesus Valencia, MD – Johns Hopkins Bayview Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1208: Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Location: Hall F1
Abstract Poster Presenter: Jia Shi, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1209: Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Jia Shi, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1210: Artificial Intelligence-based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the Capiami Cohort
1211: Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
Location: Hall F1
Abstract Poster Presenter: Kristina Svobodová, MD (she/her/hers) – Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1212: Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Location: Hall F1
Abstract Poster Presenter: Maria Rosa Pellico, MD – ASST Pini-CTO, Clinical Rheumatology Unit
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1213: Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)
2052: Prevalence of anti-neutrophil extracellular trap antibodies and their relationship with the clinical characteristics of patients with idiopathic inflammatory myopathies.
2054: A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-center Cohort
Location: Hall F1
Abstract Poster Presenter: Ami Purohit, MD – University of Miami
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2055: Construct Validity of Total Improvement Score (TIS) as an Endpoint for Clinically Meaningful Improvement in Multiple Patient-Centered Outcome Measures in Dermatomyositis
2060: Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.
2066: Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies
Location: Hall F1
Abstract Poster Presenter: Meera Shah, MD, MBBS – Topiwala National Medical College and Dr. B.Y.L Nair Charitable Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2067: Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors
Location: Hall F1
Abstract Poster Presenter: Meera Shah, MD, MBBS – Topiwala National Medical College and Dr. B.Y.L Nair Charitable Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2068: Comparing characteristics, diagnostics, and treatment in people with different idiopathic inflammatory myopathies using a large representative cohort
2070: Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.
2071: Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico
2074: Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients
2076: Nutritional Discourse in Online Myositis Communities: A Reddit Analysis of Patient-led Discussions
Location: Hall F1
Abstract Poster Presenter: Taanya Talreja, MBBS – Seth GS Medical College and KEM Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2077: Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans
Location: Hall F1
Abstract Poster Presenter: Tam Dinh, MD – University of New Mexico Internal Medicine Program
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2078: Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells
2671: Effect of Efgartigimod PH20 SC on Total Improvement Score, its Core Set Measures, and Patient/Clinician Impressions of Change: Results from the Phase 2 ALKIVIA Study of Adults with Active Idiopathic Inflammatory Myopathy
2672: Safety and efficacy of Upadacitinib in melanoma differentiation-associated gene 5-positive dermatomyositis with interstitial lung disease: a single-centre, retrospective, propensity score-matched cohort study
0769: Increased Gait Variability at Preferred Walking Speeds is Associated with Increased Physical Activity Measures in People with Knee Osteoarthritis
0770: Interrelationships of Depression, Pain, and Gait Mechanics and their Associations with Physical Activity Levels Among People with Knee Osteoarthritis
0308: Artificial Intelligence Assisted Extraction of Patient-reported Pain Outcomes in Osteoarthritis Using Prompt Engineering of Large Language Models
Location: Hall F1
Abstract Poster Presenter: Bella Mehta, MD, MS, MBBS – Hospital for Special Surgery, Weill Cornell Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0330: Prevalence of Radiographic and Symptomatic Osteoarthritis, and Ultrasound Features at the Knee: The Johnston County Health Study
Location: Hall F1
Abstract Poster Presenter: Maya Patel, BS – UNC School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0311: Time series analysis of continuous accelerometry data to determine the impact of symptomatic multiple joint osteoarthritis (MJOA) in the naturally occurring canine model
Location: Hall F1
Abstract Poster Presenter: Liubov Arbeeva, MSc – University of North Carolina, Chapel Hill
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0323: Automated Effusion-Synovitis Volume is Prognostic and Responsive to Knee Osteoarthritis Progression: Data from the Osteoarthritis Initiative
0319: Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Danielle Madison, DO – Lakeland Regional Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0317: “No Matter How Great My Doctor Is, He Hasn't Had a Knee Replacement, He Doesn't Understand All That Pain” Program Evaluation of the Moving Well Peer Coach Intervention for Total Knee Replacement
0314: What changes in quality of life can be observed in patients with knee or hip OA prior to total hip or total knee replacement surgery ? data from the KHOALA cohort
0320: Transcriptomic profiling of the skeletal muscle of knee OA patients uncovers elevated glucocorticoid and GABA signaling as mediators of skeletal muscle dysfunction in advanced disease
0310: Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO
0325: Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)
0318: Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study
Location: Hall F1
Abstract Poster Presenter: Cheng Li, MBBS – Central south university
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0324: Bile Acids Metabolism in Symptomatic Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study and Genetics of OA Consortium
Location: Hall F1
Abstract Poster Presenter: Jiatian Li, MD, PhD – Xiangya Hospital, Central South University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0327: Structural Severity Assessment of Hand Osteoarthritis Using Radiomic Analysis: Correlation with the Kellgren-Lawrence Score – Results from the DIGICOD Cohort
1736: Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA.
Location: W192A-C
Presenting Author: Kevin Burt, PhD – University of Pennsylvania
Tuesday, Oct 28th
10:45 AM - 11:00 AM Central Time
1737: CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype
1738: Coexpression and Infiltration of Endoplasmic Reticulum Stress Proteins Together With CD34+ Fibroblast-like Synoviocytes In Human Inflamed Synovial Membranes
1788: Manganese-associated Single-nucleotide Polymorphisms are Associated with Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project
1789: Spatial Analysis of Advanced Osteoarthritis Synovial Tissue
Location: Hall F1
Abstract Poster Presenter: jacob Dickman, n/a – Medical College of Wisconsin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1790: Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Lai Wang, MD;PhD – Rush University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1791: Determining the Effect of CD14 Deficiency on Osteoblastogenesis and Subchondral Bone Remodeling In Mice
Location: Hall F1
Abstract Poster Presenter: Lance Murphy, -None- – University of Pennsylvania Perelman School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1792: OA protection in African spiny (Acomys) mice is partially mediated by the gut microbiome and is transferrable to wild-type mice via microbiome transplantation
1794: OA-associated pain sensitivity is reduced in OA-protected MRL/MpJ mice, partially mediated by the gut microbiome, and transferable via microbiome transplantation
1797: SEV 101 Exosomes Isolated from Induced Pluripotent Stem Cell Derived Hyaline Cartilage Tissue Characterization of Immunomodulatory and Chondroproliferative Effects In Vitro
1808: Lightsheet imaging with 3D analysis for wholistic assessment of synovial lymphatic vasculature within joints of murine models of arthritis
Location: Hall F1
Abstract Poster Presenter: Xi Lin, PhD – University of Rochester Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2079: Association Between Symptomatic Knee Osteoarthritis and Health-related Quality of Life in Individuals with Type 2 Diabetes: A Cross-sectional Study
2081: Radiologic surveillance in the Phase II RCT of LEVI-04, a novel neurotrophin-3 inhibitor, in people with knee osteoarthritis: exclusions at screening
2082: Pharmacokinetic Profile of MM-II Following a Single Intra-Articular Injection in Patients with Knee Osteoarthritis in a Phase 2b Randomized, Controlled, Dose-Ranging Trial
2085: Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)
2088: Aging Unevenly: National Trends and Inequities in Osteoarthritis Mortality, 1999–2020
Location: Hall F1
Abstract Poster Presenter: Ghassan Makhoul, MD – St. Joseph's University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2089: Traction Therapy May Improve Hand Function in Those with Distal Interphalangeal Osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Grace Lo, MD, MSc – Baylor College of Medicine / MEDVAMC
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2091: Multiplanar MRI Quantification of Effusion-Synovitis: Reliability and Potential Investigative Utility for Inflammation-Mediated Knee Conditions
Location: Hall F1
Abstract Poster Presenter: Greg Gilles, BS – The University of Arizona Arthritis Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2092: Associations Among Biomarkers, Cytokines, and Ultrasound Features of Knee Osteoarthritis: A Cross-sectional Analysis in the Johnston County Health Study
Location: Hall F1
Abstract Poster Presenter: Jasmine Kimber, BS – University of North Carolina School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2093: Association of Acetaminophen Use with Clinical Outcomes in Older Adults with Osteoarthritis: A Global Propensity-matched Retrospective Cohort Analysis
2094: Evaluating the Accuracy of Knee Acoustic Emissions Classification of Varus Thrust
Location: Hall F1
Abstract Poster Presenter: Kari Falaas, MD – University of Minnesota
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2096: Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-site Randomized Trial
Location: Hall F1
Abstract Poster Presenter: Kimberly Hayes, BA;MA – Teachers College, Columbia University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2097: Trajectories of psychological symptoms during an 18-month Diet + Exercise intervention in overweight or obese adults with osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Lily Alomari, B.S – Kansas City University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2098: Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Natalie Keller, BS, BA – Corporal Michael J. Crescenz VA Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2100: Trabecular Bone Texture is Associated with Structural and Pain Progression in Later Stages of Knee Osteoarthritis: Longitudinal Data from the FNIH OAI Cohort
2101: LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
2105: Stratification for elevated urate identifies a pro-inflammatory synovial fluid proteome in knee osteoarthritis: a pilot study
Location: Hall F1
Abstract Poster Presenter: Tuhina Neogi, MD, PhD – Boston University School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2095: Trends in Mortality and Disability-Adjusted Life Years (DALYs) from Osteoarthritis in the United States Compared to Global Estimates: A GBD-Based Analysis (1990–2021)
Location: Hall F1
Abstract Poster Presenter: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2099: Incidence and Prevalence of Osteoarthritis in the United States Compared to Global Trends: Insights from the Global Burden of Disease Study (1990–2021)
2624: Results of Large Multi-Site Pragmatic Clinical Trial Comparing Corticosteroids or Blinded Lidocaine-only Injections in Treating Osteoarthritis of the Knee
2626: Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)
Location: S102
Presenting Author: Yusuf Yazici, MD – NYU Grossman School of Medicine
Session Coordinator: Polly Ferguson, MD – University of Iowa Carver College of Medicine
CE: 1.50
Sunday, Oct 26th
3:00 PM - 3:15 PM Central Time
0813: Impact of Tirzepatide on Musculoskeletal Pain and High-Risk Analgesic Use Among Non-Diabetic Patients with Overweight or Obesity: A Propensity Score-Matched, Active Comparator, New User Study
0814: Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes
Location: S105
Presenting Author: Tor Olofsson, MD, PhD – Lund University, Skåne University Hosptital
Sunday, Oct 26th
3:30 PM - 3:45 PM Central Time
0815: Neuropathic-like Pain Characteristics Predict Worse Pain Outcomes in Early Rheumatoid Arthritis: a Prospective Cohort Study with Embedded Neuroimaging Evaluation
Pain in Rheumatic Disease Including Fibromyalgia Poster
Location: Hall F1
CE: 0.00
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1243: Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study
Location: Hall F1
Abstract Poster Presenter: Robert Katz, MD – Rush University Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1228: Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Location: Hall F1
Abstract Poster Presenter: Emily Holladay, MPH – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1237: Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
1246: Myo Vs. Myo-fascial Injection for Myofascial Trigger Points. Is There Really a Difference? A Randomized Controlled Trial
Location: Hall F1
Abstract Poster Presenter: seda yildiz, MD – izmir sehir hastanesi
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1222: Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Ahmed Abouelella, MBBCH – College of Human Medicine, Benha University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1229: Extent versus impact: Sex-specific burden of chronic pain in older adults
1236: Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Location: Hall F1
Abstract Poster Presenter: Michael Kaplan, MD – Icahn School of Medicine at Mount Sinai
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1245: Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)
Location: Hall F1
Abstract Poster Presenter: Rubab Rizwan, MD – VBMC,Nuvance Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1231: TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
0408: Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0423: Macrophage activation syndrome-associated proteins and enhanced interferon gamma responsiveness characterize the plasma proteome of patients with Multisystem Inflammatory Syndrome in Children (MIS-C) in a pre-treatment replication single center cohort
Thieves Market Poster Presenter: Christina Gulla, DO – Hackensack University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0393: Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis
0409: Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0410: Improving Outcomes in Patients with Juvenile Idiopathic Arthritis through a Novel Chronic Condition Value-Based Care Program
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0411: Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0426: Tofacitinib in Juvenile Idiopathic Arthritis: efficacy and safety in a clinical practice setting.
0389: An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis
Location: Hall F1
Abstract Poster Presenter: Nicolino Ruperto, MD, MPH – Università Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0401: Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Location: Hall F1
Abstract Poster Presenter: Daniel Lovell, MD, MPH – Cincinnati Children's Hospital Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0415: The Impact of Social Vulnerability Index Scores in Pediatric Uveitis
Location: Hall F1
Abstract Poster Presenter: Minal Aundhia, MD – Cincinnati Children's Hospital Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0396: Quantifying Burden of Uveitis Care for Pediatric Uveitis Patients and Caregivers
Location: Hall F1
Abstract Poster Presenter: Catherine Lavallee, MD – St. Christopher's Hospital for Children
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0398: Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Location: Hall F1
Abstract Poster Presenter: Christina Gulla, DO – Hackensack University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0427: Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts
0406: Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis
Location: Hall F1
Abstract Poster Presenter: Ilaria Maccora, MD, PhD (she/her/hers) – Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0407: The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
Location: Hall F1
Abstract Poster Presenter: Ilaria Maccora, MD, PhD (she/her/hers) – Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0390: Radiographic Assessment in Juvenile Spondyloarthritis: Evaluating the axJSpA Criteria Using Radiographs Alone Versus MRI
Location: Hall F1
Abstract Poster Presenter: Pamela Weiss, MD – Childrens Hospital of Philadelphia
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0391: Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care
0424: Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India
0418: Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis
0397: Paediatric uveitis - Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom
0421: Inflammatory Orbital Diseases: Pediatric Case Series From a Tertiary Care Center
Location: Hall F1
Abstract Poster Presenter: Rasha Elrefai, MD – Baylor College of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0387: Association Between Juvenile Arthritis and Physical Activity Levels in U.S. Children: A Cross-sectional Study Using the 2016–2021 National Survey of Children’s Health
0416: Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting
0428: The OMERACT Juvenile Idiopathic Arthritis MRI Score for Active and Structural Lesions in the Sacroiliac Joints: Development and Validation in Two Longitudinal Cohorts
0422: Clinical Outcomes of Ultrasound Guidance for Corticosteroid Injections of the Ankle and Midfoot Joints and Tendon Sheaths in Children with Juvenile Idiopathic Arthritis
0429: Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Location: Hall F1
Abstract Poster Presenter: Xuemei Tang, MD, Professor, Chief Physician – Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0419: Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results
0403: IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Ekaterina Alexeeva, MD, PhD – National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University)
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0399: External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis
Location: Hall F1
Abstract Poster Presenter: Daniel Horton, MD, MS – Rutgers Robert Wood Johnson Medical School
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0400: Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Location: Hall F1
Abstract Poster Presenter: Daniel Horton, MD, MS – Rutgers Robert Wood Johnson Medical School
Sunday, Oct 26th
2:30 PM - 3:30 PM Central Time
26S48: Endothelial Insights: Mechanisms and Biomarkers of Vasculopathy in Juvenile Dermatomyositis
0819: Subcellular resolution spatial transcriptomics reveals immune-stromal crosstalk within the synovium of patients with juvenile idiopathic arthritis
Location: W183A-C
Presenting Author: Jun Inamo, MD, PhD – University of Colorado School of Medicine
Sunday, Oct 26th
3:15 PM - 3:30 PM Central Time
0820: Novel Autoantibodies Predictive of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus
0822: Clinical and Mechanistic Insight of Circulating Calprotectin and NXP2 autoantibodies in Juvenile Dermatomyositis
Location: W183A-C
Presenting Author: Kavya Sugur, PhD – Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor
Sunday, Oct 26th
4:00 PM - 4:15 PM Central Time
0823: Longitudinal model of paired peripheral blood CITE-seq and skin scRNA-seq data in juvenile systemic sclerosis (jSSc) patients following autologous stem cell transplant (ASCT) reveals reduced expression of SSc marker genes
Location: W183A-C
Presenting Author: Julia Elrod, MS – Carnegie Mellon University
Sunday, Oct 26th
4:15 PM - 4:30 PM Central Time
0824: Characterizing Immune Responses in Abatacept-treated Patients with Limited Juvenile Idiopathic Arthritis
Location: W183A-C
Presenting Author: Lwiza AitDowd, BS – Boston Children's Hospital, Harvard Medical School
Monday, Oct 27th
8:30 AM - 9:30 AM Central Time
27M12: Beneath the Surface: Expert Medical and Surgical Approaches to Difficult Cases in Juvenile Localized Scleroderma
Location: W185A-D
Moderator: Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
1277: Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
Location: Hall F1
Abstract Poster Presenter: Eileen Rife, MD – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1278: Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
Location: Hall F1
Abstract Poster Presenter: Emily Masi, MD, PhD – Cohen Children's Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1279: Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Location: Hall F1
Abstract Poster Presenter: Reagan Reid, MSc – University of Toronto
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1280: Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
1287: A Clear Pattern of Clinical Presentation in Juvenile Systemic Scleroderma Is Associated with Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1288: Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
Location: Hall F1
Abstract Poster Presenter: Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1289: Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Location: Hall F1
Abstract Poster Presenter: Jida Jaffan, MA – The Hospital for Sick Children/ University of Toronto
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1289: Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Location: Hall F1
Abstract Poster Presenter: Jida Jaffan, MA – The Hospital for Sick Children/ University of Toronto
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1290: Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-onset Systemic Lupus Erythematosus (cSLE)
1295: Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Location: Hall F1
Abstract Poster Presenter: Martha Rodriguez, MD – Riley Hospital for Children at Indiana University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1296: Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
1298: Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups
Location: Hall F1
Abstract Poster Presenter: Nellie Butler, BA – Children's Hospital of Philadelphia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1299: Pediatric Antiphospholipid Syndrome in a Large Tertiary Center
Location: Hall F1
Abstract Poster Presenter: Rasha Elrefai, MD – Baylor College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1300: International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
1303: Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases：a Two-sample Mendelian Randomization Study
Location: Hall F1
Abstract Poster Presenter: Xuemei Tang, MD, Professor, Chief Physician – Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1304: The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin - a multicenter study
Location: Hall F1
Abstract Poster Presenter: YOEL Levinsky, MD – Schneider Children's Medical Cnetr of Israel, Tel Aviv University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1305: Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) - a multicenter study
Location: Hall F1
Abstract Poster Presenter: YOEL Levinsky, MD – Schneider Children's Medical Cnetr of Israel, Tel Aviv University
Monday, Oct 27th
1:00 PM - 2:30 PM Central Time
27M35: Abstracts: Pediatric Rheumatology – Clinical I
Location: W183A-C
Abstract Moderator: Pooja Patel, DO – Ann and Robert H. Lurie Children's Hospital of Chicago
1668: A Clinically Validated Assay for Rapid Determination of Type I and Type II Interferon Activity in Pediatric Inflammatory Diseases
Location: W183A-C
Presenting Author: Pui Lee, MD, PhD – Boston Children's Hospital
Monday, Oct 27th
1:15 PM - 1:30 PM Central Time
1669: Development and Validation of Minimal Disease Activity and Disease Flare for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
1671: Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials
Location: W183A-C
Presenting Author: Alexei Grom, MD – Cincinnati Children's Hospital Medical Center
Monday, Oct 27th
2:00 PM - 2:15 PM Central Time
1672: Classification criteria, disease phenotypes and long-term outcomes of childhood Sjögren's Disease into adulthood
1743: Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis
1745: High Emotional Distress Predicts Suboptimal Cardiovascular Health Among Patients with Juvenile-Onset Lupus and Dermatomyositis: Longitudinal Analysis of the Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study
2124: Reliability and Validation of the Physician's Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)
Location: Hall F1
Abstract Poster Presenter: Eileen Rife, MD – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2125: Development and Validation of Minimal Clinically Important Difference for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
2132: The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits
Location: Hall F1
Abstract Poster Presenter: Ayah Eltoum, MD, MPH – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2133: Examination of HLA-DRB1*15-linked Candidate Antigens in Still’s Disease with and without Lung Disease and Features of Drug Hypersensitivity
2134: Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort
Location: Hall F1
Abstract Poster Presenter: Eileen Rife, MD – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2135: Medication Use and Disease Activity in Systemic Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Location: Hall F1
Abstract Poster Presenter: Ginger Janow, MD, MPH – Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2136: Confirming The Validity Of The New EULAR/ACR Classification Criteria For Pediatric Chronic Nonbacterial Osteomyelitis
2137: Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey
Location: Hall F1
Abstract Poster Presenter: Greta Rogani, MD – University Medical Center Utrecht
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2138: Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey
Location: Hall F1
Abstract Poster Presenter: Greta Rogani, MD – University Medical Center Utrecht
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2139: Real-Life Treatment Strategies for Refractory Still’s Disease: Results from a Worldwide Survey, the METAPHOR Project
Location: Hall F1
Abstract Poster Presenter: Greta Rogani, MD – University Medical Center Utrecht
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2140: Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry
2142: Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Location: Hall F1
Abstract Poster Presenter: Hannah Concannon, BS – Duke University School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2143: Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
Location: Hall F1
Abstract Poster Presenter: Janna Shim, DO – Kaiser Permanente San Jose
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2144: The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis
2148: Initial MRI Findings as Predictors of Disease Phenotype in Juvenile Dermatomyositis: A Comparative Study of Myositis Specific Antibodies NXP2-Positive and Myositis Specific Antibody-Negative Patients in a Large Tertiary Hospital
1822: The Circulating Immune Profile of Systemic JIA Patients with HLA-DRB1*15 alleles, Eosinophilia, and Lung Disease
Location: Hall F1
Abstract Poster Presenter: Jennifer Cheng, BA – Boston Children's Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1819: Spatial Transcriptomic Profiling Reveals Interferon Activation and CD8⁺ T Cell Dominance in Systemic Juvenile Idiopathic Arthritis-Macrophage Activation Syndrome Liver Inflammation
Location: Hall F1
Abstract Poster Presenter: Esraa Eloseily, MD, MSc – UT Southwestern Children's Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1820: Cytokine profiling in refractory systemic juvenile idiopathic arthritis reveals distinct signatures for macrophage activation syndrome and lung disease.
Location: Hall F1
Abstract Poster Presenter: Grant Schulert, MD, PhD – Cincinnati Children's Hospital Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1823: Genome-Wide DNA Methylation Analysis in Familial Mediterranean Fever
Location: Hall F1
Abstract Poster Presenter: Kader Cetin Gedik, MD – UPMC Children's Hospital of Pittsburgh/University of Pittsburgh
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1827: Transcriptomics and Machine Learning Unraveling the Molecular Drivers of PFAPA Flares
Location: Hall F1
Abstract Poster Presenter: Sivia Lapidus, MD – Hackensack University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1826: Single Nuclei Multiome of JDM Muscle Biopsies Reveals Novel Upregulation of Inflammatory and Vascular Pathways
Location: Hall F1
Abstract Poster Presenter: Shannon O'Connor, MD, PhD – Cincinnati Children's Hospital Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1824: Tissue-Resident Natural Killer Cells May Drive Monocyte Differentiation And Macrophage Accumulation In The Inflamed Joints Of Pediatric Juvenile Idiopathic Arthritis Patients
Location: Hall F1
Abstract Poster Presenter: Roselyn Fierkens, BS – University of Colorado-Anschutz Medical Campus
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1828: CD14+CXCL10+Monocytes Remodel the Peripheral Immune Network in sJIA via UBE2D1-Driven Inflammatory Programming
Location: Hall F1
Abstract Poster Presenter: Xuemei Tang, MD, Professor, Chief Physician – Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1815: New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential
1814: Trapped in the NET: Impaired DNase function and targeted antibodies in the pathogenesis of pediatric lupus nephritis
Location: Hall F1
Abstract Poster Presenter: Bharati Matta, PhD, MBA – The Feinstein Institutes for Medical Research
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1811: Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
1825: Serum proteomic and single cell RNA sequencing analysis reveals macrophage activation syndrome physiology and widespread complement dysregulation are associated with severe dengue infection in a pediatric cohort
1816: Single-Cell RNA-Transcriptomics of JDM Skin Identifies JDM-Associated Immune Cell Populations and Dysregulated Interferon Signaling in Immune and Endothelial Cells
Periodic Fever Syndromes, Autoinflammatory Diseases, Still’s Disease and MAS/HLH
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Miscellaneous Rheumatic & Inflammatory Diseases Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0237: Monogenic autoinflammatory diseases and undefined autoinflammatory syndrome in Western Mediterranean adults: clinical, genetic, and therapeutic insights
Location: Hall F1
Abstract Poster Presenter: Alba Maria Torrat Noves, MD – Hospital Universitari i Politècnic La Fe de Valencia
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0238: Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Alessia Gatti, MD – University of Brescia
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0239: Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study
Location: Hall F1
Abstract Poster Presenter: Alireza Meysami – Henry Ford Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0240: Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
0241: Efficacy and Safety of JAK Inhibitors in Behçet's Syndrome: A Systematic Literature Review
Location: Hall F1
Abstract Poster Presenter: Bercemhan Sulu, MD (she/her/hers) – Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0242: Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept
0243: Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0244: Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0245: Predictors of Arterial Stiffness in Connective Tissue Diseases: Insights from the Lupus Extended Autoimmune Phenotype (LEAP) Cohort Study
Location: Hall F1
Abstract Poster Presenter: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0246: Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
0256: The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review
Location: Hall F1
Abstract Poster Presenter: Kari Falaas, MD – University of Minnesota
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0257: Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
0258: Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis
Location: Hall F1
Abstract Poster Presenter: Karyssa Stonick, BS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0259: Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
0262: Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders
0266: Chronic PPI Use Association with Development of Autoimmune Conditions: Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Nanuka Tsibadze, MD – Jefferson Health - Einstein
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0267: Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
Location: Hall F1
Abstract Poster Presenter: Nur Barlas, MD – Tulane University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0268: Multicenter study and literature review of JAK inhibitor treatment in refractory uveitis due to different immune-mediated inflammatory pathologies
0277: A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a Chimeric Degradation Activating Compound (CDAC), in Healthy Participants
Location: Hall F1
Abstract Poster Presenter: Vaibhav Mundra, MD – BeOne Medicines USA, Inc.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0278: Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Location: Hall F1
Abstract Poster Presenter: Xiwei Yang, BA – Perelman School of Medicine, University of Pennsylvania
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0279: Assessment of Baseline igg4-rd Disease Characteristics and Impact upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Location: Hall F1
Abstract Poster Presenter: Yoshiya Tanaka, MD, PhD – University of Occupational and Environmental Health, Japan
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0233: Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis
0779: Interim Results of a Randomized Placebo Controlled Study of IL-1 Inhibitor Goflikicept in Patients With Familial Mediterranean Fever
Location: W183A-C
Presenting Author: Serdal Ugurlu, MD – Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology
Sunday, Oct 26th
1:45 PM - 2:00 PM Central Time
0780: Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials
1149: Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study
1153: New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
1154: Assessment of Damage Using the igg4-related Disease Damage Index
Location: Hall F1
Abstract Poster Presenter: Eduardo Martin-Nares, MD, MSc – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1155: Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
1157: Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
Location: Hall F1
Abstract Poster Presenter: Ella Steiner, -None- – Ruhr-University Bochum, Germany
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1158: Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Location: Hall F1
Abstract Poster Presenter: guishan liu, PA – Peking Union Medical College Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1159: IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1163: Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
Location: Hall F1
Abstract Poster Presenter: John Stone, MD, MPH – Massachusetts General Hospital , Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1164: Effect of TNF Inhibitors on the Postprandial Glucose Homeostasis Molecules: Amylin, Gastric Inhibitory Polypeptide, and Pancreatic Polypeptide in Rheumatic Patients
1165: Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
1167: Clinical Characteristics and Outcomes of igg4-related Disease Patients Who Chose Watchful Observation Without Treatment Intervention: A Single-center Study
Location: Hall F1
Abstract Poster Presenter: Kanako Chujo, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1168: Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory
1175: Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Location: Hall F1
Abstract Poster Presenter: Nils Venhoff, MD – Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1176: VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
1186: Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry
1187: Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Tulaton Sodsri, MD – Texas Tech University Health Sciences Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1188: Aortic Wall Shear Stress May Be a Protective Factor Against Development of Spinal Osteoproliferation
Location: Hall F1
Abstract Poster Presenter: Umut Kalyoncu, n/a – Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1189: Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
1662: Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
1665: Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort
Location: S102
Presenting Author: Hanieh Akbari, MD – Jefferson Einstein Montgomery Medical Center
Monday, Oct 27th
2:00 PM - 2:15 PM Central Time
1666: Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
Location: S102
Presenting Author: John Stone, MD, MPH – Massachusetts General Hospital , Harvard Medical School
Monday, Oct 27th
2:15 PM - 2:30 PM Central Time
1667: Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
2016: Effectiveness of Nintedanib combined with different DMARDs in joint and pulmonary domains of Rheumatoid Arthritis - Interstitial Lung Disease. National multicenter study of 74 patients
Location: Hall F1
Abstract Poster Presenter: Ana Serrano-Combarro, MD – Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2017: Baseline and 2-year Follow-up of Pulmonary Function Among CTD-ILD Subtypes
2020: Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial
2021: Can Colchicine Be a Therapeutic Option for Patients with Ankylosing Spondylitis?
Location: Hall F1
Abstract Poster Presenter: Bahaddin Ates, n/a – Cerrahpasa Faculty of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2022: Clinical Predictors of Macrophage Activation Syndrome and Treatment Outcomes in Adult-Onset Still’s Disease: A 24-Year Single-Center Experience
Location: Hall F1
Abstract Poster Presenter: Beste Acar, MD – Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2023: Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Location: Hall F1
Abstract Poster Presenter: CARMEN SECADA-GÓMEZ, MD – HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2024: Racial Disparities in Outcomes Among Patients With Neuromyelitis Optica: A Global Population-Based Study
2031: Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives
2035: Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatologic Disease
2048: DDR2 auto-phosphorylation in patients with Warburg-Cinotti syndrome promotes differentiation of fibroblasts into myofibroblasts and expansion of immature B cells with antibody production.
Location: Hall F1
Abstract Poster Presenter: Sang Jin LEE, n/a – Kyungpook National University School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2049: Descriptive Analysis of a Cohort of Neurosarcoidosis Mimics
29W19: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye
Location: W190A-B
Abstract Moderator: Lesley Ann Saketkoo, MD, MPH – University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris
2663: PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
2665: Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Systemic Lupus Erythematosus – Treatment Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Systemic Sclerosis & Related Disorders – Clinical Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
(TM01–TM11) Pediatric Thieves Market Poster
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
(TM13–TM26) Adult Thieves Market Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Vasculitis – ANCA-Associated Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0049: Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
0050: TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
0057: TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype
0061: IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
0065: Expression and Co-Localization of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues Precedes the Development of Cardiac Fibrosis in Collagen-Induced Arthritis
Location: Hall F1
Abstract Poster Presenter: Wenxian Zhou, BS – University of Nebraska Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0066: RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.
Location: Hall F1
Abstract Poster Presenter: Yidan Wang, MS – Northwestern University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0067: Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
0071: Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.
0072: Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
0073: HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Courtney Myhr, MS – University of Wisconsin-Madison
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0074: Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving ImmuneComplex Formation and Cellular Clearance
0076: Antibodies to Malondialdehyde-acetaldehyde Are Associated with Circulating Inflammatory Mediators During the Preclinical Stages of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Emma Weis, BS – University of Nebraska Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0077: Transformer-based multi-omics study identifies important role of glycine, serine and threonine metabolism pathway in rheumatoid arthritis complicated by anemia
Location: Hall F1
Abstract Poster Presenter: Fanxin Zeng, PhD – Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0078: Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
0084: Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts
Location: Hall F1
Abstract Poster Presenter: Keita Okamoto, MD;PhD – Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0085: Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Kensuke Suga, PhD – Cedars-Sinai Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0086: Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
Location: Hall F1
Abstract Poster Presenter: Kiana Chen, PhD – University of Rochester School of Medicine and Dentistry
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0087: Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms
Location: Hall F1
Abstract Poster Presenter: Laura Muñoz-Barrera, BSc – IMIBIC/Reina Sofia Hospital/University of Cordoba
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0088: Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Lyndsey Cole, MD – University of Colorado School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0089: Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis
0092: SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging
0094: Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
0097: Aberrant Histone Marks Increase the Inflammatory Phenotype of Rheumatoid Arthritis Fibroblast-like Synoviocytes (RA FLS) by Suppressing NUB1 Induction
0146: Association Between Frailty and Delirium and Hospitalization Outcomes Among Older Adults with Rheumatic Diseases
Location: Hall F1
Abstract Poster Presenter: Bhavik Bansal, MBBS – UT Southwestern Medical Centre
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0147: Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations - PREST study
0155: Effect Modification of Cigarette Smoking on the Relationship between Post Traumatic Stress Disorder and Rheumatoid Arthritis Risk
Location: Hall F1
Abstract Poster Presenter: Kelsey Coziahr, MD – University of Nebraska Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0156: Heat Exposure and Acute Care Utilization among Individuals with Rheumatic Conditions: A Time Series Framework for Identifying Delayed Associations
Location: Hall F1
Abstract Poster Presenter: Leah Santacroce, MS – Brigham and Women's Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0157: Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
0158: Association Between Newer COVID-19 Vaccines and COVID-19 Related Hospitalizations Among People with Autoimmune Rheumatic Diseases in the U.S. National COVID Cohort Collaborative (N3C)
0163: Trends in hospitalization and outcomes among patients admitted with Adult-onset Still's disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)
0166: Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination
0169: The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
0173: Association Between the Ratio of Non-high-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol and All-cause Mortality Risk in Patients with Rheumatoid Arthritis: A Survival Analysis Based on NHANES Data
Location: Hall F1
Abstract Poster Presenter: Tingting Wang, n/a – Department of Rheumatology and Immunology, Dazhou Central Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0174: Genetic and Environmental Risk Factors and Incident Rheumatoid Arthritis
0197: Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
0200: Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
0201: Real-World study of immunogenicity and safety of the adjuvant recombinant vaccine against varicella zoster virus in patients with immune-mediated inflammatory diseases treated with Janus Kinase Inhibitors in comparison with healthy individuals
0203: Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
0205: Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Location: Hall F1
Abstract Poster Presenter: Laura Mas Sanchez, MD – Hospital Universitari i Politecnic La Fe
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0206: Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
0207: The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)
0208: Current practices and challenges in tuberculosis screening and preventive treatment among patients with rheumatic diseases: A multiregional physician survey in China
Location: Hall F1
Abstract Poster Presenter: Xu Wang, PhD – Peking Union Medical College Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0209: A Retrospective Safety Analysis Based on Platelets in Arthrocentesis and Joint Injections in Cancer Patients
0237: Monogenic autoinflammatory diseases and undefined autoinflammatory syndrome in Western Mediterranean adults: clinical, genetic, and therapeutic insights
Location: Hall F1
Abstract Poster Presenter: Alba Maria Torrat Noves, MD – Hospital Universitari i Politècnic La Fe de Valencia
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0238: Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Alessia Gatti, MD – University of Brescia
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0239: Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study
Location: Hall F1
Abstract Poster Presenter: Alireza Meysami – Henry Ford Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0240: Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
0241: Efficacy and Safety of JAK Inhibitors in Behçet's Syndrome: A Systematic Literature Review
Location: Hall F1
Abstract Poster Presenter: Bercemhan Sulu, MD (she/her/hers) – Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0242: Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept
0243: Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0244: Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0245: Predictors of Arterial Stiffness in Connective Tissue Diseases: Insights from the Lupus Extended Autoimmune Phenotype (LEAP) Cohort Study
Location: Hall F1
Abstract Poster Presenter: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0246: Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
0256: The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review
Location: Hall F1
Abstract Poster Presenter: Kari Falaas, MD – University of Minnesota
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0257: Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
0258: Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis
Location: Hall F1
Abstract Poster Presenter: Karyssa Stonick, BS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0259: Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
0262: Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders
0266: Chronic PPI Use Association with Development of Autoimmune Conditions: Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Nanuka Tsibadze, MD – Jefferson Health - Einstein
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0267: Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
Location: Hall F1
Abstract Poster Presenter: Nur Barlas, MD – Tulane University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0268: Multicenter study and literature review of JAK inhibitor treatment in refractory uveitis due to different immune-mediated inflammatory pathologies
0277: A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a Chimeric Degradation Activating Compound (CDAC), in Healthy Participants
Location: Hall F1
Abstract Poster Presenter: Vaibhav Mundra, MD – BeOne Medicines USA, Inc.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0278: Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Location: Hall F1
Abstract Poster Presenter: Xiwei Yang, BA – Perelman School of Medicine, University of Pennsylvania
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0279: Assessment of Baseline igg4-rd Disease Characteristics and Impact upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study
Location: Hall F1
Abstract Poster Presenter: Yoshiya Tanaka, MD, PhD – University of Occupational and Environmental Health, Japan
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0280: Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.
0283: The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records
Location: Hall F1
Abstract Poster Presenter: Ana Valle, MD, MHS – Brigham and Women's Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0284: Glucocorticoid Tapering and Relapse Risk in Anti-ARS Antibody-Positive Myositis: A Retrospective Study in a Single-Center Cohort Treated with Immunosuppressants
Location: Hall F1
Abstract Poster Presenter: Ayaka Inoue, MD – Kakogawa Central City Hospital, Kakogawa, Japan.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0285: Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study
0287: Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies
Location: Hall F1
Abstract Poster Presenter: DANIEL CARRILLO VAZQUEZ, MD, MSc – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0288: Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Didem Saygin, MD – Rush University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0289: Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures
Location: Hall F1
Abstract Poster Presenter: Didem Saygin, MD – Rush University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0290: Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
0294: Clinical relevance of low titer positive myositis-specific autoantibodies and myositis-associated autoantibodies in patients with an underlying malignancy.
0295: Multidimensional Analysis of Fatigue in Idiopathic Inflammatory Myopathies: Clinical, Psychological, and Sociodemographic Determinants
Location: Hall F1
Abstract Poster Presenter: Manali Sarkar, MBBS (she/her/hers) – Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0296: Aggregation of HARS1 and Internalized Antibodies in Muscle Biopsies of Patients with Antisynthetase Syndrome and anti-jo1(hars) Autoantibodies
0304: Concordance for myositis-specific autoantibody detection between commercial enzyme-linked immunosorbent assay and line blot assay: a multi-center study across the Asia-Pacific region
Location: Hall F1
Abstract Poster Presenter: Takahisa Gono, MD – Nippon Medical School Graduate School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0305: From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
0338: Fractures and Changes in Bone Mineral Density During Two Years of Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis: A Systematic Literature Review and Individual Participant Data Meta-Analysis
0340: Associations with fragility fractures in a population with inflammatory bowel disease (IBD): An observational study.
Location: Hall F1
Abstract Poster Presenter: Chern Lee Choy, MBBS – University Hospitals of Morecambe Bay NHS Foundation Trust
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0341: Romosozumab in patients with Osteoporosis: Safety and Efficacy analysis in Clinical Practice
Location: Hall F1
Abstract Poster Presenter: Daniel Ramos Castro, MD – Hospital Universitari i Politecnic La Fe
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0342: Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0343: Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0344: Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
0345: Association Between Deprivation and Fracture Risk in a Regional UK Cohort
Location: Hall F1
Abstract Poster Presenter: Hashem Cheema, MBBS BSc MRCP – University Hospitals of Morecambe bay NHS foundation trust
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0346: Fibroblast Growth Factor-23 and Bone Status in Patients with Chronic Kidney Disease Compared to a Healthy Control Group and Its Relationship with Cardiovascular Risk
0347: Identifying Risk Factors for Fragility Fractures in Patients with Coeliac Disease: An Observational Study
Location: Hall F1
Abstract Poster Presenter: Kabyar Cho, MBChB, BSc – University Hospitals of Morecambe Bay NHS Foundation Trust
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0348: Correlation between Bone Mineral Density by Dual-energy X-ray Absorptiometry at the Radius and Radius Cortical Bone Thickness using Routine Hand Radiographs in Rheumatoid Arthritis Patients
0354: Greater Neighborhood Walkability is Associated with Lower Incidence of Hip Fracture in Older, Community-dwelling Women in the United States: The Cardiovascular Health Study
0360: Assessing Content Validity of a New Questionnaire Evaluating Glucocorticoid Toxicity
Location: Hall F1
Abstract Poster Presenter: John Stone, MD, MPH – Massachusetts General Hospital , Harvard Medical School
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0361: Transition in Focus: Health Care Utilization and Disease Status in Youth with Connective Tissue Diseases— A Single-Center Experience in British Columbia, Canada
0370: Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
0375: Association of Glucocorticoid Toxicity Index Scores with Quality-of-life and Healthcare Resource Utilization at 6 Months in a Real-world Cohort of Individuals Receiving Glucocorticoids
0376: An Internet-delivered, Arthritis-tailored Cognitive Behavioral Therapy for Insomnia Program for People with Co-morbid Sleep Disturbance: Comparing Baseline Characteristics of Cannabis Users and Non-users
0380: Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
0381: Improving Participation in The Lupus Foundation of America’s Research Accelerated by You (RAY) Patient Registry By Understanding Patient Preference in Communication Strategies
0382: Preventative Health Screening Practices Among 666 Women with Systemic Rheumatic Diseases from the Hospital for Special Surgery Rheumatology Women’s Reproductive Health and Wellness Cohort: A Cross-Sectional Analysis
0408: Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0423: Macrophage activation syndrome-associated proteins and enhanced interferon gamma responsiveness characterize the plasma proteome of patients with Multisystem Inflammatory Syndrome in Children (MIS-C) in a pre-treatment replication single center cohort
0430: Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD
Location: Hall F1
Abstract Poster Presenter: ender terzioglu, MD – Akdeniz University Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0431: Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
0433: In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022
0434: The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice
Location: Hall F1
Abstract Poster Presenter: Meliha Kapetanovic, MD,PhD – Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0436: Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?
0439: Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort
0448: Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
Location: Hall F1
Abstract Poster Presenter: Ioannis Koulas, MD, MSc – Jacobi Medical Center/Albert Einstein College of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0449: Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
Location: Hall F1
Abstract Poster Presenter: Joel Kremer, MD – The Corrona Research Foundation
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0450: The Fibrosis-4 Index (FIB-4) Correlates with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis
0454: Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights
0455: Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active Psoriatic Arthritis
0460: The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Ryan Salama, BA – University of Minnesota Twin Cities
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0461: Right Diagnoses For the Wrong Reasons: Limitations of Current Large-Language Model based Agentic Frameworks for Screening of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Sarthak Verma, MD (he/him/his) – Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0462: Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?
0463: Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Location: Hall F1
Abstract Poster Presenter: Solana Cushing, BA – Icahn School of Medicine at Mount Sinai
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0464: Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty
Location: Hall F1
Abstract Poster Presenter: Solana Cushing, BA – Icahn School of Medicine at Mount Sinai
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0465: Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Location: Hall F1
Abstract Poster Presenter: Suchita Nety, PhD – Harvard Medical School
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0466: Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
Location: Hall F1
Abstract Poster Presenter: Tulsi Joishy, PhD – Vanderbilt University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0467: A Machine Learning Classifier Leveraging anti-ra33, anti-pad4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA
0470: Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
0471: An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 anti-cd19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA Positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
Location: Hall F1
Abstract Poster Presenter: Ioanna Minopoulou, MD;MSc – Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0472: Detrimental Effects of Umbilical Cord Blood-derived Mesenchymal Stem Cells Intra-articular Injections on Pannus Invasiveness
0477: At the patient level, ultrasound evaluation during the follow up of rheumatoid arthritis does not modify radiographic evolution: a prospective, multicenter, randomized, pragmatic clinical trial (BCD study)
0478: Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
0481: Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
0486: Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0487: Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0488: Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
0490: Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted - DMARD in RA: A Systematic Review and Network Meta-analysis
Location: Hall F1
Abstract Poster Presenter: Jia Li, MD, PhD (she/her/hers) – Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0491: Association Of short Chain Fatty Acids and diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
0494: LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
0495: Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
0496: Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
0497: Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Location: Hall F1
Abstract Poster Presenter: Nariaki Hao, PhD – Graduate School of Medical and Dental Sciences, Niigata, Japan
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0498: Pharmacokinetic Similarity of DRL_AB, a Proposed Biosimilar Abatacept (Orencia®): Results from a Randomized, Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study in Healthy Subjects by the Intravenous Route.
0499: Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Location: Hall F1
Abstract Poster Presenter: Roy Fleischmann, MD – Metroplex Clinical Research Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0500: Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Location: Hall F1
Abstract Poster Presenter: Sama Hajizadeh, MD – Allegheny Health Network
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0501: Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety
0514: Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Location: Hall F1
Abstract Poster Presenter: Nicholas Bauer, BS – Oklahoma Medical Research Foundation
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0518: Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
0555: Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
0556: Evaluating the Efficacy of Sulfasalazine Compared to Placebo in the Treatment of Psoriatic Arthritis in Adults: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0557: Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
0558: Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Location: Hall F1
Abstract Poster Presenter: Monica Leung, n/a – Johnson & Johnson, San Diego, CA, USA
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0559: Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
Location: Hall F1
Abstract Poster Presenter: Nehal Mehta, MD MSCE – The George Washington University School of Medicine and Health Sciences
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0560: Single Cell Sequencing Analysis of Tumour Necrosis Factor Inhibitor Drug Response Reveals Enrichment of Pro-inflammatory Pathway in Non-responders and Amino Acid Metabolic Pathways in Responders
0561: Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Location: Hall F1
Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0562: Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0563: Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0564: Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Location: Hall F1
Abstract Poster Presenter: Alice Gottlieb, MD, PhD – Icahn School of Medicine at Mount Sinai
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0565: Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
0567: Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Location: Hall F1
Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0568: Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
0570: Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
0571: Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Jaejoon Lee, MD;PhD – Samsung Medical Center, Sungkyunkwan University School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0572: Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
0573: Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
0574: Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
0577: Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
0578: Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0579: Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0580: Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0581: Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0582: Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Location: Hall F1
Abstract Poster Presenter: Prabhu Vasantha Kumar, MD, DM – GKNM Hospitals & Research Institute, Coimbatore, Tamil Nadu, India
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0583: Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
0584: Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
0585: Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
0590: Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
0591: An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-world Clinical Practice
0592: An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-world Clinical Practice
0599: Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Aakash Patel, MD – Massachusetts General Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0600: Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
0601: Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
0602: Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
Location: Hall F1
Abstract Poster Presenter: Ami Vyas, PhD – University of Rhode Island
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0603: Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
Location: Hall F1
Abstract Poster Presenter: Amir Daneshvar, MD – University Hospitals Cleveland Medical Center/Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0604: Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus
0605: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
0611: Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0612: Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0614: Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
Location: Hall F1
Abstract Poster Presenter: Ileana Cecilia Reynosa Silva, MD – Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0615: Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
Location: Hall F1
Abstract Poster Presenter: Jacob Klein, MD – Ohio State University Wexner Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0618: Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study
Location: Hall F1
Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0619: Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Location: Hall F1
Abstract Poster Presenter: Luciana Seguro, MD, PhD – Hospital das Clínicas HCFMUSP, University of Sao Paulo
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0620: The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
0622: Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
0623: Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
0625: DNA methylation patterns in systemic lupus erythematosus associated with nephritis status
Location: Hall F1
Abstract Poster Presenter: Meghan Nelson, DO – National Institutes of Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0626: Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
Location: Hall F1
Abstract Poster Presenter: Nalani Sachan, PhD – NYU Grossman School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0627: Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
Location: Hall F1
Abstract Poster Presenter: Omer Pamuk, MD – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0628: Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Panagiotis Garantziotis, MD – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0630: Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus
0632: Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients with Systemic Lupus Erythematosus and Diabetes: A Propensity-Matched Retrospective Cohort Study
0634: Association of Lifestyle and Integrative Health Practices with Health-related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease
0640: Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
0642: Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Location: Hall F1
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0644: Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Location: Hall F1
Abstract Poster Presenter: Joan Merrill, MD – Oklahoma Medical Research Foundation
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0645: Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-week Results from a Phase 3 Trial
0649: Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
0650: Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Location: Hall F1
Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0651: The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Braden Zeno, BS – Ohio State University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0652: Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
0653: In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at Their Clinical Dose Regimens
0654: Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Location: Hall F1
Abstract Poster Presenter: Ed Vital, MD – University of Leeds
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0655: Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Location: Hall F1
Abstract Poster Presenter: Eric Roberts, PhD, MPH – University of California, San Francisco
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0656: Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
0657: Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
Location: Hall F1
Abstract Poster Presenter: FNU Ruchi, MD – SUNY Upstate Medical University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0659: Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
0660: Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
0662: Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
0664: Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
0665: Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
0666: Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
0669: Clinical and Laboratory Factors Associated With Biopsy-Confirmed Antimalarial-Induced Cardiomyopathy
Location: Hall F1
Abstract Poster Presenter: Youngmin Kim, MD – Brigham and Women's Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0670: Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
0672: Determinants of Progressive Microstomia in Systemic Sclerosis: Insights from the GENISOS Cohort with a Focus on GI Involvement
Location: Hall F1
Abstract Poster Presenter: Ashish Balar, MBBS, MPH – The University of Texas Health Science Center Houston
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0673: Association Between Vasoactive-vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence from a EUSTAR Study
0675: Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.
0676: Engineered glove for the objective assessment of hand dexterity in patients with systemic sclerosis: correlations with clinical features, nailfold videocapillaroscopy, and high frequency skin ultrasonography
Location: Hall F1
Abstract Poster Presenter: Elvis Hysa, MD – University of Genova
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0677: Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
0678: Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
Location: Hall F1
Abstract Poster Presenter: Wolfgang Merkt, MD – University Hospital Düsseldorf
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0679: Inhibition of TGFb3 in Systemic Sclerosis Patients Does Not Result in TGFb Pathway Modulation in Skin Biopsies or Circulation
0681: Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis
0686: Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Location: Hall F1
Abstract Poster Presenter: Ariane Herrick, MD – The University of Manchester, UK
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0687: Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification
Location: Hall F1
Abstract Poster Presenter: Arjun Mahajan, MS – Harvard Medical School
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0688: Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Location: Hall F1
Abstract Poster Presenter: Benjamin Chaigne, MD, PhD – Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0689: Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment
0690: Quantitative 18F-FDG PET-CT of the lungs detects treatment induced changes in patients with early severe diffuse cutaneous systemic sclerosis and interstitial lung disease
Location: Hall F1
Abstract Poster Presenter: Bo Broens, MD – Amsterdam UMC
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0691: Association of Elevated Platelets and CRP with Severe Disease and Poor Survival in Systemic Sclerosis
0692: A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with No Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
0693: Impact of X Chromosome Dosage on the Development of Diffuse and Limited Systemic Sclerosis in Klinefelter, Triple X, and Turner Syndromes: A Multicenter Cohort Study
Location: Hall F1
Abstract Poster Presenter: Hanieh Akbari, MD – Jefferson Einstein Montgomery Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0694: Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
0705: Multimodal Imaging Evaluation of Patients with Raynaud's Phenomenon meeting the Criteria for "Early" Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
0708: Association of Choroidal Sub-foveal Thickness with Skin Manifestations and Serum Monocyte HDL Ratio in Patients with Systemic Sclerosis-a Case Control Study
0709: Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
Location: Hall F1
Abstract Poster Presenter: Tracy Frech, MD, MS – Vanderbilt University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0710: Vascular Events in Systemic Sclerosis Patients with Anti-Phospholipid Antibodies
Location: Hall F1
Abstract Poster Presenter: Vivian Shing, BS – Mayo Clinic Alix School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0731: The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Jean-Paul Makhzoum, MD, FRCPC, MSc, FACP – Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0732: Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)
0739: Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Location: Hall F1
Abstract Poster Presenter: CARMEN SECADA-GÓMEZ, MD – HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0740: Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Location: Hall F1
Abstract Poster Presenter: CARMEN SECADA-GÓMEZ, MD – HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0741: Characteristics of African American vs. Non-African American Patients with Giant Cell Arteritis: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Dana Nachawati, DO – University Hospitals Cleveland Medical Center/Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0742: Exploring Racial Variation in the Clinical Manifestations of Giant Cell Arteritis: A Retrospective Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Dana Nachawati, DO – University Hospitals Cleveland Medical Center/Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0743: Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
0760: The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Sema Kaymaz-Tahra, MD – Bahcesehir University Faculty of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0762: Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers
0763: Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience
Location: Hall F1
Abstract Poster Presenter: Wendy Perdomo, MD – Thomas Jefferson University Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0764: Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery - Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-
0769: Increased Gait Variability at Preferred Walking Speeds is Associated with Increased Physical Activity Measures in People with Knee Osteoarthritis
0770: Interrelationships of Depression, Pain, and Gait Mechanics and their Associations with Physical Activity Levels Among People with Knee Osteoarthritis
0233: Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis
0219: Increased Engagement With the RISE Registry Clinician Dashboard Is Associated With Improving Performance on Some but Not All Rheumatology Quality Measures
0393: Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis
0442: Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Location: Hall F1
Abstract Poster Presenter: Charis Meng, MD – Hospital for Special Surgery
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0506: Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren's Disease Using High-content Human Proteome Arrays
Location: Hall F1
Abstract Poster Presenter: A. Darise Farris, PhD – Oklahoma Medical Research Foundation
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0553: Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
Location: Hall F1
Abstract Poster Presenter: Zeyu Tang, MD – Yale School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0018: Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases
0223: Timely Dermatologic Diagnosis and Management Changes in Systemic Collagen Vascular Diseases: Experiences from the Rheumatology-Dermatology Combined Clinic
Location: Hall F1
Abstract Poster Presenter: Jeanie Lee, MD – Montefiore Einstein Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0306: Direct Assessment of Intestinal Permeability as a Risk Factor for Multiple Joint Osteoarthritis in Community Cohorts of Humans and Pet Dogs
0538: Development of an Artificial Intelligence Tool for Lesion Detection in Axial Spondyloarthritis patients with Active Sacroiliitis on Magnetic Resonance Imaging
0013: Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
Location: Hall F1
Abstract Poster Presenter: Minyun Zhou, PhD – Simcere Pharmaceutical Group
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0021: Doctis: A Single Cell Rna-seq Atlas of Drug Response to Targeted Therapies
Location: Hall F1
Abstract Poster Presenter: Antonio Julià, PhD – Vall d'Hebron Hospital Research Institute
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0127: Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease
0177: Artificial Intelligence in Adult and Paediatric Rheumatology Practice and Research: Pilot Results from an International Survey
Location: Hall F1
Abstract Poster Presenter: Ana Isabel Rebollo-Giménez, MD – Department of Rheumatology, Gregorio Marañón University Hospital, Gregorio Marañón Health Research Institute
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0224: Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients: Post-Intervention Analysis
Location: Hall F1
Abstract Poster Presenter: John Hickernell, MD – Loyola University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0308: Artificial Intelligence Assisted Extraction of Patient-reported Pain Outcomes in Osteoarthritis Using Prompt Engineering of Large Language Models
Location: Hall F1
Abstract Poster Presenter: Bella Mehta, MD, MS, MBBS – Hospital for Special Surgery, Weill Cornell Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0409: Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0524: Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors
Location: Hall F1
Abstract Poster Presenter: Servet Akar, MD – Izmir Katip Çelebi University School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0719: A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis
0724: Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis - Results from Real-World Data
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0016: Pharmacology Analyses of Sail’s In Vivo hCD19 CAR-T Product Reveal Mechanistic Insights Underlying its Optimal Dose Efficiency Profile in Both Healthy Donors and SLE Patient Samples
0210: Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
Location: Hall F1
Abstract Poster Presenter: Akhil Sood, MD, MS – Washington University in St. Louis
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0218: Creating an EHR Lupus Outreach Workbench to Address Care Gaps
Location: Hall F1
Abstract Poster Presenter: Christie Bartels, MD, MS – University of Wisconsin School of Medicine and Public Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0311: Time series analysis of continuous accelerometry data to determine the impact of symptomatic multiple joint osteoarthritis (MJOA) in the naturally occurring canine model
Location: Hall F1
Abstract Poster Presenter: Liubov Arbeeva, MSc – University of North Carolina, Chapel Hill
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0411: Outcomes in Juvenile Idiopathic Arthritis Based on Geographic Region in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0513: Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
0545: Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis
0723: Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab
Location: Hall F1
Abstract Poster Presenter: Michele Moretti, MD – University of Pisa, Rheumatology Unit
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0031: Meta-Analysis of Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium
Location: Hall F1
Abstract Poster Presenter: Kevin Bu, MD;PhD – Icahn School of Medicine at Mount Sinai
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0140: Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study
0532: Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
0711: Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
0319: Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Danielle Madison, DO – Lakeland Regional Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0389: An International Delphi Survey for the Definition of New Classification Criteria for Juvenile Idiopathic Arthritis
Location: Hall F1
Abstract Poster Presenter: Nicolino Ruperto, MD, MPH – Università Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0540: Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
Location: Hall F1
Abstract Poster Presenter: Manouk de Hooge, PhD – Ghent University Hospital & Leiden University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0728: Incidence and Clinical Characteristics of ANCA-Associated Vasculitis: A Nationwide Study in Spain
0045: Genetic regulators of corticosteroid response in hepatic and adipose tissue and risk of adverse metabolic outcomes in patients with rheumatoid arthritis initiating glucocorticoids.
0317: “No Matter How Great My Doctor Is, He Hasn't Had a Knee Replacement, He Doesn't Understand All That Pain” Program Evaluation of the Moving Well Peer Coach Intervention for Total Knee Replacement
0713: Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms
Location: Hall F1
Abstract Poster Presenter: Adil Vural, MD – Cleveland Clinic
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0014: NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Location: Hall F1
Abstract Poster Presenter: Mira Tohmé, PhD – nkarta therapeutics
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0046: Association of Genetic Variation inxist and Ftx with Susceptibility to Female-biased Systemic Autoimmune Disease
0136: Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
Location: Hall F1
Abstract Poster Presenter: Ritesh Kumar Mishra, MD – JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0187: Message Testing in Online Recruitment Advertisements for a National Rheumatoid and Psoriatic Arthritis Study
0225: Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Location: Hall F1
Abstract Poster Presenter: Juan Schmukler, MD – Rush University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0309: A Composite Cumulative Cartilage Damage Metric Predicts Incident Symptomatic Knee OA: Data from the Osteoarthritis Initiative
0006: QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
0026: Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis
Location: Hall F1
Abstract Poster Presenter: Andrea-Hermina Györfi, MD – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0123: Prognosis of Cardiac Involvement in Antiphospholipid Syndrome
0314: What changes in quality of life can be observed in patients with knee or hip OA prior to total hip or total knee replacement surgery ? data from the KHOALA cohort
0396: Quantifying Burden of Uveitis Care for Pediatric Uveitis Patients and Caregivers
Location: Hall F1
Abstract Poster Presenter: Catherine Lavallee, MD – St. Christopher's Hospital for Children
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0519: A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren's Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Shu Liu, n/a – Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0547: Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
0125: The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0185: Promoting Health Services Research Rigor and Reproducibility using CodeMapper: A novel tool for harmonization, collaboration, and precision
Location: Hall F1
Abstract Poster Presenter: Emily Holladay, MPH – University of Alabama at Birmingham
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0226: Integration of the 5Ms of Geriatrics in a Novel Geri-Rheumatology Clinic
0398: Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Location: Hall F1
Abstract Poster Presenter: Christina Gulla, DO – Hackensack University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0552: Radiographic Sacroiliitis Progression in Psoriatic Arthritis
0730: Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
0100: Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Location: Hall F1
Abstract Poster Presenter: Beatriz Vellón-García, MSc – Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0109: Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
0211: Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration
0427: Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts
0523: SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
0616: Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study
0726: Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
0320: Transcriptomic profiling of the skeletal muscle of knee OA patients uncovers elevated glucocorticoid and GABA signaling as mediators of skeletal muscle dysfunction in advanced disease
0133: Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Location: Hall F1
Abstract Poster Presenter: Maria Tektonidou, PhD – National and Kapodistrian University of Athens
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0310: Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO
0313: People with Knee Osteoarthritis Infrequently Seek Medical Care for Arthritis, Even Those With Severe Disease
Location: Hall F1
Abstract Poster Presenter: Shunshun Yan, MD – Baylor College of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0390: Radiographic Assessment in Juvenile Spondyloarthritis: Evaluating the axJSpA Criteria Using Radiographs Alone Versus MRI
Location: Hall F1
Abstract Poster Presenter: Pamela Weiss, MD – Childrens Hospital of Philadelphia
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0507: Diagnostic performance of the lacrimal and salivary gland ultrasound in patients with primary Sjogren's disease of recent onset versus sicca controls.
0391: Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care
0118: Single-cell RNA sequencing of skin reveals vascular dysregulation in antiphospholipid syndrome
Location: Hall F1
Abstract Poster Presenter: Ecem Sevim, MD – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0402: Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
0033: Development and Internal Validation of Two Human Leukocyte Antigen Genetic Risk Scores for Predicting Rheumatoid Arthritis Progression and Anti-Citrullinated Protein Antibody-Positivity
0536: Can achieving sustained low disease activity through treat-to-target management arrest enthesiophyte progression in psoriatic arthritis? A two-year prospective study using high resolution peripheral quantitative computed tomography
Location: Hall F1
Abstract Poster Presenter: Isaac Cheng, PhD – The Chinese University of Hong Kong
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0037: A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/differentiation Factor 15 (GDF-15) Improves Prediction of All-cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
0124: Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Location: Hall F1
Abstract Poster Presenter: Haoyu Pan, MD – Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0307: Cytokine Profiling of Molecular Endotypes of Knee Osteoarthritis: Insights from the IMI-APPROACH cohort
0539: Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort
Location: Hall F1
Abstract Poster Presenter: Liese de Bruin, MSc – Leiden University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0025: Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Location: Hall F1
Abstract Poster Presenter: Elio Carmona, PhD – University of Pittsburgh, School of medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0139: When One Isn't Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
0424: Juvenile Idiopathic Arthritis Mimics: A Case Series on Progressive Pseudo-Rheumatoid Dysplasia and CACP Syndrome in Pediatric Patients from a Tertiary Center in South India
0528: Apolipoprotein A1 and B Levels Indicate Specific Lipid Changes in Early Treatment Naïve Psoriatic Arthritis and Correlate with 1-year Disease Activity
0009: MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
Location: Hall F1
Abstract Poster Presenter: Marisa Peluso, MS – Monte Rosa Therapeutics
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0035: Clinical and Transcriptomic Heterogeneity in Patients With RA: A Multi-Centric International Study of Anti-TNF Response
0221: A Multimodal Intervention Improves the Quantity and Quality of Disease Activity Measures Collection in a Multi-centered National Rheumatoid Arthritis Network
Location: Hall F1
Abstract Poster Presenter: Grant Cannon, MD – University of Utah and Salt Lake City VA
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0333: Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees
0533: Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission
Location: Hall F1
Abstract Poster Presenter: Avarna Agarwal, MD (she/her/hers) – Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0631: Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow up in an Inception Cohort of SLE (INSPIRE) from India
0418: Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis
0397: Paediatric uveitis - Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom
0546: Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
0387: Association Between Juvenile Arthritis and Physical Activity Levels in U.S. Children: A Cross-sectional Study Using the 2016–2021 National Survey of Children’s Health
0416: Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting
0428: The OMERACT Juvenile Idiopathic Arthritis MRI Score for Active and Structural Lesions in the Sacroiliac Joints: Development and Validation in Two Longitudinal Cohorts
0114: A Rare Variant in the extl3 Gene Is Associated with Altered Wnt Signaling Pathway in a Novel Mouse Model of Axial Spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0144: Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
0186: Validation of Asynchronous Telehealth Visit for Adults and Children with Inflammatory Arthritis and Feasibility of Applying Thermal Imaging during Visits
0222: Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey
0422: Clinical Outcomes of Ultrasound Guidance for Corticosteroid Injections of the Ankle and Midfoot Joints and Tendon Sheaths in Children with Juvenile Idiopathic Arthritis
0508: Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
0542: Transition from Psoriasis to Psoriatic Arthritis: Does Family History Influence the Time to Onset of Arthritis in Psoriasis Patients?
Location: Hall F1
Abstract Poster Presenter: Marta Flores, MD – University of Cordoba
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0429: Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Location: Hall F1
Abstract Poster Presenter: Xuemei Tang, MD, Professor, Chief Physician – Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0419: Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results
0220: National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration
0120: The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Location: Hall F1
Abstract Poster Presenter: Emre Sahin, MD – Hospital for Special Surgery
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0198: Variation in RA disease activity measure assessment and treatment change documentation in virtual vs in-office rheumatology visits
0325: Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)
0515: Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
Location: Hall F1
Abstract Poster Presenter: Nikolaos Marketos, MD, MSc, PhD – Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Greece
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0520: Implementation of Salivary Gland Ultrasound by General Radiology can Improve Detection of Glandular Inflammation in Patients with Sicca
Location: Hall F1
Abstract Poster Presenter: Stephanie Lee, MD (she/her/hers) – University of Pennsylvania and Children's Hospital of Philadelphia
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0529: Anti-peptidylarginine deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Ana-Maria Orbai, MD, MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0617: Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
0121: The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
Location: Hall F1
Abstract Poster Presenter: Emre Sahin, MD – Hospital for Special Surgery
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0181: Launch of the National Tele-Rheumatology Program (NTRP) to Expand Rheumatology Care to Rural Veterans
0217: Development of the American College of Rheumatology Implementation Guide for Integrating Patient Reported Systemic Lupus Erythematosus Quality Measures
0318: Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study
Location: Hall F1
Abstract Poster Presenter: Cheng Li, MBBS – Central south university
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0403: IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Ekaterina Alexeeva, MD, PhD – National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University)
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0509: Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
Location: Hall F1
Abstract Poster Presenter: R. Hal Scofield, MD – Oklahoma Medical Research Foundation
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0526: Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
Location: Hall F1
Abstract Poster Presenter: Yoon-Jeong Oh, MD – Uijeongbu Eulji Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0720: Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials
0043: Single-cell and Spatial Transcriptomic Profiling of Muscle Reveals Inflammatory Mechanisms in Anti-glycyl tRNA Synthetase Syndrome
Location: Hall F1
Abstract Poster Presenter: Takuya Harada, MD – Japan Institute for Health Security
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0105: Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
0183: Optimizing the Clinical Application of Rheumatology Guidelines Using Large Language Models: A Retrieval-Augmented Generation Framework Integrating EULAR and ACR Recommendations
0722: Estimating two-year risk of relapse in individuals with ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids
0101: Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Benjamin Cai, BS – Frazer Institute, The University of Queensland
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0137: Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
Location: Hall F1
Abstract Poster Presenter: Ritesh Kumar Mishra, MD – JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0184: Neurocognitive Complications of Lupus: A Multidisciplinary Program Model for Advanced Diagnostics, Management, and Clinical Research
0327: Structural Severity Assessment of Hand Osteoarthritis Using Radiomic Analysis: Correlation with the Kellgren-Lawrence Score – Results from the DIGICOD Cohort
0957: Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc
Location: Hall F1
Abstract Poster Presenter: Astrid Hofman, MSc – Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0958: Asynchronous Resolution of Inflammation and Fibrosis in a Prolonged Experimental Model Suggests Distinct Temporal Dynamics and Resolution Mechanisms in Systemic Sclerosis
0959: Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
0960: Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Cuong Tran Manh, PhD (he/him/his) – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0961: Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis
Location: Hall F1
Abstract Poster Presenter: Cuong Tran Manh, PhD (he/him/his) – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0962: Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Location: Hall F1
Abstract Poster Presenter: Dennis Bleck, PhD (he/him/his) – University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0964: A Single-cell Atlas Reveals Dermal Endothelial Heterogeneity and Disease-specific Pathways in Autoimmune Disorders
Location: Hall F1
Abstract Poster Presenter: Jinyi Qian, -None- – Shanghai Jiao Tong University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0965: Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
0966: Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset
0973: Effects of a Novel Hybrid Protein Based on S100 on Macrophage Polarization and Its Therapeutic Efficacy in a Bleomycin-Induced Systemic Sclerosis Mouse Model.
Location: Hall F1
Abstract Poster Presenter: Takuya Kotani, MD, PhD – Osaka Medical and Pharmaceutical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0974: Tissue resident macrophages derived from induced pluripotent stem cells induce tissue fibrosis in human skin equivalent models of systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Xuezhi Hong, MD – Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0975: Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
Location: Hall F1
Abstract Poster Presenter: Xuezhi Hong, MD – Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0976: LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
0982: Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases
Location: Hall F1
Abstract Poster Presenter: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0983: Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
0987: S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
0990: An Fc-engineered Agonistic anti-pd-1 Antibody Selectively Depletes pd-1+ Cells and Attenuates T Cell Activation in vitro and in vivo in a Xenogeneic Graft-versus-host Disease (GvHD) Model
0991: MTHFD2 is a Novel Metabolic Target in Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Laura McMillan – Sitryx Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0992: FoxP3Lo CD4+ T cells are functionally suppressive and expanded in the immune-mediated fibrotic diseases IgG4-related disease and systemic sclerosis
0993: NOD2 mutations mediate IL-17 predisposition in patients with Blau syndrome
Location: Hall F1
Abstract Poster Presenter: Leah Huey, BS – Oregon Health & Science University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0994: UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases
1000: A Deep-learning Based Approach Uncovers Novel Mediators of Micro-rna Restraint of type-2 Immunity
Location: Hall F1
Abstract Poster Presenter: Shaan Sekhon, BA – CNU College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1001: LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Location: Hall F1
Abstract Poster Presenter: Xiao Huang, MS – Leads Biolabs
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1002: ATF3 Inhibits Pulmonary Fibrosis via CD4+CD25−LAG3+ T Cells
Location: Hall F1
Abstract Poster Presenter: Xiao Zhang, n/a – The Eighth Affiliated Hospital of Sun Yat-sen University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1003: Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology
Location: Hall F1
Abstract Poster Presenter: Yan Zhang, PhD – Capstan Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1004: Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Location: Hall F1
Abstract Poster Presenter: Yang Yang, PhD – Boston Children's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1005: CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
1008: Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Location: Hall F1
Abstract Poster Presenter: Ahmet Gül, MD – Istanbul University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1009: Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
1010: Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Patients with Rheumatoid Arthritis: A Systematic Literature Review
1011: Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Location: Hall F1
Abstract Poster Presenter: Ethan Eickmann, BA – Brigham and Women's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1012: Racial and Gender Disparities in Gout Clinical Trials
1017: Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network
1018: Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
1019: Associations Between Mental Health Diagnoses and Acute Care Use Among Individuals with Systemic Lupus Erythematosus in the All of Us Research Program
Location: Hall F1
Abstract Poster Presenter: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1020: Cohort Study of European Ancestry, Geographic Region, Ambient Ultraviolet Irradiance and the Risk of Developing Polymyalgia Rheumatica among Women
Location: Hall F1
Abstract Poster Presenter: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1021: Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
1027: GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
1028: Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts
1031: Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
Location: Hall F1
Abstract Poster Presenter: Satani Sharkas, MD – Boston Medical Center - Brighton
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1032: Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
Location: Hall F1
Abstract Poster Presenter: Sharan Rai, PhD – Massachusetts General Hospital, Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1033: Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort
1035: Demographic and Clinical Correlates of 30 day Re-admission or Death During Admission in Patients With Rheumatologic Conditions : A Retrospective Cohort Analysis in a Single Academic Center
1037: Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Zixing Liu, MS – Johns Hopkins University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1057: Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness
1083: How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?
1088: Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1089: Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1090: Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
1092: Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Location: Hall F1
Abstract Poster Presenter: Binod Kc, MBBS – SUNY Upstate Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1093: Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Blake Baay, BS – UT Southwestern
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1094: Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1095: Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
1096: Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.
Location: Hall F1
Abstract Poster Presenter: Elisabet Perea-Martínez, MD – Rheumatology section, Hospital General Universitario de Elda
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1097: Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Location: Hall F1
Abstract Poster Presenter: Elvis Hysa, MD – University of Genova
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1098: Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Location: Hall F1
Abstract Poster Presenter: Francisco Arias, MD – University of Texas Rio Grande Valley
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1099: Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Location: Hall F1
Abstract Poster Presenter: Grace Haeun Lee, BA – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1100: Associations Between Pre-existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
1101: Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Heba Altarawneh, MD – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1102: Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Location: Hall F1
Abstract Poster Presenter: Julia Barasch, MD – Weill Cornell - New York Presbyterian
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1103: Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Location: Hall F1
Abstract Poster Presenter: Kayla Chubbs, MD – Dalhousie University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1104: Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1105: Association Between Pre-existing Rheumatoid Arthritis and Immune-related Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1106: Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Location: Hall F1
Abstract Poster Presenter: KO JEN LEE, MD, PhD – National Taiwan University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1107: Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1108: Baseline Features, Immunosuppression, and Immune-related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1109: Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
1113: Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Location: Hall F1
Abstract Poster Presenter: Qi Wang, MD – Metrohealth System/Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1114: Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Location: Hall F1
Abstract Poster Presenter: Qiang Xu, n/a – Guangzhou University of Traditional Chinese Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1115: Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Location: Hall F1
Abstract Poster Presenter: Samuel Bitoun, MD, PhD – Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1116: Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
1118: Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
1120: Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
Location: Hall F1
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1121: Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: Tao Ming Sim, MBBS – National University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1121: Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: Tao Ming Sim, MBBS – National University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1122: A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-related Problems
1149: Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study
1153: New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
1154: Assessment of Damage Using the igg4-related Disease Damage Index
Location: Hall F1
Abstract Poster Presenter: Eduardo Martin-Nares, MD, MSc – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1155: Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
1157: Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
Location: Hall F1
Abstract Poster Presenter: Ella Steiner, -None- – Ruhr-University Bochum, Germany
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1158: Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Location: Hall F1
Abstract Poster Presenter: guishan liu, PA – Peking Union Medical College Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1159: IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1163: Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
Location: Hall F1
Abstract Poster Presenter: John Stone, MD, MPH – Massachusetts General Hospital , Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1164: Effect of TNF Inhibitors on the Postprandial Glucose Homeostasis Molecules: Amylin, Gastric Inhibitory Polypeptide, and Pancreatic Polypeptide in Rheumatic Patients
1165: Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
1167: Clinical Characteristics and Outcomes of igg4-related Disease Patients Who Chose Watchful Observation Without Treatment Intervention: A Single-center Study
Location: Hall F1
Abstract Poster Presenter: Kanako Chujo, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1168: Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory
1175: Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Location: Hall F1
Abstract Poster Presenter: Nils Venhoff, MD – Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1176: VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
1186: Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry
1187: Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Tulaton Sodsri, MD – Texas Tech University Health Sciences Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1188: Aortic Wall Shear Stress May Be a Protective Factor Against Development of Spinal Osteoproliferation
Location: Hall F1
Abstract Poster Presenter: Umut Kalyoncu, n/a – Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1189: Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
1192: Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
Location: Hall F1
Abstract Poster Presenter: ANA PAULA LUPPINO-ASSAD, MD, PhD – Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo (HC/FMUSP)
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1193: Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Location: Hall F1
Abstract Poster Presenter: Angela Chang, MD – University of British Columbia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1194: Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis
1198: Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab
1201: Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Irada Choudhuri, MD – University of Pittsburgh Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1202: High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Location: Hall F1
Abstract Poster Presenter: Iris Tang, MBBS, MRCP – Department of Medicine, LKS Faculty of Medicine, University of Hong Kong
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1203: Rituximab in Treatment Refractory vs Treatment Naive Anti Signal Recognition Particle (SRP) Myositis A Case Series
1205: Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.
Location: Hall F1
Abstract Poster Presenter: Jens Schmidt, MD – Immanuel University Hospital Rüdersdorf, Brandenburg Medical School; Department of Neurology and Pain Therapy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1206: Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Location: Hall F1
Abstract Poster Presenter: Jens Schmidt, MD – Immanuel University Hospital Rüdersdorf, Brandenburg Medical School; Department of Neurology and Pain Therapy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1207: Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Jesus Valencia, MD – Johns Hopkins Bayview Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1208: Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Location: Hall F1
Abstract Poster Presenter: Jia Shi, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1209: Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Jia Shi, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1210: Artificial Intelligence-based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the Capiami Cohort
1211: Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
Location: Hall F1
Abstract Poster Presenter: Kristina Svobodová, MD (she/her/hers) – Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1212: Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Location: Hall F1
Abstract Poster Presenter: Maria Rosa Pellico, MD – ASST Pini-CTO, Clinical Rheumatology Unit
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1213: Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)
1252: Can LLMs Categorize Patient Priorities Like Humans? Comparing AI and Human Coders in Arthritis Nominal Group Discussions
Location: Hall F1
Abstract Poster Presenter: Melissa Mannion, MD – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1253: Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Location: Hall F1
Abstract Poster Presenter: Nisha Sapkota, MD – One Brooklyn Health- Interfaith Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1254: Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
1256: Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
Location: Hall F1
Abstract Poster Presenter: Shannon Teaw, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1257: Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
Location: Hall F1
Abstract Poster Presenter: Shannon Teaw, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1258: Upadacitinib in the treatment of Rheumatoid Arthritis - Interstitial Lung Disease. National multicenter study of 25 patients in clinical practice.
Location: Hall F1
Abstract Poster Presenter: Ana Serrano-Combarro, MD – Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1259: Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
1264: Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt
1266: Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
1267: Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Location: Hall F1
Abstract Poster Presenter: Leah Santacroce, MS – Brigham and Women's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1268: Development of the LupusCoach Chatbot: Results of a Focus Group
1277: Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
Location: Hall F1
Abstract Poster Presenter: Eileen Rife, MD – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1278: Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
Location: Hall F1
Abstract Poster Presenter: Emily Masi, MD, PhD – Cohen Children's Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1279: Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Location: Hall F1
Abstract Poster Presenter: Reagan Reid, MSc – University of Toronto
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1280: Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
1287: A Clear Pattern of Clinical Presentation in Juvenile Systemic Scleroderma Is Associated with Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1288: Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
Location: Hall F1
Abstract Poster Presenter: Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1289: Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Location: Hall F1
Abstract Poster Presenter: Jida Jaffan, MA – The Hospital for Sick Children/ University of Toronto
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1289: Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Location: Hall F1
Abstract Poster Presenter: Jida Jaffan, MA – The Hospital for Sick Children/ University of Toronto
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1290: Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-onset Systemic Lupus Erythematosus (cSLE)
1295: Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Location: Hall F1
Abstract Poster Presenter: Martha Rodriguez, MD – Riley Hospital for Children at Indiana University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1296: Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
1298: Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups
Location: Hall F1
Abstract Poster Presenter: Nellie Butler, BA – Children's Hospital of Philadelphia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1299: Pediatric Antiphospholipid Syndrome in a Large Tertiary Center
Location: Hall F1
Abstract Poster Presenter: Rasha Elrefai, MD – Baylor College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1300: International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
1303: Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases：a Two-sample Mendelian Randomization Study
Location: Hall F1
Abstract Poster Presenter: Xuemei Tang, MD, Professor, Chief Physician – Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1304: The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin - a multicenter study
Location: Hall F1
Abstract Poster Presenter: YOEL Levinsky, MD – Schneider Children's Medical Cnetr of Israel, Tel Aviv University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1305: Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) - a multicenter study
Location: Hall F1
Abstract Poster Presenter: YOEL Levinsky, MD – Schneider Children's Medical Cnetr of Israel, Tel Aviv University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1306: Systematic Literature Review of Digital Sleep Outcomes and Endpoints Used to Assess Rheumatoid Arthritis
1320: Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
1323: Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
1331: anti-beta-2-glycoprotein-1 Iga Antibodies Facilitate Macrophage Cholesterol Loading and Influence Coronary Atherosclerosis Progression in a Dose-dependent Manner in Rheumatoid Arthritis
1341: Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures
Location: Hall F1
Abstract Poster Presenter: Saskia Truijen, MSc – Maastricht University Medical Centre+
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1343: Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
1346: Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
Location: Hall F1
Abstract Poster Presenter: YU Chen, MD, MSc, BA (she/her/hers) – 1. Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1347: The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
1348: Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Location: Hall F1
Abstract Poster Presenter: AJ Fernandez, n/a – Eli Lilly and Company
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1349: Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study
Location: Hall F1
Abstract Poster Presenter: Andrew Ostor, MD – Australian National University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1350: Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
Location: Hall F1
Abstract Poster Presenter: Daniel Zavada, MD – Charles University, Third Faculty of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1351: Are Glucocorticoids Associated with Worse Overall Survival Among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
1353: Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
1354: Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Hongtao Jin, MD – The Second Hospital of Hebei Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1354: Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Hongtao Jin, MD – The Second Hospital of Hebei Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1355: Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
1359: Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Maya Khasho, MD – University of central florida
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1360: Evaluating Causal Effects of Biologic and Targeted Synthetic Disease-modifying Anti-rheumatic Drugs Targets in Rheumatoid Arthritis Using Mendelian Randomisation
1361: Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Location: Hall F1
Abstract Poster Presenter: Mingfang Sun, MD – Department of Rheumatology & Clinical Immunology, Daping Hospital & Research Institute of Surgery, Army Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1362: Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
1363: Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.
Location: Hall F1
Abstract Poster Presenter: NAOKI Kondo, MD, PhD – Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1364: Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
1365: Economic impact of early treatment and strict disease control in rheumatoid arthritis: a cost-minimization approach concerning biological therapy
1366: Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
1371: Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Location: Hall F1
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1372: Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Location: Hall F1
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1373: Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Location: Hall F1
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1374: AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
1375: 86-96% of Rheumatoid Arthritis (RA) Patients with RA Who Have 0 or 1 Swollen Joint or Tender Joint but Are Classified as Moderate/high on RA Indices Have 1-9 Comorbidities Recognized on a Multidimensional Health Assessment Questionnaire (MDHAQ)
1391: Assessment of Anti-ssa/ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
Location: Hall F1
Abstract Poster Presenter: Mala Masson, BA – NYU Langone Medical Center- Division of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1392: Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers
1405: A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis
1407: Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
Location: Hall F1
Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1408: When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
Location: Hall F1
Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1409: The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
1410: Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Location: Hall F1
Abstract Poster Presenter: Connor Vershel, MD – University of Texas at Houston
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1411: Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
1414: Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Location: Hall F1
Abstract Poster Presenter: Eugeniu Russu, MD, PhD – State Medical and Pharmaceutical University ”Nicolae Testemitanu”; "Timofei Mosneaga" Republican Clinical Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1415: The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1417: Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis
Location: Hall F1
Abstract Poster Presenter: Faria Sami, MD – The University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1418: Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
1419: Effectivenss of an educational program on non-radiographic axial spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1420: A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Location: Hall F1
Abstract Poster Presenter: Isadora Small, n/a – The Latin School of Chicago
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1421: Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
Location: Hall F1
Abstract Poster Presenter: Lily Mikolajczak, BS – Georgetown University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1422: Assessment of Difficulties, Modifications and Use of Work Adaptations in Patients with Axial Spondyloarthritis: Validation of the Dificultax and Modal Questionnaires
1434: Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Location: Hall F1
Abstract Poster Presenter: Adam Mayer, MD – Hackensack University Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1435: Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
1436: Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Location: Hall F1
Abstract Poster Presenter: Devy Zisman, MD – Carmel Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1437: Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
1438: Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
1441: Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Location: Hall F1
Abstract Poster Presenter: Hongbin Li, MD – Affiliated Hospital of Inner Mongolia Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1442: Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
1444: Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
1445: Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
Location: Hall F1
Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1446: Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
1447: Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
1449: Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Lianne S. Gensler, MD – University of California San Francisco
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1450: The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
Location: Hall F1
Abstract Poster Presenter: Marc Schmalzing, MD – University Hospital Wuerzburg
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1451: Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1452: Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
1453: Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1454: Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1455: Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1456: Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1457: Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1458: Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1459: Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
1460: Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
1461: Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
1462: Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
1464: Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
1465: Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
1466: Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
1469: Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
1477: Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis
Location: Hall F1
Abstract Poster Presenter: Beste Acar, MD – Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1478: Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Bin zhou, MD – The First School of Clinical Medicine, Southern Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1479: Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
Location: Hall F1
Abstract Poster Presenter: Chen Chao, MD, MBA – Montefiore Medical Center/Albert Einstein College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1480: Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
Location: Hall F1
Abstract Poster Presenter: Chen-Yu Lee, MD – Johns Hopkins University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1481: Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative
1482: Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Location: Hall F1
Abstract Poster Presenter: Erik Cimé-Aké, n/a – Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1483: Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
1486: Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Location: Hall F1
Abstract Poster Presenter: Ileana Cecilia Reynosa Silva, MD – Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1487: Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
1493: Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
1496: Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center
Location: Hall F1
Abstract Poster Presenter: Manikandan Gopal, DM – Christian Medical College Vellore
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1497: Acute Care Utilization in Patients with Antiphospholipid Syndrome And/or Systemic Lupus Erythematosus
1500: Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1501: Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes - Results from Real World Data
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1502: Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Omer Pamuk, MD – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1503: Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
1504: High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants
Location: Hall F1
Abstract Poster Presenter: Richard Oppong, PhD – NATIONAL INSTITUTES OF HEALTH
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1505: Discordance Between Physician and Patient Global Assessment of Disease Activity in a Large Multicenter Prospective SLE Cohort in the U.S. and Canada
Location: Hall F1
Abstract Poster Presenter: Romy Kallas, MD, MS – Hospital for Special Surgery
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1506: Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)
Location: Hall F1
Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1507: Temporal Trends in the Incidence of Systemic Lupus Erythematosus (SLE) in the United States (US): Holding Steady?
Location: Hall F1
Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1508: Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Location: Hall F1
Abstract Poster Presenter: Sheila Serin, MD – Ochsner Clinic Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1509: Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
1510: Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
Location: Hall F1
Abstract Poster Presenter: Sitian Zang, n/a – Department of Rheumatology and Immunology, Peking University People’s Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1511: Mental Health and Medical Burden: The Impact of Depression on Length of Stay in Lupus Patients
Location: Hall F1
Abstract Poster Presenter: Sophia Chang Stauffer, MPH – Dartmouth College, University of Illinois at Chicago
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1512: anti-u1-rnp Antibody Positivity Is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Location: Hall F1
Abstract Poster Presenter: Takemichi Matsui, MD – Icahn School of Medicine at Mount Sinai
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1513: Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Location: Hall F1
Abstract Poster Presenter: Ufuoma Mamoh, MBChB – Medstar Georgetown University (Baltimore) Internal Medicine Residency
Abstract Poster Presenter: Yan Wang, n/a (she/her/hers) – Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1515: Machine Learning–defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
Location: Hall F1
Abstract Poster Presenter: Yuke Hou, MD – Peking University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1517: The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
Location: Hall F1
Abstract Poster Presenter: Aijing Liu, PhD – Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1518: Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Location: Hall F1
Abstract Poster Presenter: Ali Ali, MD, RhMSUS – Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1519: Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
1520: Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Bahtiyar Toz, MD – Zucker School of Medicine at Hofstra/ Northwell
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1521: Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Location: Hall F1
Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1522: Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Location: Hall F1
Abstract Poster Presenter: Carlos Pena, MD – Jefferson Einstein Philadelphia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1523: Genetic architecture and translational insights for SLE progression from preclinical stages
1529: Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
1530: The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
1531: Achieving Remission and Low Disease Activity with Belimumab versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1532: Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
1536: Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Location: Hall F1
Abstract Poster Presenter: Aarat Patel, MD – GSK, US Medical Affairs
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1537: Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Melanie Hagen, MD (she/her/hers) – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1538: Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
Location: Hall F1
Abstract Poster Presenter: Minoru Hasegawa, MD;PhD – Division of Medicine, University of Fukui
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1539: The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
1541: Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
Location: Hall F1
Abstract Poster Presenter: Qizhi Yuan, PhD – Peking Union Medical College
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1542: Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-week Phase 3 Trial
1545: Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
1552: Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
1555: Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
1556: Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
1558: Gastrointestinal Symptom Severity Is Associated with Worse Patient-reported Outcomes and Dietary Patterns in Systemic Sclerosis: A Single Center Prospective Study
1570: Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Location: Hall F1
Abstract Poster Presenter: Francesco Bonomi, MD – University Hospital Careggi, Florence
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1571: Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
1572: Compromised intracellular oxygen availability and severe mitochondrial dysfunction in the skeletal muscle of patients with systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Tracy Frech, MD, MS – Vanderbilt University Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1573: WITHDRAWN
Location: Hall F1
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1574: A Rise in Serum KL-6 Levels Predicts Subsequent Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Keina Yomono, MD – Nippon Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1575: Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
Location: Hall F1
Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1576: Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
1577: Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Location: Hall F1
Abstract Poster Presenter: Luc Mouthon, MD, PhD – Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1578: Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series
1579: Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1580: Lung Vasculature Quantification on Computed Tomography Predicts New Onset of Interstitial Lung Disease in Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1581: The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
1582: Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Location: Hall F1
Abstract Poster Presenter: Marissa Savoie, MD – Hospital for Special Surgery
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1583: Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
1614: A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
1615: Prevalence of Clinical and Laboratory Manifestations of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Review and Meta-Analysis
1617: Evaluating Familiarity and Knowledge Gaps in Polymyalgia Rheumatica Among Public Health Professionals
Location: Hall F1
Abstract Poster Presenter: Erik Stone, MA – Global Healthy Living Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1618: Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study
Location: Hall F1
Abstract Poster Presenter: Fatma Alibaz-Oner, MD – MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1619: Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
1627: A Systematic Literature Review to Inform the 2025 EULAR Recommendations for Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Management of Disease Including Relapse and Complications
1628: Characterization of non-GCA, non-Takayasu Aortitis in a Single Health System Cohort
Location: Hall F1
Abstract Poster Presenter: Nuzhat Batool, MBBS – NYU Grossman Long Island School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1629: Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
1630: Validation of the classification algorithm using the modified 2022 ACR/EULAR giant cell arteritis classification criteria and Japanese Takayasu arteritis diagnostic criteria
1637: Sleep Quality as a Modifier of the Relationship Between Physical Activity and Functional Limitation in Adults with or at High Risk of Knee Osteoarthritis
1642: The Impact of Secukinumab on Bone Density in Patients with Ankylosing Spondylitis: A 1-Year Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Lemei An, MD – Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1643: Optimizing Analyses of Chair Stand Test Outcome Data in the Multicenter Osteoarthritis Study: Exploration of Approaches to Handling Missing and/or Skewed Data with Performance-based Function Measures
Location: Hall F1
Abstract Poster Presenter: Michael LaValley, PhD – Boston University School of Public Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1644: Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Misti Paudel, PhD, MPH – Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1645: A Sex-modified Association Between Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) Blood Concentration and Prevalent Arthritis Among Young and Middle-aged US Adults
1647: Clinical Phenotypes of Participants with Radiographic Osteoarthritis Attaining Patient Acceptable Symptom State in the Multicenter Osteoarthritis Study
1648: Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
1067: Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma
1228: Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Location: Hall F1
Abstract Poster Presenter: Emily Holladay, MPH – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1381: Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
1610: Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
1066: Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1123: Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Location: Hall F1
Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1237: Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
0929: SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice
1050: Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Location: Hall F1
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1077: Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort
1126: Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
1052: “prednisone… a Necessary Evil…” Developing an Evidence-based Benefits vs. Harms Shared Decision-making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Location: Hall F1
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1081: Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
1143: Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
Location: Hall F1
Abstract Poster Presenter: Shiamak Cooper, MD – Rochester General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1144: A Quantitative Study of Renal Medulla Echogenicity in 250 Vietnames Gout Patients Shows Correlation with Poor Renal Function
Location: Hall F1
Abstract Poster Presenter: Thomas Bardin, MD – Lariboisiere Hospital, Department of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1222: Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Ahmed Abouelella, MBBCH – College of Human Medicine, Benha University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1342: The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis
Location: Hall F1
Abstract Poster Presenter: Saskia Truijen, MSc – Maastricht University Medical Centre+
1609: A Multicenter Prospective Longitudinal Observational Study to Determine Safety of Extended Treatment with Rituximab in Maintaining Remission in Patients with ANCA Associated Vasculitis (AAV) - An Interim Analysis
Location: Hall F1
Abstract Poster Presenter: Ravi Kumar U, DM – Christian Medical College
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0913: Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
0923: Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens
Location: Hall F1
Abstract Poster Presenter: Julia Rood, MD, PhD – Children's Hospital of Philadelphia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0963: Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)
Location: Hall F1
Abstract Poster Presenter: Emanuele Gotelli, MD, PhD – Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1054: Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Location: Hall F1
Abstract Poster Presenter: Ye Liu, MD, MPH, DrPH – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1073: Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases
0909: Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Location: Hall F1
Abstract Poster Presenter: Marcus Hines, MD;PhD – New York University Grossman School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0927: Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus
Location: Hall F1
Abstract Poster Presenter: Mir Howlader, BA – Weill Cornell Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1062: Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort
1068: Association Between Social Determinants of Health Domains and covid-19-related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data
0908: E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Li Peng, PhD – Palleon Pharmaceuticals
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0933: Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Location: Hall F1
Abstract Poster Presenter: Yunwei Xia, BA – Feinstein Institutes for Medical Research
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1129: Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
1395: A Comparative Study of Yao Syndrome and Primary Sjögren's Syndrome
Location: Hall F1
Abstract Poster Presenter: Nayaab Bakshi, DO – Stony Brook University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1601: Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series
Location: Hall F1
Abstract Poster Presenter: Helen Au, MBBS – Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0906: Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
0910: Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
Location: Hall F1
Abstract Poster Presenter: Min-Gang Kim, PhD – Seoul National University College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0930: Potent and Selective Oral IRF5 Degrader, KT 579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Ryan Camire, PhD – Kymera Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1065: Age of Disease Onset and Risk of Serious Infection with Anti-tnf Use in Older Adults with Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Jiha Lee, MD, MHS – University of Michigan
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1137: Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
1044: Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
Abstract Poster Presenter: LEI LIU, MD – The Second Hospital affiliated to Zhejiang University, College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1238: Pain Is Associated with An Increased Risk of Frailty in Veterans with Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Nadine El-ayache, DO, PhD – VA Puget Sound Health Care System & University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1330: Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
1087: Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Zoe Reed, MPH – Oklahoma Medical Research Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1139: Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
1069: Strengthening Rheumatology Workforce Capacity and Impact on Patient Care in Louisiana: Expanding Fellowship Training Opportunities Through Strategic Partnerships
1063: Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Location: Hall F1
Abstract Poster Presenter: Farheen Malik, MD – Jacobi Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1127: The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
1223: Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1074: Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
1240: Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity
Location: Hall F1
Abstract Poster Presenter: Philip Carlucci, MD – New York University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1398: Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
1394: Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
1396: Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Nevsun Inanc, MD (she/her/hers) – Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0907: Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
0928: Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model
1611: Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Yusuke Ushio, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1056: High diagnostic rate of genetic testing in adult patients with autoinflammation: A Single Center Experience
1402: Understanding Fatigue Through Patients' Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Saviana Gandolfo, MD – Rheumatology Unit, Ospedale del mare, Naples
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1379: Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Location: Hall F1
Abstract Poster Presenter: Biji T Kurien, PhD – Oklahoma Medical Research Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0904: SLAMF7 Drives Plasma Cell Differentiation in Rheumatoid Arthritis Synovium.
0918: Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)
Location: Hall F1
Abstract Poster Presenter: Anthony Cruz, BS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1048: Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
1061: Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
1236: Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Location: Hall F1
Abstract Poster Presenter: Michael Kaplan, MD – Icahn School of Medicine at Mount Sinai
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1387: Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
1603: SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
Location: Hall F1
Abstract Poster Presenter: Julia Foos, BA – University of Toledo College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0915: A Fusion of TACI Variant and Anti-ifnar Antibody with Greater Therapeutic Effect on Related Autoimmune Disease Models
1245: Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)
Location: Hall F1
Abstract Poster Presenter: Rubab Rizwan, MD – VBMC,Nuvance Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1390: Cystic Lung Disease and Autoantibodies in Lymphocytic Interstitial Pneumonia: Exploring the Impact of Sjögren’s Syndrome
1136: The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts
1047: Primary Care Perspectives on Giant Cell Arteritis: Diagnostic Considerations, Referral Challenges, and Opportunities for Fast-Track Pathways in the U.S.
Location: Hall F1
Abstract Poster Presenter: Jon Golenbiewski, DO – Wake Forest University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1055: The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
1138: Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
Location: Hall F1
Abstract Poster Presenter: Robert Keenan, MD – Arthrosi Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1242: Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants
Location: Hall F1
Abstract Poster Presenter: Robert Katz, MD – Rush University Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1384: Systematic Review of Therapies for Central Nervous System Manifestations in Sjögren’s Disease
Location: Hall F1
Abstract Poster Presenter: Ghaith Noaiseh, MD – University of Kansas Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1594: Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
0919: Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
1041: Associated Factors and Direct Cost Analysis of Dose Reduction and Discontinuation of Biological Therapies in Rheumatoid Arthritis and Spondyloarthritis: Findings from a Colombian Cohort Within the Framework of an Integrated Management Model
0921: Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Location: Hall F1
Abstract Poster Presenter: Hannah Johnson, BS – University of Nebraska Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1042: Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
Location: Hall F1
Abstract Poster Presenter: Eric Roberts, PhD, MPH – University of California, San Francisco
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1070: Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
1386: Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
1788: Manganese-associated Single-nucleotide Polymorphisms are Associated with Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project
1789: Spatial Analysis of Advanced Osteoarthritis Synovial Tissue
Location: Hall F1
Abstract Poster Presenter: jacob Dickman, n/a – Medical College of Wisconsin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1790: Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Lai Wang, MD;PhD – Rush University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1791: Determining the Effect of CD14 Deficiency on Osteoblastogenesis and Subchondral Bone Remodeling In Mice
Location: Hall F1
Abstract Poster Presenter: Lance Murphy, -None- – University of Pennsylvania Perelman School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1792: OA protection in African spiny (Acomys) mice is partially mediated by the gut microbiome and is transferrable to wild-type mice via microbiome transplantation
1794: OA-associated pain sensitivity is reduced in OA-protected MRL/MpJ mice, partially mediated by the gut microbiome, and transferable via microbiome transplantation
1797: SEV 101 Exosomes Isolated from Induced Pluripotent Stem Cell Derived Hyaline Cartilage Tissue Characterization of Immunomodulatory and Chondroproliferative Effects In Vitro
1838: Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
Location: Hall F1
Abstract Poster Presenter: Jolien Suurmond, PhD – Leiden University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1839: Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways
1842: Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
1843: Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Norio Hanata, M.D., Ph.D. – Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1844: Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis
1847: Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
1848: DS-7011a, An Anti-TLR7 Antagonistic Monoclonal Antibody, Suppresses Human Immune Cells and Multiple Cytokines/Chemokines Related to the Pathogenesis of SLE
1850: First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
Location: Hall F1
Abstract Poster Presenter: Tayte Stephens, BS – University of Oklahoma Health Science Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1851: Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
Location: Hall F1
Abstract Poster Presenter: Tomás Cerdó, PhD – Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1852: Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort
Location: Hall F1
Abstract Poster Presenter: Victoria Werth, MD – University of Pennsylvania
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1853: SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
1878: Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database
1884: The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study
1887: Incidence, Prevalence and Mortality of Systemic Lupus Erythematosus – A 20-year territory-wide analysis of electronic health records in Hong Kong
1889: Navigating Diagnostic Challenges: Insights into the Patient Journey and Delays in Diagnosing Dermatomyositis from a Real-world Survey in the United States and Europe
1890: Quantifying the Inflammatory Toll: Smoking-Attributable Rheumatoid Arthritis Burden Across the Globe, 1990–2021
Location: Hall F1
Abstract Poster Presenter: Eva Kalra, MBBS – Trident Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1891: Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability
Location: Hall F1
Abstract Poster Presenter: Eva Kalra, MBBS – Trident Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1892: Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis
1896: Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program
1902: Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases
1903: Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California
1910: Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims
1920: Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis
Location: Hall F1
Abstract Poster Presenter: Huifang Lu, MD;PhD – UT MD Anderson Cancer Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1922: Exploration of patient and clinician perspectives on rehabilitation in contemporary rheumatology care for rheumatoid arthritis: A qualitative study
Location: Hall F1
Abstract Poster Presenter: Joel Thompson – University of North Carolina at Chapel Hill
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1923: A Real-World Survey on Physicians Perspectives of Uncontrolled Gout and Gout Management Practices
Location: Hall F1
Abstract Poster Presenter: John Botson, MD – Orthopedic Physicians Alaska
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1924: Real-World Treatment Patterns of Patients with Systemic Autoimmune Rheumatic Disease-associated Interstitial Lung Disease After Progression in The United States
1929: Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still's Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD)): Analysis of a US National Administrative Claims Database
1930: Can a Multinational Awareness Campaign Improve Referral Rates and Reduce Diagnostic Delays in Patients with Chronic Inflammatory Rheumatic Diseases? The Impact of a Prospective Interventional Study
1933: Specialist Wound Care Services Provision and Sharp Debridement Practices for Digital Ulcers (DU) Management in Systemic Sclerosis (SSc): An International Survey
1934: Analysis of the Determinants of Vaccine Acceptance and Hesitancy in Germany: A Mixed-methods Approach Incorporating Health Insurance Data and Qualitative Interviews with Patients and Physicians
1936: A Fully Automated Method for Measuring Minimum Tibiofemoral Joint Space Width in Knee Osteoarthritis Assessment: Data from the FNIH Cohort
Location: Hall F1
Abstract Poster Presenter: Ahmad Almhdie, PhD – University Hospital Center of Orleans
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1937: Does Combining Standard MRI-Based Scores with Radiographic Trabecular Bone Texture Biomarkers Improve Predictive Performance for Radiographic Knee Osteoarthritis Progression?
Location: Hall F1
Abstract Poster Presenter: Ahmad Almhdie, PhD – University Hospital Center of Orleans
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1938: Optimizing Patient Outcomes: The Experience of a Multidisciplinary Rheumatology and Hand Surgery Clinic with Point-of-Care Musculoskeletal Ultrasound Integration
1944: Musculoskeletal Ultrasound Clinic Referral Patterns and Joint Findings in a Tertiary Care Center amongst Patients with Elevated BMI and Inflammatory Arthritis
Location: Hall F1
Abstract Poster Presenter: Anna Lichtiger, MD – Montefiore Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1945: Significance of Finger Joint Tenderness With or Without Swelling in Relation to MRI, Ultrasound, and X-Ray Findings in Psoriatic Arthritis_Final results
Location: Hall F1
Abstract Poster Presenter: Ari Polachek, MD – Beilinson Hospital, Petah Tikva, Israel
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1946: Quantitative Imaging Analysis of Chest Computed Tomography in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Emily Anthone, BS – University of Nebraska Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1947: Coronary computed tomography incidental findings in rheumatoid arthritis.
1950: Pericoronary fat enhancement in rheumatoid arthritis differs from controls and associates with coronary atherosclerosis independently of epicardial fat volume
Abstract Poster Presenter: Genessis Maldonado, MD – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1955: Regional variations in the relationship between pericoronary fat enhancement and atherosclerosis may reflect differences in local vascular inflammation in rheumatoid arthritis
1958: Longitudinal analysis on imaging outcomes: should we use the individual scores from multiple readers or rather the consensus or average of readers?
Location: Hall F1
Abstract Poster Presenter: Liese de Bruin, MSc – Leiden University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1959: The development and validation of a Diagnostic Ultrasound Enthesitis Score (DUET) for Psoriatic Arthritis
1963: Efficacy of Apremilast in Patients With Psoriatic Arthritis and Pre-existing Dactylitis: Dynamic Contrast-Enhanced MRI Results From the Phase 4 MOSAIC Study
1964: Performance of Artificial Intelligence-Based Salivary Gland Ultrasound in Sjögren Syndrome
Location: Hall F1
Abstract Poster Presenter: Otto Olivas, MD – Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute FJD-UAM, Madrid, Spain
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1965: Two-Year Outcomes of Microwave Ablation for Recurrent Monoarthritis with Synovial Hypertrophy Resistant to Medical Treatment: Expanded Cohort and Long-Term Follow-Up Results
1968: Relationship between ultrasonographic and elastographic findings of the median nerve and disease activity and hand function in patients with rheumatoid arthritis
1969: Enhancing Objective Evaluation of Raynaud’s in Veterans with Scleroderma-related Hand Pain: Integrating Patient Reported Outcomes and Nailfold Capillaroscopy
Location: Hall F1
Abstract Poster Presenter: Sowmika Rao, MD – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1970: Comparison of Optical Imaging with Musculoskeletal Ultrasound in Assessment of PIP Joints of Systemic Lupus Erythematosus Patients
Location: Hall F1
Abstract Poster Presenter: Wei Tang, MD – Westchester Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1971: Intracranial Arterial Stenosis in Antiphospholipid Syndrome: A Neglected Vascular Involvement?
Location: Hall F1
Abstract Poster Presenter: Yuying Fan, n/a – Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2015: Clinical features of IgG4-related disease - a single centre experience
2016: Effectiveness of Nintedanib combined with different DMARDs in joint and pulmonary domains of Rheumatoid Arthritis - Interstitial Lung Disease. National multicenter study of 74 patients
Location: Hall F1
Abstract Poster Presenter: Ana Serrano-Combarro, MD – Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2017: Baseline and 2-year Follow-up of Pulmonary Function Among CTD-ILD Subtypes
2020: Inebilizumab Efficacy and Safety in Patients with Common, Urgent, and Fibrotic Organ Manifestations of IgG4-RD: Subgroup Analyses from the MITIGATE Trial
2021: Can Colchicine Be a Therapeutic Option for Patients with Ankylosing Spondylitis?
Location: Hall F1
Abstract Poster Presenter: Bahaddin Ates, n/a – Cerrahpasa Faculty of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2022: Clinical Predictors of Macrophage Activation Syndrome and Treatment Outcomes in Adult-Onset Still’s Disease: A 24-Year Single-Center Experience
Location: Hall F1
Abstract Poster Presenter: Beste Acar, MD – Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2023: Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Location: Hall F1
Abstract Poster Presenter: CARMEN SECADA-GÓMEZ, MD – HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2024: Racial Disparities in Outcomes Among Patients With Neuromyelitis Optica: A Global Population-Based Study
2031: Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives
2035: Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatologic Disease
2048: DDR2 auto-phosphorylation in patients with Warburg-Cinotti syndrome promotes differentiation of fibroblasts into myofibroblasts and expansion of immature B cells with antibody production.
Location: Hall F1
Abstract Poster Presenter: Sang Jin LEE, n/a – Kyungpook National University School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2049: Descriptive Analysis of a Cohort of Neurosarcoidosis Mimics
2052: Prevalence of anti-neutrophil extracellular trap antibodies and their relationship with the clinical characteristics of patients with idiopathic inflammatory myopathies.
2054: A Changing Paradigm: Reassessing the Role of Muscle Biopsy in Idiopathic Inflammatory Myopathies in a Single-center Cohort
Location: Hall F1
Abstract Poster Presenter: Ami Purohit, MD – University of Miami
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2055: Construct Validity of Total Improvement Score (TIS) as an Endpoint for Clinically Meaningful Improvement in Multiple Patient-Centered Outcome Measures in Dermatomyositis
2060: Treatment Patterns And Drug Use In Idiopathic Inflammatory Myopathies. Description Of The First Year After Diagnosis In A Swedish Myositis Cohort.
2066: Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies
Location: Hall F1
Abstract Poster Presenter: Meera Shah, MD, MBBS – Topiwala National Medical College and Dr. B.Y.L Nair Charitable Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2067: Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors
Location: Hall F1
Abstract Poster Presenter: Meera Shah, MD, MBBS – Topiwala National Medical College and Dr. B.Y.L Nair Charitable Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2068: Comparing characteristics, diagnostics, and treatment in people with different idiopathic inflammatory myopathies using a large representative cohort
2070: Characterization of Hospitalization, Patient Demographics and Impact of Idiopathic Inflammatory Myopathies on Hospitalization Outcomes in Adult Fracture Patients: A National Inpatient Sample Analysis.
2071: Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico
2074: Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients
2076: Nutritional Discourse in Online Myositis Communities: A Reddit Analysis of Patient-led Discussions
Location: Hall F1
Abstract Poster Presenter: Taanya Talreja, MBBS – Seth GS Medical College and KEM Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2077: Statin-Associated Immune-Mediated Necrotizing Myopathy in Native Americans
Location: Hall F1
Abstract Poster Presenter: Tam Dinh, MD – University of New Mexico Internal Medicine Program
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2078: Neutrophil Extracellular Traps from Patients with Idiopathic Inflammatory Myopathies Induce Interferogenic Responses in Macrophages and Myeloid Dendritic Cells
2079: Association Between Symptomatic Knee Osteoarthritis and Health-related Quality of Life in Individuals with Type 2 Diabetes: A Cross-sectional Study
2081: Radiologic surveillance in the Phase II RCT of LEVI-04, a novel neurotrophin-3 inhibitor, in people with knee osteoarthritis: exclusions at screening
2082: Pharmacokinetic Profile of MM-II Following a Single Intra-Articular Injection in Patients with Knee Osteoarthritis in a Phase 2b Randomized, Controlled, Dose-Ranging Trial
2085: Estimating the Association between Effusion-synovitis and Knee Pain in a Subset of Participants with Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative (OAI)
2088: Aging Unevenly: National Trends and Inequities in Osteoarthritis Mortality, 1999–2020
Location: Hall F1
Abstract Poster Presenter: Ghassan Makhoul, MD – St. Joseph's University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2089: Traction Therapy May Improve Hand Function in Those with Distal Interphalangeal Osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Grace Lo, MD, MSc – Baylor College of Medicine / MEDVAMC
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2091: Multiplanar MRI Quantification of Effusion-Synovitis: Reliability and Potential Investigative Utility for Inflammation-Mediated Knee Conditions
Location: Hall F1
Abstract Poster Presenter: Greg Gilles, BS – The University of Arizona Arthritis Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2092: Associations Among Biomarkers, Cytokines, and Ultrasound Features of Knee Osteoarthritis: A Cross-sectional Analysis in the Johnston County Health Study
Location: Hall F1
Abstract Poster Presenter: Jasmine Kimber, BS – University of North Carolina School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2093: Association of Acetaminophen Use with Clinical Outcomes in Older Adults with Osteoarthritis: A Global Propensity-matched Retrospective Cohort Analysis
2094: Evaluating the Accuracy of Knee Acoustic Emissions Classification of Varus Thrust
Location: Hall F1
Abstract Poster Presenter: Kari Falaas, MD – University of Minnesota
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2096: Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-site Randomized Trial
Location: Hall F1
Abstract Poster Presenter: Kimberly Hayes, BA;MA – Teachers College, Columbia University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2097: Trajectories of psychological symptoms during an 18-month Diet + Exercise intervention in overweight or obese adults with osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Lily Alomari, B.S – Kansas City University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2098: Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Natalie Keller, BS, BA – Corporal Michael J. Crescenz VA Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2100: Trabecular Bone Texture is Associated with Structural and Pain Progression in Later Stages of Knee Osteoarthritis: Longitudinal Data from the FNIH OAI Cohort
2101: LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
2107: Experience of a Fragility Fracture Coordination Unit Integrated Across Two Hospitals: An Innovative Multidisciplinary Model for Optimizing the Management of Geriatric and Non-Geriatric Patients Beyond Surgery After an Osteoporotic Bone Fragility Fracture
2108: Multidisciplinary Fragility Fracture Management Across Two Coordinated Hospitals: Evaluating Risk Factors, Treatment Approaches, and Long-Term Patient Outcomes in Those With and Without Prior Fractures
2109: Comparative Effects of IL-6 inhibition, Methotrexate, and Glucocorticoid Monotherapy on Bone Mineral Density, 3D-DXA femoral structure and Bone Turnover Markers in GCA and PMR
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2110: Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases
Location: Hall F1
Abstract Poster Presenter: Edgar Wiebe, MD – Charité University Medicine Berlin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2111: Cost-effectiveness Analysis of Biosimilar Denosumab for the Treatment of Women with Post-menopausal Osteoporosis in the United States: A Risk Based Analysis
2112: Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
2122: Safety and Efficacy of Romosozumab in the Treatment of Patients with High-Risk Fracture Osteoporosis in Clinical Practice: Experience from a Tertiary University Hospital in Spain
2124: Reliability and Validation of the Physician's Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)
Location: Hall F1
Abstract Poster Presenter: Eileen Rife, MD – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2125: Development and Validation of Minimal Clinically Important Difference for Children with Chronic Nonbacterial Osteomyelitis Using a Consensus and Data-Driven Approach
2132: The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits
Location: Hall F1
Abstract Poster Presenter: Ayah Eltoum, MD, MPH – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2133: Examination of HLA-DRB1*15-linked Candidate Antigens in Still’s Disease with and without Lung Disease and Features of Drug Hypersensitivity
2134: Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort
Location: Hall F1
Abstract Poster Presenter: Eileen Rife, MD – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2135: Medication Use and Disease Activity in Systemic Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Location: Hall F1
Abstract Poster Presenter: Ginger Janow, MD, MPH – Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2136: Confirming The Validity Of The New EULAR/ACR Classification Criteria For Pediatric Chronic Nonbacterial Osteomyelitis
2137: Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey
Location: Hall F1
Abstract Poster Presenter: Greta Rogani, MD – University Medical Center Utrecht
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2138: Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey
Location: Hall F1
Abstract Poster Presenter: Greta Rogani, MD – University Medical Center Utrecht
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2139: Real-Life Treatment Strategies for Refractory Still’s Disease: Results from a Worldwide Survey, the METAPHOR Project
Location: Hall F1
Abstract Poster Presenter: Greta Rogani, MD – University Medical Center Utrecht
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2140: Identification of immune phenotypes in systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD) using high parameter flow cytometry
2142: Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Location: Hall F1
Abstract Poster Presenter: Hannah Concannon, BS – Duke University School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2143: Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
Location: Hall F1
Abstract Poster Presenter: Janna Shim, DO – Kaiser Permanente San Jose
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2144: The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis
2148: Initial MRI Findings as Predictors of Disease Phenotype in Juvenile Dermatomyositis: A Comparative Study of Myositis Specific Antibodies NXP2-Positive and Myositis Specific Antibody-Negative Patients in a Large Tertiary Hospital
2168: Training Objective Structured Clinical Examinations in a Clinical Immunology department: Expectations and Perceptions of Medical students at Graduating Level
2172: Automating the Curation and Summarization of Rheumatology Fellowship Applications using Generative AI Agents and Transformer Models
Location: Hall F1
Abstract Poster Presenter: Andrew Trotter, n/a – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2173: Developing Musculoskeletal Ultrasound Clinical Electives: Bridging the Basic Sciences and Clinical Application in Undergraduate Medical Education
2176: Addressing Hesitancy in JAK Inhibitor Use: Outcomes from Continuing Medical Education Reveal Confidence-knowledge Gaps Among Community Rheumatologists
2178: Online Education Significantly Improved Rheumatologists’ Knowledge of the Diagnosis and Management of Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Elaine Bell, PhD – Medscape Global Education
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2179: Educational online webinars of European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) for patients, caregivers and healthcare professionals: six years’ experience
Location: Hall F1
Abstract Poster Presenter: Emanuele Gotelli, MD, PhD – Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2180: Helping Hands: Curriculum using Simulators to Teach the Hand Exam and Assessment of Small Joint Swelling in Inflammatory Arthritis
Location: Hall F1
Abstract Poster Presenter: Ibtissam Gad, MD – University of Michigan
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2181: A Pilot High-fidelity Simulation for Pediatric Rheumatology Learners
Location: Hall F1
Abstract Poster Presenter: John Bridges, MD, MS – University of Alabama at Birmingham/Children's of Alabama
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2182: Rheum for Improvement: A Needs Assessment Survey for an Internal Medicine Resident Curriculum
2185: The Evolving Digital Landscape of Social Media among Rheumatology Professionals: A Global Analysis by the EULAR SoMeR Study Group
Location: Hall F1
Abstract Poster Presenter: Latika Gupta, MD, DM, MRCP – University of Birmingham & Royal Wolverhampton NHS Trust
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2186: Developing Rheumatology Specific Anki Electronic Flashcards for Teaching Preclinical Students United States Medical Licensing Examination Board Relevant Topics
2190: Successful Implementation of an Innovative Rheumatology Curriculum for Internal Medicine Residents: Fellow-Initiated Rheumatology EDUcation Project (FIRED UP)
Location: Hall F1
Abstract Poster Presenter: Raeann Bowman, MD – University of Alabama Birmingham / UT Southwestern
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2191: Development, Validation and Performance of a Questionnaire for Assessing the Knowledge Base of Primary Care Physicians About Management of Rheumatoid Arthritis and Impact of an Information Course
2194: Utilizing Case-Based Learning to Teach the Teacher and Improve Health Insurance Literacy
Location: Hall F1
Abstract Poster Presenter: Tyler Reese, MD – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2227: The Paraoxonase-1 Q192R Polymorphism is Associated with Increased Risk of Incident Clinical Rheumatoid Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
2240: Diabetes Significantly Amplifies Risk of Cardiac Arrhythmias in Rheumatoid Arthritis Patients: Results from a Multi-Center Electronic Health Record Study
2253: Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study
2265: Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients
Location: Hall F1
Abstract Poster Presenter: Ana Serrano-Combarro, MD – Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2266: Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
2267: Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
2268: Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
2269: Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
2271: Assessing the Real-world Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic Dmards on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
2272: Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort
2273: Impact of Upadacitinib on Glucocorticoid Reduction in Patients with Moderate-to-Severe RA Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
Location: Hall F1
Abstract Poster Presenter: FRANK BUTTGEREIT, MD – Charité University Medicine Berlin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2274: Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy
2275: Agreement Between Two Rheumatoid Arthritis Response Measures Across Bts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood based Precision Medicine Test
2276: Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
2279: Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial
Location: Hall F1
Abstract Poster Presenter: Koray Tascilar, MD – Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2280: Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis
2281: Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study
Location: Hall F1
Abstract Poster Presenter: Louis Bessette, MD, MSc – Centre de l'Ostéoporose et de Rhumatologie de Québec
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2282: Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis
2287: Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Yinan Huang, PhD, MS – Department of Pharmacy Administration, University of Mississippi
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2288: Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
2288: Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
2291: Correlation and Concordance Between the Oxford Grading Scale, Ocular Staining Score, and van BijsterveldScore in the diagnosis of Sjögren's Disease
2292: Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren's Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
2296: Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
2300: Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
2302: Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
2305: Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2306: Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study
Location: Hall F1
Abstract Poster Presenter: Amir Haddad, MD – Carmel Medical Centre
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2309: Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
2318: Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists
2319: Reducing selection bias while maintaining precision through an integrated analysis: 2-year longitudinal analysis of imaging outcomes in the SPondyloArthritis Caught Early cohort
Location: Hall F1
Abstract Poster Presenter: Liese de Bruin, MSc – Leiden University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2320: Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors
2323: Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
2324: Early Prediction of Complex Forms of Spondyloarthritis Using Artificial Intelligence: A Modeling Study Based on Routine Clinical Data
Location: Hall F1
Abstract Poster Presenter: MOHAMMED KHALIL JNYAH, MD (he/him/his) – University Hospital Center Hassan II of Fez, Faculty of Medicine, Dentistry and pharmacy Sidi Mohamed Ben Abdellah of Fez, Morocco
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2325: Association of galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Natalia Guajardo-Jauregui, MD – Hospital Universitario "Dr. Jose E. Gonzalez", Monterrey, Mexico
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2326: Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Rafael Bassara Macedo, MD – Rheumatology Division - University of São Paulo
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2327: Persistent Pain in PsA: A Distinct Phenotype of Depression, Fatigue, And Catastrophizing
2330: Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans - A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2331: Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
2338: Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
2339: Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST
Location: Hall F1
Abstract Poster Presenter: Alen Zabotti, MD, MSc – Azienda Sanitaria Universitaria del Friuli Centrale
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2340: Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial
Location: Hall F1
Abstract Poster Presenter: Alexander Garaiman, n/a – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2341: Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Ana-Maria Orbai, MD, MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2342: Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe
Location: Hall F1
Abstract Poster Presenter: Andrew Ostor, MD – Australian National University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2343: Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Location: Hall F1
Abstract Poster Presenter: Asim Khanfar, MD – Rochester General Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2344: Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
2345: Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
2346: Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
Location: Hall F1
Abstract Poster Presenter: Daniel Zavada, MD – Charles University, Third Faculty of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2347: Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Location: Hall F1
Abstract Poster Presenter: Fabian Proft, MD – Charité Universityhospital Berlin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2348: Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
2351: Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
2352: Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
2353: Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Xu Jian, PhD – First Affiliated Hospital of Kunming Medical University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2354: ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
2355: Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
Location: Hall F1
Abstract Poster Presenter: KURT OELKE, MD – rheumatic disease center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2356: Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
2357: Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
2358: Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
2359: Combination Of TNF Inhibitors And NSAIDs Versus TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis
2360: Treatment adherence in ankylosing spondylitis: A comparison of TNFi, IL-17i, and JAKi using real-world data
Location: Hall F1
Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2361: Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis
2362: Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
Location: Hall F1
Abstract Poster Presenter: Mauro Keiserman, MD – Rheumatology Section, Pontifical Catholic University, School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2363: Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2364: Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2365: Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2366: Association Between Skin and Joint Symptom Control and Patient-reported Pain and Health Status Among Patients with Psoriatic Arthritis in the Corevitas Psoriatic Arthritis/spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drugs
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2367: Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2368: Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2369: Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2370: Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
2373: Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
2375: Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
2376: Efficacy And Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis Stratified by Disease Course: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 2/3 Trial
Location: Hall F1
Abstract Poster Presenter: Xiaofei Shi, MD – The First Affiliated Hospital of Henan University of Science and Technology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2377: Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Aakash Patel, MD – Massachusetts General Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2378: Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
2380: Factors Influencing Time to Diagnosis in Systemic Lupus Erythematosus: A Real-World Retrospective Analysis
Location: Hall F1
Abstract Poster Presenter: April Barnado, MD, MSc – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2381: Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Angela Lu, BS – Albert Einstein College of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2382: Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
Location: Hall F1
Abstract Poster Presenter: Ansaam Daoud, MD – Case Western Reserve University/University Hospitals
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2383: The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort
2385: The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes
Location: Hall F1
Abstract Poster Presenter: Billy Kim, MD – Hospital for Special Surgery
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2386: anti-trim72 Auto-antibodies in Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes
Location: Hall F1
Abstract Poster Presenter: Braden Zeno, BS – Ohio State University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2387: Lupus Damage Index Revision – Item Generation and Reduction Phases
2391: Antinuclear Antibody Positivity in Patients with Psoriasis and Psoriatic Arthritis and the Risk of Developing Clinical Symptoms of SLE Following TNF Inhibitor Therapy
2396: A Machine Learning Algorithm Based on a 15-autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
2397: Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
2398: Analytical Performance of the hep-2 Substrate Diagnostic Kit for ANA as an Initial Step in the Evaluation of a Novel Fully Automated IFA Analyzer in a Laboratory in England
2399: Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
Location: Hall F1
Abstract Poster Presenter: Gregg Silverman, MD – NYU Grossman School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2400: Prevalence and Predictors of Types and Subtypes of Pulmonary Diseases in Systemic Lupus Erythematosus: A Population-Based Cross-Sectional Study Using High-Resolution Computed Tomography Scan and Pulmonary Function Testing
2401: Associations Between Serum Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Activity and Chronicity Features in Diagnostic and Per-protocol Repeat Kidney Biopsies in Patients with Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2402: High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2403: Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
2404: Clinical features of Elderly-onset Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Jessica Dai, BS – New York University Grossman School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2405: Machine Learning in SLE Diagnosis: Performance of the SLE Risk Probability Index Questionnaire in a Multicenter Cohort of Patients with Systemic Lupus Erythematosus
2406: Machine Learning-Based Artificial Intelligence in Systemic Lupus Erythematosus: A Systematic Review of Outcome Prediction and Patient Stratification
2407: Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
2416: Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
2421: Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria
Location: Hall F1
Abstract Poster Presenter: Nicholas Bauer, BS – Oklahoma Medical Research Foundation
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2422: Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus
2427: Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease
2428: Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes
Location: Hall F1
Abstract Poster Presenter: Shae Chambers, BA – University of Pennsylvania
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2429: mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
2429: mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
2441: Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Location: Hall F1
Abstract Poster Presenter: Cynthia Aranow, MD – Feinstein Institutes for Medical Research
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2442: Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
2445: Achievement of Treat to Target Measures with Upadacitinib in Patients with Systemic Lupus Erythematosus: Phase 2 Randomized Sleek Clinical Trial Results
2449: Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren's Syndrome: An Analysis Using Japanese Inpatient Database
Location: Hall F1
Abstract Poster Presenter: Hiroshi Shiba, MD – Suwa central hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2450: Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
2458: Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
2459: Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Location: Hall F1
Abstract Poster Presenter: Milena Delai, MD – Beth Israel Deaconess Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2460: Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Location: Hall F1
Abstract Poster Presenter: Pablo Martinez Calabuig, Sr, MD – HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN/ Escuela de doctoradoUniversidad Católica de Valencia San Vicente Mártir, Valencia, Spain
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2461: Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing
Location: Hall F1
Abstract Poster Presenter: Panagiotis Garantziotis, MD – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2462: Precision Dosing is Needed to Establish Predictable Exposure to the Active Metabolite of Mycophenolate Mofetil (MMF) in Pediatric Lupus Nephritis (LN)
Location: Hall F1
Abstract Poster Presenter: Pooja Patel, DO – Ann and Robert H. Lurie Children's Hospital of Chicago
2464: IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study
2465: CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
2467: Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis
2477: Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)
Location: Hall F1
Abstract Poster Presenter: Corrado Campochiaro, MD – IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2478: Endothelial Cell Biomarker Expression Suggests Increased Cell Adhesion in Juvenile SSc, Increased Cytokine Expression in JDM, and an Intermediate Phenotype in Overlap Syndrome Patients
2480: Respiratory Muscle Weakness in a Systemic Sclerosis Cohort
Location: Hall F1
Abstract Poster Presenter: Fabian Mendoza, MD – Thomas Jefferson University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2481: Prevalence and Trends of Suicidal Ideation Among Hospitalized Adults with Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis (2016–2020)
Location: Hall F1
Abstract Poster Presenter: Fatima Khdeir, MD – ECU Health Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2482: Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
Location: Hall F1
Abstract Poster Presenter: Francesco Bonomi, MD – University Hospital Careggi, Florence
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2483: Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?
Location: Hall F1
Abstract Poster Presenter: Gulsen Ozen, MD – University of Iowa Carver College of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2484: Phenotype of systemic sclerosis patients with positive anti–NOR-90 antibodies
Location: Hall F1
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2485: Prevalence of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease
Location: Hall F1
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2486: In Vitro Antifibrotic Effects of Nerandomilast on Cell Types Relevant to Intestinal Remodeling and Fibrosis in Systemic Sclerosis
2488: Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Kanako Chujo, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2489: Unraveling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum
Location: Hall F1
Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2490: Unmasking Mortality Risk: The Impact of Systemic Sclerosis in Stress-InducedCardiomyopathy
2493: Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs
2497: Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
Location: Hall F1
Abstract Poster Presenter: Pietro Bearzi, MD – Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2498: Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease
2500: Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
2502: Deciphering Systemic Sclerosis Phenotypes: A Novel Approach Using Clustering Algorithms and Proteomic Insights. Results from the PRECISESADS Study
2503: Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial
2527: Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
Location: Hall F1
Abstract Poster Presenter: Eduardo Borba, PhD – Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2528: Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease
2530: Broad Screening of Inflammation-Associated Proteins Identifies Serum CCL19 and CCL2 as Versatile Biomarkers of Disease Activity in IgG4-Related Disease
2533: Patterns of skin lesion transcriptomics in different forms of vasculitis
Location: Hall F1
Abstract Poster Presenter: Karyssa Stonick, BS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2534: Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61
Location: Hall F1
Abstract Poster Presenter: Koichi Sugihara, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2535: Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region
2543: Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods
Location: Hall F1
Abstract Poster Presenter: Sinem Nihal Esatoglu, MD (she/her/hers) – Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2544: Diagnostic value of vein wall thickness measurement for patients with suspected Behçet syndrome
Location: Hall F1
Abstract Poster Presenter: Sinem Nihal Esatoglu, MD (she/her/hers) – Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2545: Prevalence, Clinical Correlations and Outcomes of Cryoglobulinemic Vasculitis: a Retrospective Monocentric Study (2013–2023)
Location: Hall F1
Abstract Poster Presenter: Valeria Manfrè, MD – Division of Rheumatology, Department of Medicine, University of Udine, Italy; Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, WI
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2546: Diagnostic Journey, Clinical Burden, And Quality Of Life Of Patients With IGg4-Related Disease: Results Of A Cross-Sectional Survey Of Patients And Physicians In The United States
Location: Hall F1
Abstract Poster Presenter: Yasmin Hernandez-Barco, MD – Massachusetts General Hospital, Harvard Medical School
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2547: Assessing the Reach of a Virtual Education Program: Lupus & You: Answers. Advocacy. Action
2550: Development of a ‘Training Toolkit’ to Support Advanced Practice Providers (APPs) Entry into a Rheumatology Musculoskeletal Ultrasound Subspecialty Clinic
2554: Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
2561: Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus
2562: Enhancing Hand Osteoarthritis Classification with Generative AI: A CycleGAN and EfficientNetB7 Approach
Location: Hall F1
Abstract Poster Presenter: Ming Zhang, PhD – Boston University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2563: Factors Associated With Medication Use in the Preconception and Perinatal Period Among Women With Autoimmune Disorders: A Systematic Review
Location: Hall F1
Abstract Poster Presenter: Olivia Novosel, BSc – Temerty Faculty of Medicine, University of Toronto
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2564: An Illustration-based Patient-reported Outcome Measure Reveals Concealed Symptoms in Patients with Rheumatoid Arthritis and the Factor Contributing to the Discrepancy Between Patient and Evaluator Global Assessments
Location: Hall F1
Abstract Poster Presenter: Tetsuya Tomita, MD – Morinomiya University of Medical Sciences
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2565: Assessing Participation in the Lupus Sister Circle Support Group
Location: Hall F1
Abstract Poster Presenter: Wendy Rodgers, MPH – Lupus Foundation of America
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2566: Using Abdominal CT-Derived Bone Mineral Density and Psoas Volume for Opportunistic Osteoporosis Screening and Fracture Risk Assessment
Location: Hall F1
Abstract Poster Presenter: Ye Liu, MD, MPH, DrPH – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
TM57: Mysteries of the Brain: A case of Cognitive Impairment and Hearing Loss
Thieves Market Poster Presenter: Raeann Bowman, MD – University of Alabama Birmingham / UT Southwestern
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1779: Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium
Location: Hall F1
Abstract Poster Presenter: Wenxian Zhou, BS – University of Nebraska Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1809: Mass Spectrometry-Based N-Terminomics Uncovers Proteolytic Signatures and Pathways in Juvenile Idiopathic Arthritis Synovial Fluid
1860: GLUT and FAPα as molecular imaging markers for interstitial lung disease in systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Bo Broens, MD – Amsterdam UMC
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2003: Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
Location: Hall F1
Abstract Poster Presenter: Julia Buchfuhrer, DO – JB Arthritis and Rheumatology Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2200: Obstetric and Neonatal Complications in Women living with Axial Spondyloarthritis: a population-based, matched cohort study
1998: Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
Location: Hall F1
Abstract Poster Presenter: Herbert Baraf, MD, FACP, MACR – National Institute of Arthritis and Musculoskeletal and Skin Diseases
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2201: Adherence to Reproductive Health Guidelines in Lupus Care: Insights from Patient and Physician Surveys
Location: Hall F1
Abstract Poster Presenter: Akhil Sood, MD, MS – Washington University in St. Louis
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2229: National Multicenter study of Baricitinib in Rheumatoid Arthritis - Interstitial Lung Disease: effectiveness and progressive lung disease
Location: Hall F1
Abstract Poster Presenter: Ana Serrano-Combarro, MD – Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2523: Predictors of Glucocorticoid-Free Clinical Remission at Week 48 in Newly Diagnosed Microscopic Polyangiitis and Granulomatosis with Polyangiitis: from nation-wide registry in Japan (J-CANVAS)
Location: Hall F1
Abstract Poster Presenter: Yusuke Ushio, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1819: Spatial Transcriptomic Profiling Reveals Interferon Activation and CD8⁺ T Cell Dominance in Systemic Juvenile Idiopathic Arthritis-Macrophage Activation Syndrome Liver Inflammation
Location: Hall F1
Abstract Poster Presenter: Esraa Eloseily, MD, MSc – UT Southwestern Children's Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1856: Spatial Proteomic-based Phenotyping of Fibroblast Populations and their Microenvironment in Systemic Sclerosis Primary Heart Involvement
Location: Hall F1
Abstract Poster Presenter: Andrea-Hermina Györfi, MD – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University.
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1982: Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Location: Hall F1
Abstract Poster Presenter: Kuan-Tung Lin, MD – North East Medical Services
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1993: Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
2513: Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
1820: Cytokine profiling in refractory systemic juvenile idiopathic arthritis reveals distinct signatures for macrophage activation syndrome and lung disease.
Location: Hall F1
Abstract Poster Presenter: Grant Schulert, MD, PhD – Cincinnati Children's Hospital Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1867: Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics
Location: Hall F1
Abstract Poster Presenter: Laura Much, MSc – Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1980: Improving Vaccination Rates in the Rheumatology Clinic
Location: Hall F1
Abstract Poster Presenter: Kajal Patel, DO – Prisma Health Rheumatology Fellowship Program
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2009: Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout
2217: Improving Patient Counseling on Medication Safety During Reproductive Years
Location: Hall F1
Abstract Poster Presenter: Lauren He, MD – University of Michigan
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2247: A Pilot Study to Identify Novel Autoantibody Biomarkers in Rheumatoid Arthritis (RA) Patients Using Immunome Protein Array
Location: Hall F1
Abstract Poster Presenter: Margaret Ma, MD,PhD – National University Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2507: Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)
Location: Hall F1
Abstract Poster Presenter: Camille Mettler, MD – APHP, Service de Médecine Interne, Hôpital Bichat
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1823: Genome-Wide DNA Methylation Analysis in Familial Mediterranean Fever
Location: Hall F1
Abstract Poster Presenter: Kader Cetin Gedik, MD – UPMC Children's Hospital of Pittsburgh/University of Pittsburgh
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1861: Accelerated and Gene-specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Brecca Miller, n/a (she/her/hers) – Center for Human Genetics and Genomics, NYU Grossman School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1999: Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
Location: Hall F1
Abstract Poster Presenter: Herbert Baraf, MD, FACP, MACR – National Institute of Arthritis and Musculoskeletal and Skin Diseases
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2220: Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
Location: Hall F1
Abstract Poster Presenter: Rashmi Dhital, MD – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2242: Analysis of Bronchoalveolar Fluid Cytokine Profile as a Way to Understand the Lung Disease Associated with Systemic Juvenile Idiopathic Arthritis
Abstract Poster Presenter: Patricia Pioli, PhD – Geisel School of Medicine at Dartmouth
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1914: Performance Comparison of Artificial Intelligence tools ChatGPT, Bing AI, and Google Bard for Clinical Rheumatology Decision Support: When AI Talks Rheumatology
2007: Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
Location: Hall F1
Abstract Poster Presenter: Min Jung Kim, MD – Seoul Metropolitan Government Boramae Medical center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2222: Neonatal Myocardial Strain in Offspring born to Mothers with Systemic Lupus Erythematosus: Pilot Data from the LEGACY Cohort
Location: Hall F1
Abstract Poster Presenter: Reem Farhat, MD – McGill University, Faculty of Medicine and Health Sciences
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2249: Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies
1824: Tissue-Resident Natural Killer Cells May Drive Monocyte Differentiation And Macrophage Accumulation In The Inflamed Joints Of Pediatric Juvenile Idiopathic Arthritis Patients
Location: Hall F1
Abstract Poster Presenter: Roselyn Fierkens, BS – University of Colorado-Anschutz Medical Campus
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1875: Fcγ-receptor activation by circulating immune complexes in autoimmunity and CD19.CAR-T cell therapy
Location: Hall F1
Abstract Poster Presenter: Wolfgang Merkt, MD – University Hospital Düsseldorf
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1984: Improving Lipid Screening Rates in Rheumatic Disease Patients: An Academic Fellowship Quality Improvement Project
2010: Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli
Location: Hall F1
Abstract Poster Presenter: Tony Merriman, PhD – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2221: Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Rashmi Dhital, MD – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2236: Treatment-induced autoantibodies in Rheumatoid Arthritis patients receiving anti-TNF inhibitors or JAK inhibitors
1828: CD14+CXCL10+Monocytes Remodel the Peripheral Immune Network in sJIA via UBE2D1-Driven Inflammatory Programming
Location: Hall F1
Abstract Poster Presenter: Xuemei Tang, MD, Professor, Chief Physician – Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1863: bag3 in Systemic Sclerosis: Possible Therapeutic Target and Biomarker for Pulmonary Fibrosis
Location: Hall F1
Abstract Poster Presenter: Claudia Iannone, MD – University of Milan, Gaetano Pini CTO
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1987: Evaluating User Engagement and Real-World Impact of a PMR-Specific Digital Symptom Assessment Tool: A 12-Month Analysis of PainSpot™
2004: Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry
2259: Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
1979: Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis
2005: Elevated Serum Uric Acid as an Independent Risk Factor for Multiple Stent Placement in Non-Hypertensive, Non-Diabetic Patients with Coronary Artery Disease: A Retrospective Cohort Analysis
Location: Hall F1
Abstract Poster Presenter: Lemei An, MD – Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2208: Contraception and Pregnancy Experiences of Veterans from Minoritized Populations with Rheumatoid Arthritis
2514: Comparison of Demographics and Outcomes of Inpatient Hospitalization of Severe Asthma Patients with Eosinophilic Granulomatosis with Polyangitis. A Study on the National Inpatient Sample Database
1990: Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
Location: Hall F1
Abstract Poster Presenter: Alex Tinianow, MD – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2095: Trends in Mortality and Disability-Adjusted Life Years (DALYs) from Osteoarthritis in the United States Compared to Global Estimates: A GBD-Based Analysis (1990–2021)
Location: Hall F1
Abstract Poster Presenter: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2219: Transcriptomic and Immune Landscape of Recurrent Pregnancy Loss and Unexplained Infertility in Systemic Lupus Erythematosus
2520: Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
Location: Hall F1
Abstract Poster Presenter: Thomas Neumann, MD – Kantonsspital St. Gallen
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1778: Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers
2198: Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach
2521: DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort
2209: Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS
Location: Hall F1
Abstract Poster Presenter: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2335: The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.
2522: Clinical Outcomes and Prognostic Impact of Cardiac and Cerebrovascular Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Yuko Shirota, MD., PhD., – Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1859: Unraveling Disparities in Systemic Lupus Erythematosus-Related Mortality Among U.S. Adults (≥25 Years) with Malignancy: A Longitudinal Analysis of Gender, Race, and Geographic Inequities Using CDC WONDER (1999–2020)"
Location: Hall F1
Abstract Poster Presenter: Ayesha Khan, n/a – Dow Medical College
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1975: Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
2013: Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
Location: Hall F1
Abstract Poster Presenter: Yu Xue, MD – Huashan Hospital,Fudan University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2214: Hydroxychloroquine and Pregnancy Outcomes in Lupus: Results from a population-based cohort study
2250: Clinical and Serological Predictors of Interstitial Lung Disease in Rheumatoid Arthritis: Are Anti-Citrullinated Protein Antibodies Truly Relevant?
1988: Advancing Vascular Assessment: Combining NIRS-VOT and Ultrasound-based Brachial Artery Diameter for Improved Diagnostics in Healthy Controls and APS
2202: Epidemiologic Evaluation of Postpartum Mental Health for Women Living with Systemic Lupus Erythematosus: A Population-Based Cohort Study Among Medicaid Enrollees
2000: Can Uric Acid Protect Joints? Lower Incidence of Large Joint Replacements Among Individuals with Higher SUA
Location: Hall F1
Abstract Poster Presenter: Janis Timsans, MD – Päijät-Häme Central Hospital, Department of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2099: Incidence and Prevalence of Osteoarthritis in the United States Compared to Global Trends: Insights from the Global Burden of Disease Study (1990–2021)
2211: Maternal Adverse Pregnancy Outcomes and Risk Factors in Patients with Systemic Lupus Erythematosus in the United States
Location: Hall F1
Abstract Poster Presenter: Grace Haeun Lee, BA – Massachusetts General Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2243: Differences In GDF-15 Levels In Rheumatoid Arthritis Patients With Remission Or Mild Disease Activity Are Associated With Fewer Depressive Symptoms: Clinical Data And Bioinformatic Analysis
2245: Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Location: Hall F1
Abstract Poster Presenter: Lie Dai, PhD – Sun Yat-sen University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2215: Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes
2235: Proportion of Early Rheumatoid Arthritis Patients with Improved, Stable, or Worsened Lung Function Over 1-Year: Results from a Multicenter, Prospective Cohort Study
2212: Impact of the 2020 ACR Reproductive Health Guidelines on Treatment Strategies and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
2254: Association of Disease Activity with Insomnia, Depression, and Fatigue in Patients with Rheumatoid Arthritis: A Multicenter Prospective Observational Study
1811: Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
2199: Disparities in Reproductive Health Counseling Among Hispanic Women with Autoimmune Rheumatic Diseases: Insights from a Patient-Reported Survey in an Urban Safety-Net Setting
2262: Assessment of Small Airway Disease in Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2301: Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
Location: Hall F1
Abstract Poster Presenter: Sara Stern, MD – University of Utah
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2504: Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021
Location: Hall F1
Abstract Poster Presenter: Anuya Natu, MBBS – John H Stroger, Jr. Hospital of Cook County
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2213: Awareness Regarding Contraceptive Measures, Drug Usage And Factors Affecting Pregnancy Among Patients With Autoimmune Rheumatic Diseases
2308: Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
2234: Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Cheuk Yin Tam, n/a – Department of Medicine and Therapeutics, The Chinese University of Hong Kong
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2203: Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine
2233: Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)
Location: Hall F1
Abstract Poster Presenter: Caleb Marlin, PhD – Oklahoma Medical Research Foundation
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2241: RADAR: A Deep Learning Pipeline for Automated Scoring of Joint Damage in Rheumatoid Arthritis Radiographs
2260: Generative AI model identifies patients with Rheumatoid Arthritis (RA) months prior the diagnosis date: results from a large real-world RA cohort
2196: Recognition and Treatment of Idiopathic Granulomatous Mastitis: A Case Series
Location: Hall F1
Abstract Poster Presenter: Jenny Solomon, MD – NYU Langone Long Island
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2246: Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study
Location: Hall F1
Abstract Poster Presenter: Lucas Pires, MD – State University of Campinas (UNICAMP) - Brazil
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2297: Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study
Location: Hall F1
Abstract Poster Presenter: Faye Yu, BSc – Johnson & Johnson Innovative Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2332: Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
2312: Sociodemographic Characteristics and Healthcare Utilization in Patients with IBD-Associated Arthritis vs. IBD Alone: A Nationwide Inpatient Analysis
Location: Hall F1
Abstract Poster Presenter: Faria Sami, MD – The University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2315: Alterations in the Gut Microbiome in Ankylosing Spondylitis and Their Correlation with Disease Activity
Location: Hall F1
Abstract Poster Presenter: Hyemin Jeong, MD – Soonchunhyang University Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2516: Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023)
1858: Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cellsvia a Clathrin Endocytosis Mechanism and Interact with Their Intracellular Antigen
2008: Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
2244: Bone Mineral Density Trajectories and Fracture Risk in Rheumatoid Arthritis: A 7-Year Longitudinal Analysis Using Group-Based Trajectory Modeling
Location: Hall F1
Abstract Poster Presenter: Kei Hirose, MD – Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2298: When Imaging and Biopsy Disagree: Diagnostic Value of Doppler Ultrasound and Histologic Features beyond the Focus Score
1825: Serum proteomic and single cell RNA sequencing analysis reveals macrophage activation syndrome physiology and widespread complement dysregulation are associated with severe dengue infection in a pediatric cohort
1862: Comprehensive analysis of the major histocompatibility complex in systemic sclerosis-associated interstitial lung disease identifies novel associated loci and potential progression biomarkers
Location: Hall F1
Abstract Poster Presenter: Carlos de la Rosa Báez, MSc – Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine López-Neyra, CSIC
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1985: Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
Location: Hall F1
Abstract Poster Presenter: Rachel Galvao, MD – University of Pennsylvania Health System
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2011: A Phase 1 Placebo Controlled, Single (SAD) and Multiple Dose Escalation (MAD) Safety and Pharmacokinetic (PK) Study of a Novel Colchicine Analogue ABP-745 in Healthy Volunteers (HV)
2225: The Impact of Pregnancy Planning on the Prevalence of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Retrospective Study from Three Japanese Tertiary Referral Centers
Location: Hall F1
Abstract Poster Presenter: Takehiro Nakai, MD – St. Luke's International Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2255: Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
2299: Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
1776: Preclinical Development of a Novel TL1A-Targeting Antibody with Extended Half-life and Low Immunogenicity Risk for the Treatment of Inflammatory Diseases
1816: Single-Cell RNA-Transcriptomics of JDM Skin Identifies JDM-Associated Immune Cell Populations and Dysregulated Interferon Signaling in Immune and Endothelial Cells
2012: A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
2248: Elevated Anti-PAD Autoantibodies in a Singaporean Chinese Rheumatoid Arthritis (RA) Cohort with Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) Positivity: A Case-control Exploratory Study
Location: Hall F1
Abstract Poster Presenter: Margaret Ma, MD,PhD – National University Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2293: CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Location: Hall F1
Abstract Poster Presenter: Antoine Sreih, MD – Cullinan Therapeutics
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1775: Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM
1821: Transcriptiomics of tear RNA from children with active and inactive chronic anterior uveitis
Location: Hall F1
Abstract Poster Presenter: Grant Schulert, MD, PhD – Cincinnati Children's Hospital Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1869: A Mirna Signature Consisting of High let7i-5p, High mir-483-5p, Low mir-223- 3p Characterizes Connective Tissue Diseases with Interstitial Lung Disease
0829: Multi-Center Use of an Online Case-Based Simulation to Evaluate Medical Trainee Use of Diagnostic Imaging and Lab Tests to Correctly Diagnose MSK Complaints
Time-Independent Disease State Identification Defines Distinct Trajectories Determined by Localized vs Systemic Inflammation in Patients with Early Rheumatoid Arthritis
Panelist: Michael Weisman, MD – Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA
Monday, Oct 27th
4:00 PM - 5:00 PM Central Time
27M70: Stats Bootcamp 2: Methods for Analyzing Groupings that Cannot be Directly Observed and Measured: An Introduction to Latent Structures and Latent Variable Models
2168: Training Objective Structured Clinical Examinations in a Clinical Immunology department: Expectations and Perceptions of Medical students at Graduating Level
2172: Automating the Curation and Summarization of Rheumatology Fellowship Applications using Generative AI Agents and Transformer Models
Location: Hall F1
Abstract Poster Presenter: Andrew Trotter, n/a – University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2173: Developing Musculoskeletal Ultrasound Clinical Electives: Bridging the Basic Sciences and Clinical Application in Undergraduate Medical Education
2176: Addressing Hesitancy in JAK Inhibitor Use: Outcomes from Continuing Medical Education Reveal Confidence-knowledge Gaps Among Community Rheumatologists
2178: Online Education Significantly Improved Rheumatologists’ Knowledge of the Diagnosis and Management of Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Elaine Bell, PhD – Medscape Global Education
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2179: Educational online webinars of European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) for patients, caregivers and healthcare professionals: six years’ experience
Location: Hall F1
Abstract Poster Presenter: Emanuele Gotelli, MD, PhD – Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2180: Helping Hands: Curriculum using Simulators to Teach the Hand Exam and Assessment of Small Joint Swelling in Inflammatory Arthritis
Location: Hall F1
Abstract Poster Presenter: Ibtissam Gad, MD – University of Michigan
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2181: A Pilot High-fidelity Simulation for Pediatric Rheumatology Learners
Location: Hall F1
Abstract Poster Presenter: John Bridges, MD, MS – University of Alabama at Birmingham/Children's of Alabama
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2182: Rheum for Improvement: A Needs Assessment Survey for an Internal Medicine Resident Curriculum
2185: The Evolving Digital Landscape of Social Media among Rheumatology Professionals: A Global Analysis by the EULAR SoMeR Study Group
Location: Hall F1
Abstract Poster Presenter: Latika Gupta, MD, DM, MRCP – University of Birmingham & Royal Wolverhampton NHS Trust
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2186: Developing Rheumatology Specific Anki Electronic Flashcards for Teaching Preclinical Students United States Medical Licensing Examination Board Relevant Topics
2190: Successful Implementation of an Innovative Rheumatology Curriculum for Internal Medicine Residents: Fellow-Initiated Rheumatology EDUcation Project (FIRED UP)
Location: Hall F1
Abstract Poster Presenter: Raeann Bowman, MD – University of Alabama Birmingham / UT Southwestern
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2191: Development, Validation and Performance of a Questionnaire for Assessing the Knowledge Base of Primary Care Physicians About Management of Rheumatoid Arthritis and Impact of an Information Course
Guidelines on the Use of Machine Learning Models in Rheumatology: Recommendations for Reporting of Model Specifications and Results for Authors and Reviewers
2198: Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach
2226: Factors Associated with Contraceptive Counseling by Rheumatologists for Reproductive-Aged Female Patients Prescribed Teratogenic Medications
Location: Hall F1
Abstract Poster Presenter: Yongjay Kim, BA – Cornell University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2209: Pregnancy outcomes in Systemic Lupus Erythematosus: Insights from a multicenter Spanish Study on the impact of antiphospholipid antibodies and APS
Location: Hall F1
Abstract Poster Presenter: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2214: Hydroxychloroquine and Pregnancy Outcomes in Lupus: Results from a population-based cohort study
2202: Epidemiologic Evaluation of Postpartum Mental Health for Women Living with Systemic Lupus Erythematosus: A Population-Based Cohort Study Among Medicaid Enrollees
2212: Impact of the 2020 ACR Reproductive Health Guidelines on Treatment Strategies and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Single-Center Retrospective Study
2199: Disparities in Reproductive Health Counseling Among Hispanic Women with Autoimmune Rheumatic Diseases: Insights from a Patient-Reported Survey in an Urban Safety-Net Setting
2203: Maternal and Fetal Outcomes Associated with IL-17 Inhibitor Exposure During Pregnancy in Patients with Seronegative Arthritis: A Case Series of Nine
2225: The Impact of Pregnancy Planning on the Prevalence of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Retrospective Study from Three Japanese Tertiary Referral Centers
Location: Hall F1
Abstract Poster Presenter: Takehiro Nakai, MD – St. Luke's International Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2210: Changes in Treatment Pathways Over Time in Pregnancies with Active Lupus Nephritis
2631: Dapirolizumab Pegol, a Novel CD40L Inhibitor, Showed No Adverse Outcomes in an In Vivo Non-Human Primate Reprotoxicity Study and Displayed Minimal to No Human Placental Transfer in an Ex Vivo Study
The Role of the Mammalian Commensal Intestinal Microbiota in Intestinal and Systemic Immunity Affecting the Development and Mitigation of Ocular Inflammation
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Rheumatoid Arthritis – Etiology and Pathogenesis Poster
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
Rheumatoid Arthritis – Treatment Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0049: Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
0050: TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis
0057: TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype
0061: IL-22 Contributes to Autoantibody-induced Arthritis Via Modulation of Inflammatory Cytokine and Chemokine Expression in the Inflamed Synovium of a Murine Model
0065: Expression and Co-Localization of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues Precedes the Development of Cardiac Fibrosis in Collagen-Induced Arthritis
Location: Hall F1
Abstract Poster Presenter: Wenxian Zhou, BS – University of Nebraska Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0066: RA-required synovial tissue-resident monocyte lineage cells are comprised of three distinct subpopulations.
Location: Hall F1
Abstract Poster Presenter: Yidan Wang, MS – Northwestern University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0067: Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
0071: Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.
0072: Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs
0073: HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Courtney Myhr, MS – University of Wisconsin-Madison
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0074: Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving ImmuneComplex Formation and Cellular Clearance
0076: Antibodies to Malondialdehyde-acetaldehyde Are Associated with Circulating Inflammatory Mediators During the Preclinical Stages of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Emma Weis, BS – University of Nebraska Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0077: Transformer-based multi-omics study identifies important role of glycine, serine and threonine metabolism pathway in rheumatoid arthritis complicated by anemia
Location: Hall F1
Abstract Poster Presenter: Fanxin Zeng, PhD – Departmant of Clinical Research Center, Sichuan Clinical Research Center for Medical Imaging, Dazhou Central Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0078: Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
0084: Regulation of the same chemokine gene transcription by different histone lysine methyltransferases, MLL1 and MLL3, in rheumatoid arthritis synovial fibroblasts
Location: Hall F1
Abstract Poster Presenter: Keita Okamoto, MD;PhD – Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0085: Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Kensuke Suga, PhD – Cedars-Sinai Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0086: Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State
Location: Hall F1
Abstract Poster Presenter: Kiana Chen, PhD – University of Rochester School of Medicine and Dentistry
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0087: Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms
Location: Hall F1
Abstract Poster Presenter: Laura Muñoz-Barrera, BSc – IMIBIC/Reina Sofia Hospital/University of Cordoba
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0088: Imbalance of Inflammation-Regulating Microorganisms and Predicted Metabolomic Pathways Associates With Disease Evolution in Individuals At-Risk for Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Lyndsey Cole, MD – University of Colorado School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0089: Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis
0092: SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging
0094: Distinct immune-molecular signatures modulated ex vivo by JAK and TNF predict Rheumatoid Arthritis therapy outcomes in patients naïve to biologic and targeted synthetic DMARDs
0097: Aberrant Histone Marks Increase the Inflammatory Phenotype of Rheumatoid Arthritis Fibroblast-like Synoviocytes (RA FLS) by Suppressing NUB1 Induction
0430: Retrospective evaluation of the clinical impact of democgraphic , serological , clinical , radiological parameters and treatment modalities in patients with RA-ILD
Location: Hall F1
Abstract Poster Presenter: ender terzioglu, MD – Akdeniz University Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0431: Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
0433: In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022
0434: The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice
Location: Hall F1
Abstract Poster Presenter: Meliha Kapetanovic, MD,PhD – Lund University, Department for clinical sciences Lund, section of rheumatology and Lund University Hospital Lund and Malmö
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0436: Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?
0439: Osteoarthritis and Other Degenerative Musculoskeletal Disorders Are Common and Often Associated with Active Inflammation in Difficult-to-Treat Rheumatoid Arthritis: A Cross-Sectional Cohort
0448: Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
Location: Hall F1
Abstract Poster Presenter: Ioannis Koulas, MD, MSc – Jacobi Medical Center/Albert Einstein College of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0449: Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
Location: Hall F1
Abstract Poster Presenter: Joel Kremer, MD – The Corrona Research Foundation
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0450: The Fibrosis-4 Index (FIB-4) Correlates with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis
0454: Models to predict flare and sustained remission in Rheumatoid Arthritis patients on optimization treatment with bDMARDs: clinical and molecular insights
0455: Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active Psoriatic Arthritis
0460: The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Ryan Salama, BA – University of Minnesota Twin Cities
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0461: Right Diagnoses For the Wrong Reasons: Limitations of Current Large-Language Model based Agentic Frameworks for Screening of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Sarthak Verma, MD (he/him/his) – Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0462: Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?
0463: Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis
Location: Hall F1
Abstract Poster Presenter: Solana Cushing, BA – Icahn School of Medicine at Mount Sinai
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0464: Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty
Location: Hall F1
Abstract Poster Presenter: Solana Cushing, BA – Icahn School of Medicine at Mount Sinai
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0465: Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Location: Hall F1
Abstract Poster Presenter: Suchita Nety, PhD – Harvard Medical School
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0466: Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
Location: Hall F1
Abstract Poster Presenter: Tulsi Joishy, PhD – Vanderbilt University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0467: A Machine Learning Classifier Leveraging anti-ra33, anti-pad4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA
0470: Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
0471: An Open-label, Randomized, Controlled Phase 1/2 Study to Assess the Safety and Efficacy of KYV-101 anti-cd19 CAR-T Cell Therapy in Active and Difficult-to-treat ACPA Positive Rheumatoid Arthritis: Preliminary Results of the COMPARE Trial
Location: Hall F1
Abstract Poster Presenter: Ioanna Minopoulou, MD;MSc – Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0472: Detrimental Effects of Umbilical Cord Blood-derived Mesenchymal Stem Cells Intra-articular Injections on Pannus Invasiveness
0477: At the patient level, ultrasound evaluation during the follow up of rheumatoid arthritis does not modify radiographic evolution: a prospective, multicenter, randomized, pragmatic clinical trial (BCD study)
0478: Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
0481: Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
0486: Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0487: Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0488: Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH
0490: Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted - DMARD in RA: A Systematic Review and Network Meta-analysis
Location: Hall F1
Abstract Poster Presenter: Jia Li, MD, PhD (she/her/hers) – Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0491: Association Of short Chain Fatty Acids and diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
0494: LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
0495: Effectiveness and Safety of Iguratimod with Background Methotrexate Therapy in Indian Patients with Rheumatoid Arthritis: A Randomized Double Blinded Placebo Controlled Study
0496: Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
0497: Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Location: Hall F1
Abstract Poster Presenter: Nariaki Hao, PhD – Graduate School of Medical and Dental Sciences, Niigata, Japan
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0498: Pharmacokinetic Similarity of DRL_AB, a Proposed Biosimilar Abatacept (Orencia®): Results from a Randomized, Single Dose, Double-Blind, Parallel Arm, Comparative Pharmacokinetic Study in Healthy Subjects by the Intravenous Route.
0499: Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Location: Hall F1
Abstract Poster Presenter: Roy Fleischmann, MD – Metroplex Clinical Research Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0500: Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Location: Hall F1
Abstract Poster Presenter: Sama Hajizadeh, MD – Allegheny Health Network
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0501: Phase 1b Study of SBT777101, an Engineered CAR-T-Regulatory Cell Product, in Patients With Rheumatoid Arthritis: Interim Demographics and Safety
0795: Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response
0872: Silencing of Schnurri-3 protects from TNF-induced bone loss and is accompanied by upregulation of type I Interferon-Stimulated Genes (ISGs) in osteoblasts.
1320: Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
1323: Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
1331: anti-beta-2-glycoprotein-1 Iga Antibodies Facilitate Macrophage Cholesterol Loading and Influence Coronary Atherosclerosis Progression in a Dose-dependent Manner in Rheumatoid Arthritis
1341: Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures
Location: Hall F1
Abstract Poster Presenter: Saskia Truijen, MSc – Maastricht University Medical Centre+
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1343: Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
1346: Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
Location: Hall F1
Abstract Poster Presenter: YU Chen, MD, MSc, BA (she/her/hers) – 1. Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1347: The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
1348: Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Location: Hall F1
Abstract Poster Presenter: AJ Fernandez, n/a – Eli Lilly and Company
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1349: Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study
Location: Hall F1
Abstract Poster Presenter: Andrew Ostor, MD – Australian National University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1350: Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
Location: Hall F1
Abstract Poster Presenter: Daniel Zavada, MD – Charles University, Third Faculty of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1351: Are Glucocorticoids Associated with Worse Overall Survival Among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
1353: Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
1354: Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Hongtao Jin, MD – The Second Hospital of Hebei Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1354: Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Hongtao Jin, MD – The Second Hospital of Hebei Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1355: Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
1359: Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Maya Khasho, MD – University of central florida
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1360: Evaluating Causal Effects of Biologic and Targeted Synthetic Disease-modifying Anti-rheumatic Drugs Targets in Rheumatoid Arthritis Using Mendelian Randomisation
1361: Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Location: Hall F1
Abstract Poster Presenter: Mingfang Sun, MD – Department of Rheumatology & Clinical Immunology, Daping Hospital & Research Institute of Surgery, Army Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1362: Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
1363: Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.
Location: Hall F1
Abstract Poster Presenter: NAOKI Kondo, MD, PhD – Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1364: Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
1365: Economic impact of early treatment and strict disease control in rheumatoid arthritis: a cost-minimization approach concerning biological therapy
1366: Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
1371: Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Location: Hall F1
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1372: Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Location: Hall F1
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1373: Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Location: Hall F1
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1374: AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
1375: 86-96% of Rheumatoid Arthritis (RA) Patients with RA Who Have 0 or 1 Swollen Joint or Tender Joint but Are Classified as Moderate/high on RA Indices Have 1-9 Comorbidities Recognized on a Multidimensional Health Assessment Questionnaire (MDHAQ)
1342: The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis
Location: Hall F1
Abstract Poster Presenter: Saskia Truijen, MSc – Maastricht University Medical Centre+
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1330: Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
1677: First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care
1678: Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study
1679: Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort
1750: Urinary Proteomic Signature Identifies Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Location: W183A-C
Presenting Author: Jia Shi, MD – University of Washington
Tuesday, Oct 28th
11:15 AM - 11:30 AM Central Time
1751: Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III
Location: Hall F1
CE: 0.00
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
Rheumatoid Arthritis – Treatment Poster III
Location: Hall F1
CE: 0.00
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2227: The Paraoxonase-1 Q192R Polymorphism is Associated with Increased Risk of Incident Clinical Rheumatoid Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
2240: Diabetes Significantly Amplifies Risk of Cardiac Arrhythmias in Rheumatoid Arthritis Patients: Results from a Multi-Center Electronic Health Record Study
2253: Wrist-worn Wearable Device Data Can Be a New Digital Biomarker For Disease Activity In Rheumatoid Arthritis: a Multicenter Single-arm Prospective Study
2265: Progressive Interstitial Lung Disease associated to Rheumatoid Arthritis despite Abatacept therapy. Data from a large national multicenter cohort of 526 patients
Location: Hall F1
Abstract Poster Presenter: Ana Serrano-Combarro, MD – Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2266: Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of All-Cause Mortality and All-Cause Cancer: A Population-Based Cohort Study
2267: Impact of Baseline Cardiovascular Risk Factors Comorbidities on an Adalimumab Biosimilar Efficacy, Quality of Life and Safety In Patients with Patients with Moderately to Severely Active Rheumatoid Arthritis: Results from the AURIEL-RA study
2268: Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
2269: Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
2271: Assessing the Real-world Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic Dmards on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
2272: Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: A Case Series from the RA UCLouvain Brussels Cohort
2273: Impact of Upadacitinib on Glucocorticoid Reduction in Patients with Moderate-to-Severe RA Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study
Location: Hall F1
Abstract Poster Presenter: FRANK BUTTGEREIT, MD – Charité University Medicine Berlin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2274: Importance Of Fc Region On Therapeutic Survival In Rheumatoid Arthritis Patients With Anti-TNF Therapy
2275: Agreement Between Two Rheumatoid Arthritis Response Measures Across Bts DMARD Treatment Classes in a Large, Prospective Observational Study Supporting the Development and Clinical Validation of a Novel Blood based Precision Medicine Test
2276: Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
2279: Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial
Location: Hall F1
Abstract Poster Presenter: Koray Tascilar, MD – Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2280: Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis
2281: Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study
Location: Hall F1
Abstract Poster Presenter: Louis Bessette, MD, MSc – Centre de l'Ostéoporose et de Rhumatologie de Québec
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2282: Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis
2287: Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Yinan Huang, PhD, MS – Department of Pharmacy Administration, University of Mississippi
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2288: Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
2288: Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
2247: A Pilot Study to Identify Novel Autoantibody Biomarkers in Rheumatoid Arthritis (RA) Patients Using Immunome Protein Array
Location: Hall F1
Abstract Poster Presenter: Margaret Ma, MD,PhD – National University Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2242: Analysis of Bronchoalveolar Fluid Cytokine Profile as a Way to Understand the Lung Disease Associated with Systemic Juvenile Idiopathic Arthritis
2249: Evaluation of a Screening Tool for Identifying Risk of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with Targeted Therapies
2259: Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
2250: Clinical and Serological Predictors of Interstitial Lung Disease in Rheumatoid Arthritis: Are Anti-Citrullinated Protein Antibodies Truly Relevant?
2243: Differences In GDF-15 Levels In Rheumatoid Arthritis Patients With Remission Or Mild Disease Activity Are Associated With Fewer Depressive Symptoms: Clinical Data And Bioinformatic Analysis
2245: Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Location: Hall F1
Abstract Poster Presenter: Lie Dai, PhD – Sun Yat-sen University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2235: Proportion of Early Rheumatoid Arthritis Patients with Improved, Stable, or Worsened Lung Function Over 1-Year: Results from a Multicenter, Prospective Cohort Study
2254: Association of Disease Activity with Insomnia, Depression, and Fatigue in Patients with Rheumatoid Arthritis: A Multicenter Prospective Observational Study
2262: Assessment of Small Airway Disease in Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2234: Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Cheuk Yin Tam, n/a – Department of Medicine and Therapeutics, The Chinese University of Hong Kong
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2256: Improved Outcomes of Acute Myocardial Infarction Among Patients with Rheumatoid Arthritis: A Propensity Matched National Study
2233: Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)
Location: Hall F1
Abstract Poster Presenter: Caleb Marlin, PhD – Oklahoma Medical Research Foundation
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2241: RADAR: A Deep Learning Pipeline for Automated Scoring of Joint Damage in Rheumatoid Arthritis Radiographs
2260: Generative AI model identifies patients with Rheumatoid Arthritis (RA) months prior the diagnosis date: results from a large real-world RA cohort
2246: Different Populations, Different SDAI Cut-Off? A Proposal for a New Remission Threshold in Brazilian RA Patients from a National Multicenter Study
Location: Hall F1
Abstract Poster Presenter: Lucas Pires, MD – State University of Campinas (UNICAMP) - Brazil
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2257: Impact of Family History of RA in Patients Evaluated for Arthralgia: A Comprehensive Analysis of the Reuma-check Cohort
2244: Bone Mineral Density Trajectories and Fracture Risk in Rheumatoid Arthritis: A 7-Year Longitudinal Analysis Using Group-Based Trajectory Modeling
Location: Hall F1
Abstract Poster Presenter: Kei Hirose, MD – Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2255: Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
2248: Elevated Anti-PAD Autoantibodies in a Singaporean Chinese Rheumatoid Arthritis (RA) Cohort with Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) Positivity: A Case-control Exploratory Study
Location: Hall F1
Abstract Poster Presenter: Margaret Ma, MD,PhD – National University Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2264: Male Sex and Obesity Are Risk Factors for Sarcopenia in RA: Korea National Health and Nutrition Survey 2008–2011
Location: Hall F1
Abstract Poster Presenter: Yoon-Jeong Oh, MD – Uijeongbu Eulji Medical Center
Wednesday, Oct 29th
9:30 AM - 11:00 AM Central Time
29W07: Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization
2640: Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
Location: W190A-B
Presenting Author: Sho Fukui, MD, MPH – Brigham and Women's Hospital / Kyorin University Hospital
Wednesday, Oct 29th
10:00 AM - 10:15 AM Central Time
2641: Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
2642: Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
2681: Derivation and Validation of Inflammation-Adjusted Lipid Measures to Improve Cardiovascular Risk Prediction in Rheumatoid Arthritis
Location: W183A-C
Presenting Author: Tate Johnson, MD – University of Nebraska Medical Center
Wednesday, Oct 29th
11:45 AM - 12:00 PM Central Time
2682: Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial
2683: Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Location: W183A-C
Presenting Author: Stevie Barry, MBChB – University of Pennsylvania Health System Program
Wednesday, Oct 29th
12:15 PM - 12:30 PM Central Time
2684: Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
2686: Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Location: W183A-C
Presenting Author: Koray Tascilar, MD – Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology
Rheumatologic Mimics
Monday, Oct 27th
4:00 PM - 5:00 PM Central Time
27M71: Fake Rheum: Case-Based Approach to Rheumatology Mimics
0672: Determinants of Progressive Microstomia in Systemic Sclerosis: Insights from the GENISOS Cohort with a Focus on GI Involvement
Location: Hall F1
Abstract Poster Presenter: Ashish Balar, MBBS, MPH – The University of Texas Health Science Center Houston
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0673: Association Between Vasoactive-vasodilating Therapy and Reduced Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: Evidence from a EUSTAR Study
0675: Neutrophil-to-Lymphocyte Ratio as a biomarker for disease onset and a predictor for mortality in Systemic Sclerosis – real-world data from a large healthcare provider in Israel.
0676: Engineered glove for the objective assessment of hand dexterity in patients with systemic sclerosis: correlations with clinical features, nailfold videocapillaroscopy, and high frequency skin ultrasonography
Location: Hall F1
Abstract Poster Presenter: Elvis Hysa, MD – University of Genova
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0677: Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
0678: Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
Location: Hall F1
Abstract Poster Presenter: Wolfgang Merkt, MD – University Hospital Düsseldorf
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0679: Inhibition of TGFb3 in Systemic Sclerosis Patients Does Not Result in TGFb Pathway Modulation in Skin Biopsies or Circulation
0681: Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis
0686: Use of a Smartphone App which Incorporates Feedback to Patients to Monitor Systemic Sclerosis-related Digital Ulcers – a Potential New Tool for Remote Clinical Monitoring
Location: Hall F1
Abstract Poster Presenter: Ariane Herrick, MD – The University of Manchester, UK
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0687: Distinct Cancer Risk Profiles in Patients with Systemic Sclerosis with Autoantibody Stratification
Location: Hall F1
Abstract Poster Presenter: Arjun Mahajan, MS – Harvard Medical School
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0688: Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Location: Hall F1
Abstract Poster Presenter: Benjamin Chaigne, MD, PhD – Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0689: Development of an Articular Activity Score in Systemic Sclerosis (ASSESS): Identifying Core Instruments for Disease Activity Assessment
0690: Quantitative 18F-FDG PET-CT of the lungs detects treatment induced changes in patients with early severe diffuse cutaneous systemic sclerosis and interstitial lung disease
Location: Hall F1
Abstract Poster Presenter: Bo Broens, MD – Amsterdam UMC
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0691: Association of Elevated Platelets and CRP with Severe Disease and Poor Survival in Systemic Sclerosis
0692: A Randomised Open Label Pilot Trial Comparing Mycophenolate Mofetil with No Immunosuppression in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)
0693: Impact of X Chromosome Dosage on the Development of Diffuse and Limited Systemic Sclerosis in Klinefelter, Triple X, and Turner Syndromes: A Multicenter Cohort Study
Location: Hall F1
Abstract Poster Presenter: Hanieh Akbari, MD – Jefferson Einstein Montgomery Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0694: Treatment of Sjögren’s disease by blocking FcRn: clinical and translational data from RHO, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod
0705: Multimodal Imaging Evaluation of Patients with Raynaud's Phenomenon meeting the Criteria for "Early" Systemic Sclerosis according to LeRoy versus Healthy Controls: a Prospective Cross-sectional study
0708: Association of Choroidal Sub-foveal Thickness with Skin Manifestations and Serum Monocyte HDL Ratio in Patients with Systemic Sclerosis-a Case Control Study
0709: Systemic Sclerosis Inducible Pluripotential Stem Cells Reprogrammed into Endothelial Cells Identify Vascular Permeability May Not Be Cytokine Driven
Location: Hall F1
Abstract Poster Presenter: Tracy Frech, MD, MS – Vanderbilt University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0710: Vascular Events in Systemic Sclerosis Patients with Anti-Phospholipid Antibodies
Location: Hall F1
Abstract Poster Presenter: Vivian Shing, BS – Mayo Clinic Alix School of Medicine
Sunday, Oct 26th
1:00 PM - 2:30 PM Central Time
26S29: Abstracts: Systemic Sclerosis & Related Disorders – Basic Science
Abstract Moderator: Lauren Smith, MD – Medstar Georgetown University Hospital
CE: 0.00
Sunday, Oct 26th
3:00 PM - 3:15 PM Central Time
0843: Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis
0880: Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications
0881: Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease
0881: Circulating Monocytes with High Interferon Signature as Precursors to Osteopontin Expressing Lung Macrophages in Patients with Systemic Sclerosis and Progressive Interstitial Lung Disease
0882: Serum KL-6 as a Predictive Biomarker for Interstitial Lung Disease Progression and Mortality in Systemic Sclerosis: A Prospective Cohort Study
Location: S102
Presenting Author: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Monday, Oct 27th
11:00 AM - 11:15 AM Central Time
0883: Predictive Significance of Serum Proteins for the Course of Systemic Sclerosis-Related Interstitial Lung Disease in the Multicenter CONQUER Cohort
0957: Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc
Location: Hall F1
Abstract Poster Presenter: Astrid Hofman, MSc – Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0958: Asynchronous Resolution of Inflammation and Fibrosis in a Prolonged Experimental Model Suggests Distinct Temporal Dynamics and Resolution Mechanisms in Systemic Sclerosis
0959: Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
0960: Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Cuong Tran Manh, PhD (he/him/his) – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0961: Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis
Location: Hall F1
Abstract Poster Presenter: Cuong Tran Manh, PhD (he/him/his) – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0962: Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Location: Hall F1
Abstract Poster Presenter: Dennis Bleck, PhD (he/him/his) – University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0964: A Single-cell Atlas Reveals Dermal Endothelial Heterogeneity and Disease-specific Pathways in Autoimmune Disorders
Location: Hall F1
Abstract Poster Presenter: Jinyi Qian, -None- – Shanghai Jiao Tong University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0965: Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
0966: Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset
0973: Effects of a Novel Hybrid Protein Based on S100 on Macrophage Polarization and Its Therapeutic Efficacy in a Bleomycin-Induced Systemic Sclerosis Mouse Model.
Location: Hall F1
Abstract Poster Presenter: Takuya Kotani, MD, PhD – Osaka Medical and Pharmaceutical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0974: Tissue resident macrophages derived from induced pluripotent stem cells induce tissue fibrosis in human skin equivalent models of systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Xuezhi Hong, MD – Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0975: Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
Location: Hall F1
Abstract Poster Presenter: Xuezhi Hong, MD – Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0976: LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
1555: Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
1556: Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
1558: Gastrointestinal Symptom Severity Is Associated with Worse Patient-reported Outcomes and Dietary Patterns in Systemic Sclerosis: A Single Center Prospective Study
1570: Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Location: Hall F1
Abstract Poster Presenter: Francesco Bonomi, MD – University Hospital Careggi, Florence
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1571: Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
1572: Compromised intracellular oxygen availability and severe mitochondrial dysfunction in the skeletal muscle of patients with systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Tracy Frech, MD, MS – Vanderbilt University Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1573: WITHDRAWN
Location: Hall F1
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1574: A Rise in Serum KL-6 Levels Predicts Subsequent Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Keina Yomono, MD – Nippon Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1575: Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
Location: Hall F1
Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1576: Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
1577: Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Location: Hall F1
Abstract Poster Presenter: Luc Mouthon, MD, PhD – Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1578: Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series
1579: Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1580: Lung Vasculature Quantification on Computed Tomography Predicts New Onset of Interstitial Lung Disease in Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1581: The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
1582: Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Location: Hall F1
Abstract Poster Presenter: Marissa Savoie, MD – Hospital for Special Surgery
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1583: Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
0963: Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)
Location: Hall F1
Abstract Poster Presenter: Emanuele Gotelli, MD, PhD – Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
Systemic Sclerosis & Related Disorders – Basic Science Poster II
Location: Hall F1
CE: 0.00
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
Systemic Sclerosis & Related Disorders – Clinical Poster III
Location: Hall F1
CE: 0.00
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2470: Impaired Myocardial Flow Reserve on 82-Rubidium Positron Emission Tomography in Patients with Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Attila Feher, MD, PhD – Yale University School of Medicine - New Haven, CT
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2471: Automated Feedback and Quality Control in Nailfold Capillaroscopy: A Tool for Clinical and Educational Use
2477: Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)
Location: Hall F1
Abstract Poster Presenter: Corrado Campochiaro, MD – IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2478: Endothelial Cell Biomarker Expression Suggests Increased Cell Adhesion in Juvenile SSc, Increased Cytokine Expression in JDM, and an Intermediate Phenotype in Overlap Syndrome Patients
2480: Respiratory Muscle Weakness in a Systemic Sclerosis Cohort
Location: Hall F1
Abstract Poster Presenter: Fabian Mendoza, MD – Thomas Jefferson University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2481: Prevalence and Trends of Suicidal Ideation Among Hospitalized Adults with Systemic Lupus Erythematosus (SLE): A National Inpatient Sample Analysis (2016–2020)
Location: Hall F1
Abstract Poster Presenter: Fatima Khdeir, MD – ECU Health Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2482: Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
Location: Hall F1
Abstract Poster Presenter: Francesco Bonomi, MD – University Hospital Careggi, Florence
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2483: Is There a Seasonal Variation in Raynaud’s Phenomenon Severity in Patients with Systemic Sclerosis?
Location: Hall F1
Abstract Poster Presenter: Gulsen Ozen, MD – University of Iowa Carver College of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2484: Phenotype of systemic sclerosis patients with positive anti–NOR-90 antibodies
Location: Hall F1
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2485: Prevalence of progressive pulmonary fibrosis in systemic sclerosis-associated interstitial lung disease
Location: Hall F1
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2486: In Vitro Antifibrotic Effects of Nerandomilast on Cell Types Relevant to Intestinal Remodeling and Fibrosis in Systemic Sclerosis
2488: Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Kanako Chujo, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2489: Unraveling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum
Location: Hall F1
Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2490: Unmasking Mortality Risk: The Impact of Systemic Sclerosis in Stress-InducedCardiomyopathy
2493: Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs
2497: Unraveling the Complexity of Interferon Responses in Peripheral Blood Mononuclear Cells in Systemic Sclerosis at Single-Cell Resolution
Location: Hall F1
Abstract Poster Presenter: Pietro Bearzi, MD – Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2498: Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease
2500: Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
2502: Deciphering Systemic Sclerosis Phenotypes: A Novel Approach Using Clustering Algorithms and Proteomic Insights. Results from the PRECISESADS Study
2503: Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial
1856: Spatial Proteomic-based Phenotyping of Fibroblast Populations and their Microenvironment in Systemic Sclerosis Primary Heart Involvement
Location: Hall F1
Abstract Poster Presenter: Andrea-Hermina Györfi, MD – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University.
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1867: Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics
Location: Hall F1
Abstract Poster Presenter: Laura Much, MSc – Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1861: Accelerated and Gene-specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Brecca Miller, n/a (she/her/hers) – Center for Human Genetics and Genomics, NYU Grossman School of Medicine
1859: Unraveling Disparities in Systemic Lupus Erythematosus-Related Mortality Among U.S. Adults (≥25 Years) with Malignancy: A Longitudinal Analysis of Gender, Race, and Geographic Inequities Using CDC WONDER (1999–2020)"
Location: Hall F1
Abstract Poster Presenter: Ayesha Khan, n/a – Dow Medical College
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1873: TGF-β-Driven Mitochondrial Stress Activates cGAS-STING Signalling via Impaired Mitophagy in Systemic Sclerosis Endothelial Cells
1876: Targeting the NK cell checkpoint NKG2A promotes lung fibrosis resolution by enhancing immune clearance of senescent myofibroblasts
Location: Hall F1
Abstract Poster Presenter: Wolfgang Merkt, MD – University Hospital Düsseldorf
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1865: Shared and unique molecular signatures across different autoantibody groups in systemic sclerosis: a multi-omics analysis
Location: Hall F1
Abstract Poster Presenter: Hanlin Yin, MD, PhD – Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1858: Antinuclear Antibodies from Systemic Sclerosis Patients Enter Cellsvia a Clathrin Endocytosis Mechanism and Interact with Their Intracellular Antigen
1862: Comprehensive analysis of the major histocompatibility complex in systemic sclerosis-associated interstitial lung disease identifies novel associated loci and potential progression biomarkers
Location: Hall F1
Abstract Poster Presenter: Carlos de la Rosa Báez, MSc – Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine López-Neyra, CSIC
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1855: Small Bowel Microbial Dysbiosis and Impaired Intestinal Absorptive Function in Systemic Sclerosis- A Single Center Prospective Study
1869: A Mirna Signature Consisting of High let7i-5p, High mir-483-5p, Low mir-223- 3p Characterizes Connective Tissue Diseases with Interstitial Lung Disease
0514: Transitional Monocytes and Innate T Cell Populations Help Distinguish Ro Seropositive vs Ro Seronegative Sjögren’s Disease Using Whole Blood Immunophenotyping
Location: Hall F1
Abstract Poster Presenter: Nicholas Bauer, BS – Oklahoma Medical Research Foundation
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0518: Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
0506: Discovery-based Identification of Non-canonical Autoantibody Specificities in Ro Seronegative Sjögren's Disease Using High-content Human Proteome Arrays
Location: Hall F1
Abstract Poster Presenter: A. Darise Farris, PhD – Oklahoma Medical Research Foundation
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0513: Real-world Clinical and Diagnostic Features of Patients with Isolated Anti-SSB Antibodies Compared to Those with Combination Anti-SSA and Anti-SSB Antibodies
0519: A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren's Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Shu Liu, n/a – Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0511: Submandibular Gland Ratio Stratifies Salivary Function and Reveals a Senescence Peak in Anti-SSA Positive Sjögren’s Syndrome
Location: Hall F1
Abstract Poster Presenter: Chiao‐Feng Cheng, MD – National Taiwan University Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0521: Umbilical cord-derived mesenchymal stem cells suppress the pathogenesis of primary Sjögren's disease by inducing Bach2 expression
0507: Diagnostic performance of the lacrimal and salivary gland ultrasound in patients with primary Sjogren's disease of recent onset versus sicca controls.
0508: Serum immune complexes assessed using a cell-reporter assay are associated with serum IFN-alpha levels, disease activity and the risk of incident lymphoma in the ASSESS prospective cohort
0517: Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
Location: Hall F1
Abstract Poster Presenter: Qiguo Cui, MMed – Southern Medical Univercity
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0515: Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
Location: Hall F1
Abstract Poster Presenter: Nikolaos Marketos, MD, MSc, PhD – Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Greece
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0520: Implementation of Salivary Gland Ultrasound by General Radiology can Improve Detection of Glandular Inflammation in Patients with Sicca
Location: Hall F1
Abstract Poster Presenter: Stephanie Lee, MD (she/her/hers) – University of Pennsylvania and Children's Hospital of Philadelphia
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0509: Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
Location: Hall F1
Abstract Poster Presenter: R. Hal Scofield, MD – Oklahoma Medical Research Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes
Location: Hall F1
CE: 0.00
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1380: Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
1391: Assessment of Anti-ssa/ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
Location: Hall F1
Abstract Poster Presenter: Mala Masson, BA – NYU Langone Medical Center- Division of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1392: Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers
1381: Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
1398: Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
1394: Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
1396: Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Nevsun Inanc, MD (she/her/hers) – Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1401: Real World Treatment Patterns and Health Care Resource Use in Patients With Newly Diagnosed Sjögren’s Disease (SjD) in the United States
1402: Understanding Fatigue Through Patients' Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Saviana Gandolfo, MD – Rheumatology Unit, Ospedale del mare, Naples
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1379: Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Location: Hall F1
Abstract Poster Presenter: Biji T Kurien, PhD – Oklahoma Medical Research Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1387: Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
1386: Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
1680: Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review
Location: S103
Presenting Author: Valeria Manfrè, MD – Division of Rheumatology, Department of Medicine, University of Udine, Italy; Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, WI
Monday, Oct 27th
1:15 PM - 1:30 PM Central Time
1681: Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.
1683: Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort
1685: The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
2291: Correlation and Concordance Between the Oxford Grading Scale, Ocular Staining Score, and van BijsterveldScore in the diagnosis of Sjögren's Disease
2292: Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren's Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
2296: Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
2300: Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
2302: Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease
2301: Use of lived experiences in childhood Sjogren Disease to develop outcome measures for an N-of-1 treatment trial.
Location: Hall F1
Abstract Poster Presenter: Sara Stern, MD – University of Utah
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2297: Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study
Location: Hall F1
Abstract Poster Presenter: Faye Yu, BSc – Johnson & Johnson Innovative Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2303: Metabolic impact of low dose IL‐2 therapy for primary Sjögren’s Disease in a double‐blind, randomized clinical trial
2299: Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
2293: CLN-978, a CD19 x CD3-Directed T Cell Engager, Leads to Rapid and Deep B Cell Depletion In Vitro and In Vivo, Supporting Clinical Development Across Multiple Autoimmune Diseases
Location: Hall F1
Abstract Poster Presenter: Antoine Sreih, MD – Cullinan Therapeutics
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2304: Updates in the local treatments in Primary Sjögren's Syndrome “Efficacy and Safety”
What Causes Acinar Cell Dysfunction in Sjögren’s Disease? A Narrative Involving Fibroblast-mediated, Antigen-independent Activation of Tissue-resident CD8+ T-cells
0555: Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
0556: Evaluating the Efficacy of Sulfasalazine Compared to Placebo in the Treatment of Psoriatic Arthritis in Adults: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0557: Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
0558: Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Location: Hall F1
Abstract Poster Presenter: Monica Leung, n/a – Johnson & Johnson, San Diego, CA, USA
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0559: Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
Location: Hall F1
Abstract Poster Presenter: Nehal Mehta, MD MSCE – The George Washington University School of Medicine and Health Sciences
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0560: Single Cell Sequencing Analysis of Tumour Necrosis Factor Inhibitor Drug Response Reveals Enrichment of Pro-inflammatory Pathway in Non-responders and Amino Acid Metabolic Pathways in Responders
0561: Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Location: Hall F1
Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0562: Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0563: Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0564: Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Location: Hall F1
Abstract Poster Presenter: Alice Gottlieb, MD, PhD – Icahn School of Medicine at Mount Sinai
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0565: Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
0567: Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Location: Hall F1
Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0568: Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
0570: Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
0571: Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Jaejoon Lee, MD;PhD – Samsung Medical Center, Sungkyunkwan University School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0572: Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
0573: Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
0574: Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
0577: Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
0578: Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0579: Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0580: Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0581: Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0582: Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Location: Hall F1
Abstract Poster Presenter: Prabhu Vasantha Kumar, MD, DM – GKNM Hospitals & Research Institute, Coimbatore, Tamil Nadu, India
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0583: Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
0584: Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
0585: Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
0590: Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
0591: An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-world Clinical Practice
0592: An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-world Clinical Practice
0553: Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
Location: Hall F1
Abstract Poster Presenter: Zeyu Tang, MD – Yale School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0538: Development of an Artificial Intelligence Tool for Lesion Detection in Axial Spondyloarthritis patients with Active Sacroiliitis on Magnetic Resonance Imaging
0524: Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors
Location: Hall F1
Abstract Poster Presenter: Servet Akar, MD – Izmir Katip Çelebi University School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0530: Evaluating ChatGPT's Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties
0545: Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis
0532: Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
0540: Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
Location: Hall F1
Abstract Poster Presenter: Manouk de Hooge, PhD – Ghent University Hospital & Leiden University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0544: Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort
0100: Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
Location: Hall F1
Abstract Poster Presenter: Beatriz Vellón-García, MSc – Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0109: Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
0523: SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
0536: Can achieving sustained low disease activity through treat-to-target management arrest enthesiophyte progression in psoriatic arthritis? A two-year prospective study using high resolution peripheral quantitative computed tomography
Location: Hall F1
Abstract Poster Presenter: Isaac Cheng, PhD – The Chinese University of Hong Kong
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0522: The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
0539: Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort
Location: Hall F1
Abstract Poster Presenter: Liese de Bruin, MSc – Leiden University Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0528: Apolipoprotein A1 and B Levels Indicate Specific Lipid Changes in Early Treatment Naïve Psoriatic Arthritis and Correlate with 1-year Disease Activity
0533: Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission
Location: Hall F1
Abstract Poster Presenter: Avarna Agarwal, MD (she/her/hers) – Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0537: HLA-B27 and Axial Involvement as Independent Risk Factors for Uveitis in Spondyloarthritis: New Insights from a 15-Year Real-Life Study
0546: Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
0114: A Rare Variant in the extl3 Gene Is Associated with Altered Wnt Signaling Pathway in a Novel Mouse Model of Axial Spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0542: Transition from Psoriasis to Psoriatic Arthritis: Does Family History Influence the Time to Onset of Arthritis in Psoriasis Patients?
Location: Hall F1
Abstract Poster Presenter: Marta Flores, MD – University of Cordoba
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0103: Common and Rare Variant Contributions to Familial Aggregation in Spondyloarthritis
0526: Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
Location: Hall F1
Abstract Poster Presenter: Yoon-Jeong Oh, MD – Uijeongbu Eulji Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0105: Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
0551: Enthesitis Beyond the Surface: Ultrasonographic Unmasking of Preclinical Psoriatic Arthritis in Cutaneous Psoriasis
Location: Hall F1
Abstract Poster Presenter: Victor Cazac, n/a – Norwalk Hospital, Nuvance Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0101: Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Benjamin Cai, BS – Frazer Institute, The University of Queensland
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0548: Artificial Intelligence in Axial Spondyloarthritis Diagnosis: Integrating Structural and Inflammatory Lesionsfrom Sacrum MRI
Location: Hall F1
Abstract Poster Presenter: Seonyoung Kang, MD – Samsung Medical Center, Sungkyunkwan University School of Medicine
Sunday, Oct 26th
4:15 PM - 5:15 PM Central Time
26S67: Shifting the Spotlight: New Horizons in the Diagnosis and Management of Psoriatic Arthritis
27M18: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies
Location: W196A-C
Abstract Moderator: Alexis Ogdie, MD – University of Pennsylvania
Abstract Moderator: Soumya Reddy, MD – NYU Grossman School of Medicine
CE: 0.00
Monday, Oct 27th
10:00 AM - 10:15 AM Central Time
0873: Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
0874: Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
Location: W196A-C
Presenting Author: Atul Deodhar, MD – Oregon Health & Science University
Monday, Oct 27th
10:30 AM - 10:45 AM Central Time
0875: Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
0876: Effect of QX002N on Clinical and Radiographic Outcomes in Ankylosing Spondylitis: Results from a Phase III Randomized, Double-blind, Placebo-Controlled Study
Location: W196A-C
Presenting Author: Xiaofeng Zeng, MD – Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID)
Monday, Oct 27th
11:00 AM - 11:15 AM Central Time
0877: Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II
Location: Hall F1
CE: 0.00
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II
Location: Hall F1
CE: 0.00
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1405: A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis
1407: Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
Location: Hall F1
Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1408: When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
Location: Hall F1
Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1409: The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
1410: Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Location: Hall F1
Abstract Poster Presenter: Connor Vershel, MD – University of Texas at Houston
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1411: Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
1414: Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Location: Hall F1
Abstract Poster Presenter: Eugeniu Russu, MD, PhD – State Medical and Pharmaceutical University ”Nicolae Testemitanu”; "Timofei Mosneaga" Republican Clinical Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1415: The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1417: Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis
Location: Hall F1
Abstract Poster Presenter: Faria Sami, MD – The University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1418: Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
1419: Effectivenss of an educational program on non-radiographic axial spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1420: A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Location: Hall F1
Abstract Poster Presenter: Isadora Small, n/a – The Latin School of Chicago
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1421: Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
Location: Hall F1
Abstract Poster Presenter: Lily Mikolajczak, BS – Georgetown University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1422: Assessment of Difficulties, Modifications and Use of Work Adaptations in Patients with Axial Spondyloarthritis: Validation of the Dificultax and Modal Questionnaires
1434: Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Location: Hall F1
Abstract Poster Presenter: Adam Mayer, MD – Hackensack University Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1435: Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
1436: Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Location: Hall F1
Abstract Poster Presenter: Devy Zisman, MD – Carmel Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1437: Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
1438: Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
1441: Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Location: Hall F1
Abstract Poster Presenter: Hongbin Li, MD – Affiliated Hospital of Inner Mongolia Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1442: Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
1444: Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
1445: Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
Location: Hall F1
Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1446: Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
1447: Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
1449: Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Lianne S. Gensler, MD – University of California San Francisco
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1450: The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
Location: Hall F1
Abstract Poster Presenter: Marc Schmalzing, MD – University Hospital Wuerzburg
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1451: Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1452: Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
1453: Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1454: Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1455: Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1456: Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1457: Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1458: Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1459: Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
1460: Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
1461: Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
1462: Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
1464: Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
1465: Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
1466: Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
Abstract Moderator: Sibel Aydin, MD – University of Ottawa - Ottawa
CE: 0.00
Monday, Oct 27th
3:00 PM - 3:15 PM Central Time
1710: Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level
1712: Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center
1715: Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Location: S103
Presenting Author: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
Tuesday, Oct 28th
10:00 AM - 11:30 AM Central Time
28T15: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III
Location: Hall F1
CE: 0.00
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III
Location: Hall F1
CE: 0.00
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2305: Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2306: Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study
Location: Hall F1
Abstract Poster Presenter: Amir Haddad, MD – Carmel Medical Centre
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2309: Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
2318: Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists
2319: Reducing selection bias while maintaining precision through an integrated analysis: 2-year longitudinal analysis of imaging outcomes in the SPondyloArthritis Caught Early cohort
Location: Hall F1
Abstract Poster Presenter: Liese de Bruin, MSc – Leiden University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2320: Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors
2323: Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
2324: Early Prediction of Complex Forms of Spondyloarthritis Using Artificial Intelligence: A Modeling Study Based on Routine Clinical Data
Location: Hall F1
Abstract Poster Presenter: MOHAMMED KHALIL JNYAH, MD (he/him/his) – University Hospital Center Hassan II of Fez, Faculty of Medicine, Dentistry and pharmacy Sidi Mohamed Ben Abdellah of Fez, Morocco
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2325: Association of galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Natalia Guajardo-Jauregui, MD – Hospital Universitario "Dr. Jose E. Gonzalez", Monterrey, Mexico
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2326: Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Rafael Bassara Macedo, MD – Rheumatology Division - University of São Paulo
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2327: Persistent Pain in PsA: A Distinct Phenotype of Depression, Fatigue, And Catastrophizing
2330: Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans - A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2331: Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
2338: Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
2339: Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST
Location: Hall F1
Abstract Poster Presenter: Alen Zabotti, MD, MSc – Azienda Sanitaria Universitaria del Friuli Centrale
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2340: Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial
Location: Hall F1
Abstract Poster Presenter: Alexander Garaiman, n/a – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2341: Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Ana-Maria Orbai, MD, MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2342: Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe
Location: Hall F1
Abstract Poster Presenter: Andrew Ostor, MD – Australian National University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2343: Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Location: Hall F1
Abstract Poster Presenter: Asim Khanfar, MD – Rochester General Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2344: Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
2345: Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
2346: Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
Location: Hall F1
Abstract Poster Presenter: Daniel Zavada, MD – Charles University, Third Faculty of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2347: Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
Location: Hall F1
Abstract Poster Presenter: Fabian Proft, MD – Charité Universityhospital Berlin
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2348: Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
2351: Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
2352: Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
2353: Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Xu Jian, PhD – First Affiliated Hospital of Kunming Medical University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2354: ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
2355: Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
Location: Hall F1
Abstract Poster Presenter: KURT OELKE, MD – rheumatic disease center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2356: Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
2357: Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
2358: Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
2359: Combination Of TNF Inhibitors And NSAIDs Versus TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis
2360: Treatment adherence in ankylosing spondylitis: A comparison of TNFi, IL-17i, and JAKi using real-world data
Location: Hall F1
Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2361: Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis
2362: Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
Location: Hall F1
Abstract Poster Presenter: Mauro Keiserman, MD – Rheumatology Section, Pontifical Catholic University, School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2363: Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2364: Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2365: Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2366: Association Between Skin and Joint Symptom Control and Patient-reported Pain and Health Status Among Patients with Psoriatic Arthritis in the Corevitas Psoriatic Arthritis/spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drugs
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2367: Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2368: Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2369: Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2370: Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
2373: Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
2375: Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
2376: Efficacy And Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis Stratified by Disease Course: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 2/3 Trial
Location: Hall F1
Abstract Poster Presenter: Xiaofei Shi, MD – The First Affiliated Hospital of Henan University of Science and Technology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2307: Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
2335: The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.
2308: Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
2312: Sociodemographic Characteristics and Healthcare Utilization in Patients with IBD-Associated Arthritis vs. IBD Alone: A Nationwide Inpatient Analysis
Location: Hall F1
Abstract Poster Presenter: Faria Sami, MD – The University of Alabama at Birmingham
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2315: Alterations in the Gut Microbiome in Ankylosing Spondylitis and Their Correlation with Disease Activity
Location: Hall F1
Abstract Poster Presenter: Hyemin Jeong, MD – Soonchunhyang University Hospital
Tuesday, Oct 28th
1:00 PM - 2:00 PM Central Time
28T40: Beyond NETs: Alternative Roles of Neutrophils in Spondyloarthritis
Location: W181A-C
Moderator: Iannis Adamopoulos, PhD – Harvard Medical School, BIDMC, Division of Rheumatology
2635: Differences in structural lesions of the spine between patients with early axSpA and non-axSpA chronic back pain: 2-year results of the SPACE Cohort
2636: Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
Location: W183A-C
Presenting Author: Raj Sengupta, MD – Royal National Hospital for Rheumatic Diseases
Tuesday, Oct 28th
4:00 PM - 4:15 PM Central Time
2637: Initial Phospholipid Transferase Activity Is Predictive of Five-Year Sacroiliac Radiographic Progression in Axial Spondyloarthritis: Findings From the DESIR Cohort
2687: Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
2688: Single cell RNA-seq immune profiling of blood samples from a psoriatic disease clinical trial reveals a CD4 T cell population associated with response to IL-23 blockade
2689: Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
0599: Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Aakash Patel, MD – Massachusetts General Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0600: Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
0601: Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review
0602: Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
Location: Hall F1
Abstract Poster Presenter: Ami Vyas, PhD – University of Rhode Island
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0603: Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data
Location: Hall F1
Abstract Poster Presenter: Amir Daneshvar, MD – University Hospitals Cleveland Medical Center/Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0604: Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus
0605: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
0611: Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0612: Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0614: Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
Location: Hall F1
Abstract Poster Presenter: Ileana Cecilia Reynosa Silva, MD – Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0615: Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant
Location: Hall F1
Abstract Poster Presenter: Jacob Klein, MD – Ohio State University Wexner Medical Center
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0618: Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study
Location: Hall F1
Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0619: Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Location: Hall F1
Abstract Poster Presenter: Luciana Seguro, MD, PhD – Hospital das Clínicas HCFMUSP, University of Sao Paulo
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0620: The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission
0622: Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes
0623: Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
0625: DNA methylation patterns in systemic lupus erythematosus associated with nephritis status
Location: Hall F1
Abstract Poster Presenter: Meghan Nelson, DO – National Institutes of Health
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0626: Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)
Location: Hall F1
Abstract Poster Presenter: Nalani Sachan, PhD – NYU Grossman School of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0627: Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
Location: Hall F1
Abstract Poster Presenter: Omer Pamuk, MD – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0628: Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Panagiotis Garantziotis, MD – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0630: Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus
0632: Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients with Systemic Lupus Erythematosus and Diabetes: A Propensity-Matched Retrospective Cohort Study
0634: Association of Lifestyle and Integrative Health Practices with Health-related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease
0640: Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
0642: Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Location: Hall F1
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0644: Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Location: Hall F1
Abstract Poster Presenter: Joan Merrill, MD – Oklahoma Medical Research Foundation
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0645: Achievement of Low Disease Activity and Remission in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-week Results from a Phase 3 Trial
0649: Belimumab Real-World Effectiveness in Chinese Patients with Systemic Lupus Erythematosus: Interim Analysis of an Ambidirectional, Observational Cohort Study (RELIABLE)
0650: Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Location: Hall F1
Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0651: The ERβ Agonist, OSU-ERβ-012, Suppresses Systemic, Kidney and Heart Inflammation in a Chimeric Mouse Model of Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Braden Zeno, BS – Ohio State University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0652: Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
0653: In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at Their Clinical Dose Regimens
0654: Obinutuzumab Shows Promise in Lupus Nephritis Regardless of Baseline Serological Markers: An Exploratory Post Hoc Analysis of a Phase II Trial
Location: Hall F1
Abstract Poster Presenter: Ed Vital, MD – University of Leeds
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0655: Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Location: Hall F1
Abstract Poster Presenter: Eric Roberts, PhD, MPH – University of California, San Francisco
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0656: Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
0657: Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
Location: Hall F1
Abstract Poster Presenter: FNU Ruchi, MD – SUNY Upstate Medical University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0659: Human papillomavirus infection and systemic lupus erythematosus under biologic therapy: a retrospective analysis in a multicenter cohort
0660: Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
0662: Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
0664: Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
0665: Infusion-Related Reactions (IRRs) and Hematologic Events Associated With Obinutuzumab in Lupus Nephritis: A Secondary Analysis of a Phase III Trial
0666: Reported Adverse Events Associated With Systemic Lupus Erythematosus (SLE) Treatment: Insights From the FDA Adverse Event Reporting System (FAERS) 2023
0669: Clinical and Laboratory Factors Associated With Biopsy-Confirmed Antimalarial-Induced Cardiomyopathy
Location: Hall F1
Abstract Poster Presenter: Youngmin Kim, MD – Brigham and Women's Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0670: Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
0613: A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights from an Inception Cohort
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0616: Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study
0631: Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow up in an Inception Cohort of SLE (INSPIRE) from India
0617: Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera
0801: Achieving Sustained Lupus Low Disease Activity State and Remission with Ianalumab (VAY736) in Patients with Systemic Lupus Erythematosus: A Post Hoc Analysis from a Phase II Study
Location: S103
Presenting Author: Ed Vital, MD – University of Leeds
Sunday, Oct 26th
1:15 PM - 1:30 PM Central Time
0802: Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
0803: Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
0806: Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation
0838: Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
Location: S102
Presenting Author: Brad Rovin, MD – The Ohio State University
Sunday, Oct 26th
3:30 PM - 3:45 PM Central Time
0839: Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking
Location: S102
Presenting Author: Iris Tang, MBBS, MRCP – Department of Medicine, LKS Faculty of Medicine, University of Hong Kong
Sunday, Oct 26th
3:45 PM - 4:00 PM Central Time
0840: Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases
Location: S102
Presenting Author: Andrea Fava, MD – Johns Hopkins University
Sunday, Oct 26th
4:00 PM - 4:15 PM Central Time
0841: Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study
Location: S102
Presenting Author: Kinga Grzybowski, MD – Jefferson Einstein Montgomery Hospital
Sunday, Oct 26th
4:15 PM - 4:30 PM Central Time
0842: Association of Urinary Biomarkers with Histological Features in Diagnostic and Per-protocol Repeat Kidney Biopsies in Lupus Nephritis
Location: S102
Presenting Author: Andrea Fava, MD – Johns Hopkins University
Monday, Oct 27th
10:30 AM - 11:30 AM Central Time
27M31: Rheumatology Research Foundation Memorial Lecture: To Memoralize Dr. Eng Tan
1469: Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
1477: Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis
Location: Hall F1
Abstract Poster Presenter: Beste Acar, MD – Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1478: Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Bin zhou, MD – The First School of Clinical Medicine, Southern Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1479: Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
Location: Hall F1
Abstract Poster Presenter: Chen Chao, MD, MBA – Montefiore Medical Center/Albert Einstein College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1480: Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
Location: Hall F1
Abstract Poster Presenter: Chen-Yu Lee, MD – Johns Hopkins University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1481: Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative
1482: Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Location: Hall F1
Abstract Poster Presenter: Erik Cimé-Aké, n/a – Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1483: Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
1486: Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Location: Hall F1
Abstract Poster Presenter: Ileana Cecilia Reynosa Silva, MD – Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1487: Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
1493: Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
1496: Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center
Location: Hall F1
Abstract Poster Presenter: Manikandan Gopal, DM – Christian Medical College Vellore
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1497: Acute Care Utilization in Patients with Antiphospholipid Syndrome And/or Systemic Lupus Erythematosus
1500: Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1501: Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes - Results from Real World Data
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1502: Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Omer Pamuk, MD – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1503: Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
1504: High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants
Location: Hall F1
Abstract Poster Presenter: Richard Oppong, PhD – NATIONAL INSTITUTES OF HEALTH
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1505: Discordance Between Physician and Patient Global Assessment of Disease Activity in a Large Multicenter Prospective SLE Cohort in the U.S. and Canada
Location: Hall F1
Abstract Poster Presenter: Romy Kallas, MD, MS – Hospital for Special Surgery
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1506: Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)
Location: Hall F1
Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1507: Temporal Trends in the Incidence of Systemic Lupus Erythematosus (SLE) in the United States (US): Holding Steady?
Location: Hall F1
Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1508: Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Location: Hall F1
Abstract Poster Presenter: Sheila Serin, MD – Ochsner Clinic Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1509: Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
1510: Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
Location: Hall F1
Abstract Poster Presenter: Sitian Zang, n/a – Department of Rheumatology and Immunology, Peking University People’s Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1511: Mental Health and Medical Burden: The Impact of Depression on Length of Stay in Lupus Patients
Location: Hall F1
Abstract Poster Presenter: Sophia Chang Stauffer, MPH – Dartmouth College, University of Illinois at Chicago
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1512: anti-u1-rnp Antibody Positivity Is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Location: Hall F1
Abstract Poster Presenter: Takemichi Matsui, MD – Icahn School of Medicine at Mount Sinai
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1513: Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Location: Hall F1
Abstract Poster Presenter: Ufuoma Mamoh, MBChB – Medstar Georgetown University (Baltimore) Internal Medicine Residency
Abstract Poster Presenter: Yan Wang, n/a (she/her/hers) – Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1515: Machine Learning–defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
Location: Hall F1
Abstract Poster Presenter: Yuke Hou, MD – Peking University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1517: The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
Location: Hall F1
Abstract Poster Presenter: Aijing Liu, PhD – Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1518: Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Location: Hall F1
Abstract Poster Presenter: Ali Ali, MD, RhMSUS – Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1519: Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
1520: Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Bahtiyar Toz, MD – Zucker School of Medicine at Hofstra/ Northwell
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1521: Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Location: Hall F1
Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1522: Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Location: Hall F1
Abstract Poster Presenter: Carlos Pena, MD – Jefferson Einstein Philadelphia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1523: Genetic architecture and translational insights for SLE progression from preclinical stages
1529: Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
1530: The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
1531: Achieving Remission and Low Disease Activity with Belimumab versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1532: Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
1536: Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Location: Hall F1
Abstract Poster Presenter: Aarat Patel, MD – GSK, US Medical Affairs
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1537: Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Melanie Hagen, MD (she/her/hers) – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1538: Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
Location: Hall F1
Abstract Poster Presenter: Minoru Hasegawa, MD;PhD – Division of Medicine, University of Fukui
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1539: The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
1541: Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
Location: Hall F1
Abstract Poster Presenter: Qizhi Yuan, PhD – Peking Union Medical College
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1542: Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-week Phase 3 Trial
1545: Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
1552: Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
1717: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort
1718: Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
Location: S102
Presenting Author: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Monday, Oct 27th
3:45 PM - 4:00 PM Central Time
1689: Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
1719: Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study
1720: Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Location: S102
Presenting Author: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
Monday, Oct 27th
4:15 PM - 4:30 PM Central Time
1691: Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm
Location: W192A-C
Presenting Author: Andrea Gutierrez, BS – University of Texas Southwestern Medical School
Monday, Oct 27th
4:15 PM - 4:30 PM Central Time
1721: Excess Mortality in SLE Is Concentrated in Lupus Nephritis and aPL-Positive Subsets: A population-based inception cohort study
1838: Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
Location: Hall F1
Abstract Poster Presenter: Jolien Suurmond, PhD – Leiden University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1839: Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways
1842: Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
1843: Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Norio Hanata, M.D., Ph.D. – Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1844: Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis
1847: Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
1848: DS-7011a, An Anti-TLR7 Antagonistic Monoclonal Antibody, Suppresses Human Immune Cells and Multiple Cytokines/Chemokines Related to the Pathogenesis of SLE
1850: First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
Location: Hall F1
Abstract Poster Presenter: Tayte Stephens, BS – University of Oklahoma Health Science Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1851: Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage
Location: Hall F1
Abstract Poster Presenter: Tomás Cerdó, PhD – Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1852: Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort
Location: Hall F1
Abstract Poster Presenter: Victoria Werth, MD – University of Pennsylvania
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
1853: SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
2380: Factors Influencing Time to Diagnosis in Systemic Lupus Erythematosus: A Real-World Retrospective Analysis
Location: Hall F1
Abstract Poster Presenter: April Barnado, MD, MSc – Vanderbilt University Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2381: Renal Tubular Complement C9 Deposition is Linked to Tubulointerstitial Fibrosis and Progression to Chronic Kidney Disease in Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Angela Lu, BS – Albert Einstein College of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2382: Autoimmune Hemolytic Anemia in SLE: A Real-World National Cohort Study
Location: Hall F1
Abstract Poster Presenter: Ansaam Daoud, MD – Case Western Reserve University/University Hospitals
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2383: The Age-Adjusted Charlson Comorbidity Index (CCI) Predicts All-Cause Mortality in Systemic Lupus Erythematosus (SLE) Patients: Data from the Almenara Lupus Cohort
2385: The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes
Location: Hall F1
Abstract Poster Presenter: Billy Kim, MD – Hospital for Special Surgery
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2386: anti-trim72 Auto-antibodies in Systemic Lupus Erythematosus Patients and a Lupus Mouse Model with Myocarditis Compromise Membrane Repair in Mouse & Human Cardiomyocytes
Location: Hall F1
Abstract Poster Presenter: Braden Zeno, BS – Ohio State University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2387: Lupus Damage Index Revision – Item Generation and Reduction Phases
2391: Antinuclear Antibody Positivity in Patients with Psoriasis and Psoriatic Arthritis and the Risk of Developing Clinical Symptoms of SLE Following TNF Inhibitor Therapy
2396: A Machine Learning Algorithm Based on a 15-autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
2397: Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
2398: Analytical Performance of the hep-2 Substrate Diagnostic Kit for ANA as an Initial Step in the Evaluation of a Novel Fully Automated IFA Analyzer in a Laboratory in England
2399: Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
Location: Hall F1
Abstract Poster Presenter: Gregg Silverman, MD – NYU Grossman School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2400: Prevalence and Predictors of Types and Subtypes of Pulmonary Diseases in Systemic Lupus Erythematosus: A Population-Based Cross-Sectional Study Using High-Resolution Computed Tomography Scan and Pulmonary Function Testing
2401: Associations Between Serum Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Activity and Chronicity Features in Diagnostic and Per-protocol Repeat Kidney Biopsies in Patients with Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2402: High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2403: Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
2404: Clinical features of Elderly-onset Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Jessica Dai, BS – New York University Grossman School of Medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2405: Machine Learning in SLE Diagnosis: Performance of the SLE Risk Probability Index Questionnaire in a Multicenter Cohort of Patients with Systemic Lupus Erythematosus
2406: Machine Learning-Based Artificial Intelligence in Systemic Lupus Erythematosus: A Systematic Review of Outcome Prediction and Patient Stratification
2407: Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis
2416: Direct and Indirect Costs Associated with Damage Accrual: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
2421: Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria
Location: Hall F1
Abstract Poster Presenter: Nicholas Bauer, BS – Oklahoma Medical Research Foundation
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2422: Cluster Analysis of Autoantibodies in Patients with Systemic Lupus Erythematosus
2427: Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease
2428: Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes
Location: Hall F1
Abstract Poster Presenter: Shae Chambers, BA – University of Pennsylvania
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2429: mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
2429: mHealth-enabled Peer Coaching for Fatigue in Systemic Lupus Erythematosus (SLE): Preliminary Results from the Restore Energy, Activity Can Help (REACH) Pilot Randomized Controlled Trial
2441: Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Location: Hall F1
Abstract Poster Presenter: Cynthia Aranow, MD – Feinstein Institutes for Medical Research
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2442: Reduction in Extrafollicular B Cell Responses in SLE Patients after CAR T Cell Therapy
2445: Achievement of Treat to Target Measures with Upadacitinib in Patients with Systemic Lupus Erythematosus: Phase 2 Randomized Sleek Clinical Trial Results
2449: Patient Characteristics, Treatment and Prognosis in Patients with Neuromyelitis OpticaSpectrum Disorder Coexisting with Systemic Lupus Erythematosus or Sjögren's Syndrome: An Analysis Using Japanese Inpatient Database
Location: Hall F1
Abstract Poster Presenter: Hiroshi Shiba, MD – Suwa central hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2450: Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
2458: Obecabtagene autoleucel (obe-cel), a CD19-targeting Autologous Chimeric Antigen Receptor T-cell Therapy (CAR T) with a fast off-rate binding domain, in Patients (pts) with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Preliminary Results from the Phase I CARLYSLE Study
2459: Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up
Location: Hall F1
Abstract Poster Presenter: Milena Delai, MD – Beth Israel Deaconess Medical Center
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2460: Comparative Efficacy of Belimumab, Anifrolumab, and Rituximab in SLE: A Retrospective Analysis of Serological and Clinical Outcomes
Location: Hall F1
Abstract Poster Presenter: Pablo Martinez Calabuig, Sr, MD – HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN/ Escuela de doctoradoUniversidad Católica de Valencia San Vicente Mártir, Valencia, Spain
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2461: Targeting treatment-resistant Systemic Lupus Erythematosus through transcriptome-informed drug repurposing
Location: Hall F1
Abstract Poster Presenter: Panagiotis Garantziotis, MD – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2462: Precision Dosing is Needed to Establish Predictable Exposure to the Active Metabolite of Mycophenolate Mofetil (MMF) in Pediatric Lupus Nephritis (LN)
Location: Hall F1
Abstract Poster Presenter: Pooja Patel, DO – Ann and Robert H. Lurie Children's Hospital of Chicago
2464: IMC-002 (IMM0306), a First-in-Class Bi-specific Fusion Protein, Demonstrates Improvements in Systemic Lupus Erythematosus (SLE) Disease Activity Measures and Biomarkers in Patients with Moderate to Severe Active SLE in the Open-label Phase 1b/2 Study
2465: CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
2467: Complete Renal Responses and Safety for Belimumab Versus Placebo in a Post Hoc Mycophenolate Mofetil Subgroup with Active Proliferative Lupus Nephritis
2597: Altered Tryptophan Metabolism in Neuropsychiatric Lupus: A Cluster Analysis to Identify Distinct Subgroups
Location: S103
Presenting Author: Yang Wu, MD, PhD – University of Washington; Chinese Academy of Medical Sciences & Peking Union Medical College
Tuesday, Oct 28th
1:15 PM - 1:30 PM Central Time
2598: Keratinocyte-Secreted Leukemia Inhibitory Factor Counteracts Type I IFN-Induced Antigen-Presenting Phenotype in Melanocytes: Utility in Cutaneous Lupus Skin
2599: Identification of a New Pathogenic Axis in Antiphospholipid Syndrome Linking Antiphospholipid Antibodies, Liver Function, and Circulating Proatherogenic Metabolites
Location: S103
Presenting Author: Beatriz Vellón-García, MSc – Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
Tuesday, Oct 28th
1:45 PM - 2:00 PM Central Time
2600: Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution
2601: Characterisation of immunometabolic reprogramming at the single cell level in patients with systemic lupus erythematosus and preclinical autoimmunity
2645: Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-analysis of Data from the Centers for Disease Control and Prevention Lupus Registries
Location: W192A-C
Presenting Author: Peter Izmirly, MD – New York University Grossman School of Medicine
Wednesday, Oct 29th
9:45 AM - 10:00 AM Central Time
2646: DNA methylation-based clustering reveals clinically distinct subtypes of systemic lupus erythematosus
Location: W192A-C
Presenting Author: Meghan Nelson, DO – National Institutes of Health
Wednesday, Oct 29th
10:00 AM - 10:15 AM Central Time
2647: Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features
2648: Transcriptome analysis of quiescent SLE cases uncovers dysregulated pathways associated with disease flares
Location: W192A-C
Presenting Author: Lorenzo Beretta, MD – Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano
Wednesday, Oct 29th
10:30 AM - 10:45 AM Central Time
2649: Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
2697: A Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-maintenance Treatment for Class III/IV±V Lupus Nephritis
2694: Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
2696: Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
2698: Comparative Efficacy of Tacrolimus-Based Induction Therapy with and without Mycophenolate Mofetil in Lupus Nephritis: A Target Trial Emulation Study
Location: W375C
Presenting Author: YUN KYU KIM, MD – Seoul National University
Tech Med and Telemedicine
Monday, Oct 27th
8:30 AM - 9:30 AM Central Time
27M06: The Great AI Debate: Unlocking Potential or Unleashing Chaos?
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I
Location: Hall F1
CE: 0.00
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0731: The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Jean-Paul Makhzoum, MD, FRCPC, MSc, FACP – Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0732: Blocking GM-CSF receptor alpha with mavrilimumab reduces production of growth factors involved in vascular remodeling in an ex-vivo model of temporal artery culture from patients with giant-cell arteritis (GCA)
0739: Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Location: Hall F1
Abstract Poster Presenter: CARMEN SECADA-GÓMEZ, MD – HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0740: Intravenous versus subcutaneous administration of Tocilizumab in aortitis associated with giant cell arteritis: multicenter open-label study of 196 patients
Location: Hall F1
Abstract Poster Presenter: CARMEN SECADA-GÓMEZ, MD – HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0741: Characteristics of African American vs. Non-African American Patients with Giant Cell Arteritis: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Dana Nachawati, DO – University Hospitals Cleveland Medical Center/Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0742: Exploring Racial Variation in the Clinical Manifestations of Giant Cell Arteritis: A Retrospective Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Dana Nachawati, DO – University Hospitals Cleveland Medical Center/Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0743: Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
0760: The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Sema Kaymaz-Tahra, MD – Bahcesehir University Faculty of Medicine
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0762: Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers
0763: Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience
Location: Hall F1
Abstract Poster Presenter: Wendy Perdomo, MD – Thomas Jefferson University Hospital
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0764: Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery - Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-
0724: Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis - Results from Real-World Data
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0723: Neutrophil and Eosinophil Extracellular Traps in Eosinophilic Granulomatosis with Polyangiitis: Phenotype-based Characterization and Response to Mepolizumab
Location: Hall F1
Abstract Poster Presenter: Michele Moretti, MD – University of Pisa, Rheumatology Unit
Sunday, Oct 26th
10:30 AM - 12:30 PM Central Time
0711: Analytical Performance of a Novel, Fully Automated Multiplexed Microarray Immunoassay Prototype for the Simultaneous Detection of Autoantibodies to GBM, PR3, and MPO: A Multicenter Evaluation
0730: Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
0726: Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence
0722: Estimating two-year risk of relapse in individuals with ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids
0893: Transcriptomic insights into GCA compared to clinically diverse controls: Inflammation, Aging, Therapeutic Targets and the role of SPP1 in the temporal artery
1614: A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
1615: Prevalence of Clinical and Laboratory Manifestations of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Review and Meta-Analysis
1617: Evaluating Familiarity and Knowledge Gaps in Polymyalgia Rheumatica Among Public Health Professionals
Location: Hall F1
Abstract Poster Presenter: Erik Stone, MA – Global Healthy Living Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1618: Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study
Location: Hall F1
Abstract Poster Presenter: Fatma Alibaz-Oner, MD – MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1619: Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
1627: A Systematic Literature Review to Inform the 2025 EULAR Recommendations for Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Management of Disease Including Relapse and Complications
1628: Characterization of non-GCA, non-Takayasu Aortitis in a Single Health System Cohort
Location: Hall F1
Abstract Poster Presenter: Nuzhat Batool, MBBS – NYU Grossman Long Island School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1629: Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
1630: Validation of the classification algorithm using the modified 2022 ACR/EULAR giant cell arteritis classification criteria and Japanese Takayasu arteritis diagnostic criteria
1610: Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
1598: Use of JAK Inhibitors in Medium- and Small-Sized Vasculitides: a Retrospective Multicenter Study
Location: Hall F1
Abstract Poster Presenter: Caterina Ricordi, MD – AUSL-IRCCS of Reggio Emilia and University of Modena and Reggio Emilia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1609: A Multicenter Prospective Longitudinal Observational Study to Determine Safety of Extended Treatment with Rituximab in Maintaining Remission in Patients with ANCA Associated Vasculitis (AAV) - An Interim Analysis
Location: Hall F1
Abstract Poster Presenter: Ravi Kumar U, DM – Christian Medical College
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1597: Effectiveness and Safety of Rituximab Biosimilars in Small Vessel Vasculitis: a Systematic Literature Review
1611: Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Yusuke Ushio, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1595: Subcordal Stenosis is a Glucocorticoid-Responsive Manifestation of Granulomatosis with Polyangiitis
1603: SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
Location: Hall F1
Abstract Poster Presenter: Julia Foos, BA – University of Toledo College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1596: GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency
1605: Combined Anti-IL-5/IL-5R and Dupilumab Therapy in Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Miriam Guerini, MBChB – IRCCS Policlinico San Matteo, University of Pavia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1594: Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
Ultrasound Should Not Replace Biopsy for the Diagnosis of Giant Cell Arteritis
Location: W375B
Speaker: Peter Grayson, MD, MSc – National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Tuesday, Oct 28th
10:00 AM - 11:30 AM Central Time
28T13: Abstracts: Vasculitis – ANCA-Associated
Location: S103
Abstract Moderator: Jean-Paul Makhzoum, MD, FRCPC, MSc, FACP – Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal
Abstract Moderator: Luc Mouthon, MD, PhD – Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP
CE: 0.00
Tuesday, Oct 28th
10:00 AM - 10:15 AM Central Time
1764: Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
1765: Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
1766: Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study
Location: S103
Presenting Author: Caterina Ricordi, MD – AUSL-IRCCS of Reggio Emilia and University of Modena and Reggio Emilia
Tuesday, Oct 28th
10:45 AM - 11:00 AM Central Time
1767: Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis
1769: Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
2527: Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
Location: Hall F1
Abstract Poster Presenter: Eduardo Borba, PhD – Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2528: Broad Screening of the Human Proteome Identifies a Cassette of Six Autoantigens that Distinguishes IgG4-Related Disease
2530: Broad Screening of Inflammation-Associated Proteins Identifies Serum CCL19 and CCL2 as Versatile Biomarkers of Disease Activity in IgG4-Related Disease
2533: Patterns of skin lesion transcriptomics in different forms of vasculitis
Location: Hall F1
Abstract Poster Presenter: Karyssa Stonick, BS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2534: Frequency of Ocular and Gastrointestinal Lesions Is Increased in Japanese Behçet’s Disease Patients with HLA-B61
Location: Hall F1
Abstract Poster Presenter: Koichi Sugihara, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2535: Behçet’s syndrome: distinct features in 344 pediatric and adult patients in a non-endemic region
2543: Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods
Location: Hall F1
Abstract Poster Presenter: Sinem Nihal Esatoglu, MD (she/her/hers) – Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2544: Diagnostic value of vein wall thickness measurement for patients with suspected Behçet syndrome
Location: Hall F1
Abstract Poster Presenter: Sinem Nihal Esatoglu, MD (she/her/hers) – Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2545: Prevalence, Clinical Correlations and Outcomes of Cryoglobulinemic Vasculitis: a Retrospective Monocentric Study (2013–2023)
Location: Hall F1
Abstract Poster Presenter: Valeria Manfrè, MD – Division of Rheumatology, Department of Medicine, University of Udine, Italy; Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, WI
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2546: Diagnostic Journey, Clinical Burden, And Quality Of Life Of Patients With IGg4-Related Disease: Results Of A Cross-Sectional Survey Of Patients And Physicians In The United States
Location: Hall F1
Abstract Poster Presenter: Yasmin Hernandez-Barco, MD – Massachusetts General Hospital, Harvard Medical School
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2512: Contribution of the CALLY index at diagnosis to early prediction of all-cause mortality in patients with ANCA-associated vasculitis
Location: Hall F1
Abstract Poster Presenter: Jang Woo Ha, MD – Yonsei university college of medicine
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2523: Predictors of Glucocorticoid-Free Clinical Remission at Week 48 in Newly Diagnosed Microscopic Polyangiitis and Granulomatosis with Polyangiitis: from nation-wide registry in Japan (J-CANVAS)
Location: Hall F1
Abstract Poster Presenter: Yusuke Ushio, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2513: Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
2507: Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)
Location: Hall F1
Abstract Poster Presenter: Camille Mettler, MD – APHP, Service de Médecine Interne, Hôpital Bichat
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2519: A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
Location: Hall F1
Abstract Poster Presenter: Shiamak Cooper, MD – Rochester General Hospital
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2505: Avacopan is Not Associated With An Increased Risk of Infection Compared to Glucocorticoids in Patients with ANCA-Associated Vasculitis
2514: Comparison of Demographics and Outcomes of Inpatient Hospitalization of Severe Asthma Patients with Eosinophilic Granulomatosis with Polyangitis. A Study on the National Inpatient Sample Database
2520: Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
Location: Hall F1
Abstract Poster Presenter: Thomas Neumann, MD – Kantonsspital St. Gallen
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2521: DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort
2522: Clinical Outcomes and Prognostic Impact of Cardiac and Cerebrovascular Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Yuko Shirota, MD., PhD., – Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2504: Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021
Location: Hall F1
Abstract Poster Presenter: Anuya Natu, MBBS – John H Stroger, Jr. Hospital of Cook County
Tuesday, Oct 28th
10:30 AM - 12:30 PM Central Time
2517: Predictors for Mortality in Patients Who Received Plasmapheresis for Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
2700: Neutrophil Transcriptomics and Maturation Pathways in VEXAS Syndrome
Location: W187A-C
Presenting Author: Benjamin Turturice, MD;PhD – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
Wednesday, Oct 29th
12:00 PM - 12:15 PM Central Time
2701: Ophthalmic Manifestations of Relapsing Polychondritis
Location: W187A-C
Presenting Author: Akash Gupta, MD – Duke University School of Medicine
Wednesday, Oct 29th
12:15 PM - 12:30 PM Central Time
2702: Diagnostic Performance of Vascular Ultrasound in Giant Cell Arteritis – A Single Center Experience
2703: Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Location: W187A-C
Presenting Author: Ruoheng Zeng, BS – Perelman School of Medicine
Wednesday, Oct 29th
12:45 PM - 1:00 PM Central Time
2704: Complete metabolic response on PET/CT in giant-cell arteritis-related large vessel vasculitis : comparison of two strategies using glucocorticoids or glucocorticoids + tocilizumab
